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Abstract 
The v6.3Glide Program (Schrödinger Suite, Schrödinger Inc., New York NY, USA) was used 
to screen >9x106 compounds from several ligand sources including ZINC Chemical and 
Ambinter Chemical Databases. The selection of the four compounds DPT1 1 – DPT4 4 was 
based on their potential inhibition in both the ectodomain (oligomerization region) and 
endodomain (cytoplasmic tyrosine kinase domain) regions of EGFR when docked into 1IVO 
|246 – 253|S and 2J6M grids and not on Gscores. Their MTS bioevaluation (in 8 x 103 
cells/mL) revealed the following: DPT1 1, IG50 3.980 µM, IC50 8.900 nM; DPT2 2, IG50 0.250 
µM, IC50 0.400 nM; DPT3 3, IG50 1.590 µM, IC50 1.500 nM; and DPT4 4, IG50 1.590 µM, IC50 
1.100 nM. Moreover, their western blotting indicated the following: DPT1 1, 1.00, 10.00 & 
100.00 µM showed strong pY – EGFR signals; DPT2 2 1.00 µM showed strong pY – EGFR 
signal while a weak pY – ERK 1 & 2 signal; DPT3 3 10.00 µM showed strong pY – EGFR signal 
while its 100.00 µM showed strong pY – ERK 1 & 2 signal and DPT4 4 1.00 µM showed 
strong pY – EGFR signal but its 100.00 µM showed strong pY - EGFR signal. DPT5 5 & DPT6 
6 (RTKI-like compounds) and zm-2 8 were MTS assayed (in 5 x 103 cells/mL) and found DPT5 
5, IG75 28.18 µM, IC50 0.389 µM; DPT6 6, IG75 40.46 µM, IC50 30.460 µM; zm2 8, threshold 
conc. 0,130 µM, IC50 0.405 µM.  
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Chapter one 
Introduction 
 
1.0 Cancer- the emperor of all maladies  
Cancer remains a global health burden despite elaborate high-tech approaches it has 
received to be tamed [1]. For instance, the WHO recorded 7.6 x 106 deaths in 2008 [2, 3] 
and 8.2 x 106 in 2012 [4, 5] and predicts that by 2020 it would be 1 x 107 deaths [6] and a 
20.3 x 106 in 2030 [7]. Cancer is a dynamic molecular group of complex heterogeneous 
diseases [8, 9] that subvert the entire cell communication pathway [10] of the infected cells. 
Some known cancer hallmarks as it progresses are abnormally high cell proliferation, 
migration, invasion, and metastasis [11]. Additional ones are evasion to growth suppressors, 
resistance to cell death (anti-apoptotic), immortality replication, formation of angiogenesis,  
exhibition of genetic diversification due to genomic instability and mutation, creation of 
tumor-promoting inflammation and ability to generate a suitable tumor microenvironment 
[12]. Future cancer management remains a serious challenge globally [13] due to its complex 
nature and poor prognosis [14, 15], hence our introduction of the disease as the emperor 
of all maladies [16]. Chemotherapy is essential in the overall cancer management plan 
despite  the substantial challenges and setbacks such as resistance to targeted therapies 
[17] from mutational changes [18] and life-threatening side effects on short and/or long 
term use [19]. Search for anticancer drugs remains an intensive research area [20]. Advances 
in cancer molecular biology has assisted to identify new ways to inhibit its growth, leading 
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to new, more selective, and less toxic forms of its therapy [21]. This information foregrounds 
the basis for the innovation of novel small molecules capable of inhibiting well established 
pathways involving specific aberrant receptors like the human epidermal growth factor 
receptor (hERBB1–ERBB4 or ErbB1 – ErbB4) subfamily [22] of receptor tyrosine kinase (RTK) 
family and their cognate ligands [23]. The definitive role of this exemplary cell surface 
receptor, EGFR-RTK (ERBB1-RTK) in cancer has made it a target template for drug design of 
several types of inhibitors [24, 25].  
1.1 The cell surface receptors (membrane or transmembrane receptors)  
The cell surface receptors are specialized complex integral proteins that play a key role in 
mediating communication or signal transduction between the interior and exterior of the 
cell. They are generally entrenched in the cell's plasma membrane and are also referred to 
transmembrane or membrane receptors [26]. However, those found in the cellular 
cytoplasm are described as cytoplasmic receptors [27] and those in the cell's nucleus as 
nuclear receptors [28, 29]. Each or a group of receptors within a given site does have specific 
signaling molecules attached [30, 31]. Cell surface receptors are central to the regulation of 
both cellular and systemic physiology and act as conveyor mediators between the 
extracellular and intracellular phases of the cell by facilitating protein trafficking and 
regulating most intracellular processes [32]. The binding molecule to the cell surface 
receptor (R) such as a neurotransmitter, hormone, pharmaceutical drug or a toxin is the 
ligand (L). All cell surface receptors share some common features as proteins, such as high 
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specificity for cognate ligands to form reversible complexes (R⇆L) with equilibrium 
constants K1 (association) and K2 (dissociation), whose response amplitude is dependent on 
their concentrations as shown: 
[R] + [L] ⇆ [R: L] 
The formation of the [R: L] complex normally initiates major biochemical processes, for 
example, oligomerization, of the individual proteins via trans auto-phosphorylation of 
proteins as noticed in the protein tyrosine kinases [33]. 
1.2 EGF-induced human EGFR activation: basis for western blotting 
The mature human EGFR (hEGFR) is a construct of 1186 amino acid (aa) residues, 
glycosylated, and has a modular structure comprised of a ligand-binding extracellular 
domain of 621 aa residues tethered to the plasma membrane by a single transmembrane 
region of 23 hydrophobic aa residues and is attached to a cytoplasmic domain constituted 
of 542 aa residues. The latter contains a 300 aa tyrosine kinase catalytic region flanked by a 
juxtamembrane domain and a C-terminal domain [34]. The auto-phosphorylation of the C-
terminal domain tyrosine residues occurs when epidermal growth factor (EGF) binds the 
receptor [35]. Full members of the hErbB (hERBB) RTK (ErbB-RTK) subfamily are ErbB1 
(EGFR, ERBB1, HER1), ErbB2 (ERBB2, HER2), ErbB3 (ERBB3, HER3) and ErbB4 (ERBB4, HER4) 
are structurally composed of the four domains [36] and are key regulators of cell-to-cell 
inductive processes and cell fate [37]. Using specific primary antibodies and appropriate 
secondary antibodies Western blotting (WB) may be used to predict the activities of the 
 
   
 
25 
 
generated hits [38]. The procession appears thus: when Ligand binds → oligomerization 
(dimerization) occurs → auto-phosphorylation of tyrosine kinase domain ensues → 
activation of downstream signaling pathways starts → cytoskeletal and gene transcriptional 
activities follow. Figure 1 illustrates this scheme. In carcinogenesis, the pathways are over 
actively deregulated [39, 40]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. EGF-induced activation of EGFR.  
Traditionally, two EGFs bind two EGFRs in a 2EGF:2EGFR fashion through a dimerization or an 
oligomerization process to become dimers (oligomers). The phosphorylation-dephosphorylation 
reversible process in the EGFR-RTK activation that leads to EGFR accessory proteins recruitment 
usually follows this pattern. Source: Revised from Schubbert et al., 2007.   
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1.3 The role of ErbB-RTK subfamily in carcinogenesis 
Carcinogenesis defines the process in which normal cells turn into cancer cells following 
mutation [41] and epimutation [42] of the genetic material of normal cells, thereby 
upsetting the normal balance between proliferation and apoptosis [43]. For the imbalance  
to result to cancer, it may require a series of several mutations in one or more classes of the 
genes [44]. The carcinogenic role of the ErbB-RTK subfamily is well reported [45]. Each of 
the four domains in the family has a  set number of aa residues that differ from each other 
[36], thus rendering the noticeable basic structural differences among them. This is 
evidenced in their unique ligand type and other features [36]. For instance, ErbB2 does not 
have a reported ligand of its own, yet, it is the most favored in heterodimerization 
participation with other subfamily members [46]. Furthermore, ErbB3 is devoid of the 
tyrosine kinase domain but has its unique or shared ligands [47]. The ErbB1 and ErbB4 are 
structurally the closest in the subfamily, yet, individually have distinct or shared cognate 
ligands [48] (Figure 12). The ErbB-RTK subfamily is regarded as central to most epithelial and 
mesenchymal cellular processes, thus clinically accepted as a target to anticancer drug 
development [49, 50]. The subfamily is implicated in a number of non-hematopoietic 
cancers such as glioma, prostate, CRC (colorectal cancer), NSCLC (non-small cell lung 
cancer), breast, etc. [51]. A few cognate ligands of the subfamily are known to be involved 
in a number of carcinomas [52, 53]. For examples, the transforming growth factor-alpha 
(TGFα) is a known active ligand in colon cancer [54] and epidermal growth factor (EGF) in 
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lung cancer [55]. The excessive ErbB subfamily receptor signaling brings about a wide variety 
of carcinomas contained in Table 1 [52, 56]. 
 
 
 
 
 
Expression of ErbB subfamily in Carcinomas [57, 58] 
Carcinoma erbB1˄ erbB2˅ erbB3ᵐ erbB4ᵚ 
Breast 14-1%* 10-7%* p p 
Ovary 30-5%* 20-2%* p p* 
Renal 50-90% 24-40% p n 
Lung (NSCLC) 40-0%* 3-56%* p* P 
Head and Neck (SCCHN) 30-5%* 32-2%* p* P 
Table 1. ErbB-RTK receptor subfamily members in carcinomas.  
The reported carcinogenic involvement of the subfamily covers many types of human cells 
in the body. The mechanisms may be a combination of an upregulation, expression, co-
expression, overexpression or a combination of two or more of these, due often to mutation. 
Estimates are expressed in percentage and positive (p) or negative (n), meaning the member 
plays a role or not. 
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Colorectal 25-75% 7%* n n 
Pancreas 30-0%* n n P 
Glioma 40-0%* n n n 
Bladder 31-8%* 7-36% n n 
Esophagus P* 13-73% n n 
Stomach p* 5-55%* n n 
Prostate P p* p P 
Melanoma P p p P 
Thyroid P n p P 
Endometrial p* p* n n 
Skin (squamous) P n n P 
Lung (small) P n n P 
Cervical p* n n n 
Sarcomas P n n n 
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1.4 Sampled classes of Anti-ErbB - RTK based on mechanisms  
The ample presence of the subfamily members in human  tissues and organs [52, 59] makes 
it a suitable drug target in search and development of novel anticancer [60]. There are two 
well-established mechanisms upon which some anti-EGFR agents have been developed, viz, 
the receptor tyrosine kinase inhibitors (RTKIs or TKIs) [61] and monoclonal antibodies (mAbs) 
[62]. Additionally, there are search for newer mechanisms ongoing [63].  
1.4.1 Anti-heat-shock protein90s (Hsp90) 
Hsp90 are abundant proteins known for maintenance of cellular homeostasis and are 
inducible under a variety of duress [64]. These proteins normally ensure other tyrosine 
proteins fold properly, hence are called molecular chaperons and accumulation occurs when 
there are pathological conditions like cancer [65]. Most RTKs such as EGFR require 
Chronic Myelogenous 
Leukemia 
n n n P 
* Clinical studies have linked overexpression and/or mutation of the receptor to worse 
prognosis; ˄Mutation and/or overexpression; ˅Overexpression and/or upregulation (gain-
of-function); ᵐ Expression and/or co-expression with erbB2; ᵚ Expression and/or co-
expression with erbB2; p positive ; n negative; SCCHN- Squamous carcinoma cell of the 
Head and neck; NSCLC- Non-small cell lung cancer. Source: 
http://www.cellsignal.com/reference/kinase_disease.html 
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chaperons to maintain their competent activation conformation as these interact and 
stabilize kinases as well as eliminate misfolded kinases [66]. This makes the Hsp90 antitumor 
target useful for kinase-related chaperone machinery. The anti-Hsp90 agents inhibit the 
function of the protein by binding to its (the protein) unusual ADP/ATP-binding pocket [67]. 
Investigational anti-Hsp90 drugs include compounds in Figure 2. Geldanamycin, for instance, 
affects ErbB2, EGF, v-Src and Raf-1. Other compounds include cisplatin, radicol, and 
novobiocin [68].  
 
 
 
 
 
1.4.2 Dimeric compounds as anti-EGFR drugs 
Dimerization is an essential prerequisite in the ErbB – RTK subfamily signal transduction 
(Figure 9) and it is the lowest hierarchical possible and an exemplar of oligomerization 
mechanisms most studied as either a homodimer or heterodimer. The dimeric compounds 
are developed to interact with each monomer of the dimeric protein target as inhibitors for 
use as anticancer drugs [69]. It emphasizes the associations that can lead to a ‘closed 
Figure 2. Samples of anti-Hsp90 anti-EGFR compounds. 
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structure’ with its intrinsic symmetry unperturbed and therefore stable. Such dimers have 
mechanistically been successful in the development of orally active anticancer agents [70]. 
Some natural dimeric compounds with anti-proliferative activity are curcumin [71], 
artemisinin and courmemycin  [72] shown in Figure 3. 
 
 
 
 
 
 
1.4.3 Antisense drugs as anti-EGFR dimerization agents 
Antisense oligonucleotides have been investigated for therapy of various ailments such as 
cancer [73]. The group’s activity is based on genetic sequence of a particular gene known to 
be involved in the cancer type and, thus designed to bind the messenger RNA (mRNA) [74] 
produced by that gene to inactivate it, thereby turning the gene ‘off’ [75]. The search for 
such drugs that decrease the expression of EGFR while regulating the cell proliferation for 
potential anticancer therapy defines the anti-sense phenomenon [76]. Typical antisense 
oligodeoxynucleotides include GEM 231 (Figure 4), a compound with a mixed-backbone of 
Figure 3. Examples of dimeric anti-cancer drugs from natural sources. 
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an oligonucleotide structure that is said to have anti-tumor activity in vitro and in vivo 
through targeting PKA (protein kinase A) RIα-subunit [77]. It is used in the treatment of 
breast, lung, and prostate carcinomas. The expression of EGFR and type I cyclic adenosine 
monophosphate (cAMP)-dependent protein kinase (PKAI) is associated with neoplastic 
transformation that affects the receptor [78], accordingly the antisense target. 
 
 
 
1.4.4 Inhibitors of angiogenesis as anti-EGFR 
Tumor cells release specific pro-angiogenic factors such as angiogenin, vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF) and transforming growth factor-β (TGF-
β), which stimulate endothelial cell proliferation, migration, and invasion [79]. Although the 
inhibition of the VEGF pathway has been the target against its vasculogenesis and 
angiogenesis, the key role of EGFR in angiogenesis is inhibited, thus, by blocking VEGFR EGFR 
is repressed. Figure 5 exemplified angiogenesis inhibitors with anti-EGFR activity. Cetuximab 
and panitumumab are known Anti-EGFR mAbs that block VEGFR activity as well [80]. 
 
 
5'-GCG UGC CTC CTC AC U GGC-3' 
Figure 4. GEM®231. PKA Riα antisense structure. The shows the bases that 
represent the 2’-O-methyl oligonucleosides as underlined. 18-mer mixed 
backbone (RNA-DNA) phosphorothioate oligonucleotide. Source: Mani et al., 
2003. 
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1.4.5 The small-molecule receptor tyrosine kinase inhibitors (RTKIs) and monoclonal 
antibodies (mAbs) 
Small-molecule RTKIs and mAbs have been the most promising and widely used agents. 
Although all target EGFR, they have different mechanisms as the RTKIs act in the cytoplasmic 
tyrosine kinase domain while the mAbs act on the extracellular domain. The mAbs are often 
considered as first peptide anti-dimerization agents [81]. Some selected structures of RTKIs, 
lapatinib, canertinib, erlotinib, and gefitinib (section 1.4.4), [80] are shown in Figure 6. 
Among the mAbs in clinical use are cetuximab, rituximab, bevacizumab, trastuzumab, etc. 
[82]. 
Figure 5. Samples of selected angiogenesis inhibitors (curcumin emphasized). 
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1.4.6 Antibody-based immune-conjugates or antibody-drug conjugates (ADCs) 
This is a class of highly potent anticancer targeted therapeutics [83]. They are complex 
molecules made of an antibody (a whole mAb or its antibody fragment) linked through a 
stable chemical linker with labile bonds (cleavable bonds) to split at defined conditions such 
as certain enzymes or a specified pH [84], to a biologically active antitumor compound [85]. 
Examples of functional linkers in use the hydrazine bond linker, thioether bond linker, amide 
bond linker, disulfide bond linker, etc. [86]. These have been designed to improve the 
therapeutic window of chemotherapeutic agents or render the drug inactive (by acting as a 
prodrug) through altering its in vivo distribution due to conjugation with tumor-targeting 
monoclonal antibodies [83]. Trastuzumab-Emtansine (EQ75-ADR) is such an example that 
targets ErbB2 in breast cancer therapy [63]. Antibody-based immunoconjugates are largely 
investigational agents. Figure 7 shows a few examples. 
 
Figure 6. Structures of selected RTKIs in clinical application. 
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1.4.7 Anti-EGFR anti-dimerization agents 
Since members of the ErbB - RTK subfamily control vital signaling processes once activated 
by canonical ligands to cause oligomerization sequential to the catalytic activation of the 
intracellular kinase domains on recruitment of accessory proteins (Figure 1), it is logical to 
devise anti-dimerization agents that prevent dimerization from occurring even if the ligands 
are in place, on grounds of therapy. The use of small molecules as anti-dimerization (anti-
oligomerization) agents remains yet to be fully exploited, thus only a few small molecules 
claim success against cancer [87] and another against psoriasis [88]. Figure 8 shows the 
structures of the two compounds tagged P and Y.  
 
Figure 7. Samples of antibody-based immunoconjugates with their linkers. 
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1.5 Dimerization: a prerequisite for protein posttranslational modifications 
One of the posttranslational modifications (PTMs) in EGFR - RTKs is the reversible 
phosphorylation-dephosphoryaltion event in the cytoplasmic kinase domain. PTMs are the 
most ubiquitous natural protein-protein interactions in biological systems [89]. The key roles 
of the protein kinases in these cellular activities are exploited for drug targets [90]. Protein 
kinases transfer a phosphate, generally from ATP, which is reversed by the phosphatases 
under regulation, resulting in a fragile but sensitive equilibrium of phosphorylation-
dephosphorylation process. Perturbation of this fragility can cause defects in key cellular 
functions. Some specific roles controlled by dimerization in protein-protein interactions 
generally (as shown in Figure 9) include facilitation of proximity and orientation in protein 
interactions [91], sets differential regulation for heterodimerization process [92], specifically 
regulates EGF-EGFR shed off [93], enhances specific protein-protein interaction [94], 
generates temporal and spatial boundaries [95] and regulates monomer to dimer transition 
[96]. These roles increase in complexity in oligomerization [97].  
Figure 8. Two typical potentially active anti-ErbB anti-dimeric small molecules.  
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1.5.1 The mechanisms of dimerization in EGFR 
The relevance of dimerization (oligomerization) is aforementioned.  Several families of 
growth factors induce dimerization by their oligomeric disposition, e.g. platelet-derived 
growth factor (PDGF) while monomeric growth factors like EGF contain two binding sites for 
their receptors hence can cross-link two neighboring ErbB subfamily members [98]. The 
binding to the two receptors is simultaneous across a dimer interface, requiring additional 
stabilizing interactions between the monomer receptor molecules themselves. EGF, a 
protein consisting of  53 amino acid residues, has shown it can singly bind simultaneously 
two receptor molecules to appear like 2[EGFR] plus [EGF], described as a 2:1 fashion, to 
Figure 9. Some general 
regulatory roles of 
dimerization. Most 
biological systems show 
dimerization as 
exemplified by EGFR.  
Dimerization 
Facilitates 
proximity & 
orientation
Regulates 
EGF-EGFR 
shed off
Enhances 
specificity
Regulates 
monomer-
to-dimer 
transition
Generates 
temporal & 
spatial 
boundaries
Increases 
protein-
protein 
complexity
Sets 
differential 
regulation by 
hetero-
dimerization
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effect dimerization of the extracellular domain of the EGFR [99, 100]. However, the more 
detailed fashion that has received global attention in a similar stoichiometric manner is 
2[EGFR:EGF] or 2[EGFR] plus 2[EGF], that is, a 2:2 fashion [98, 101]. A number of models 
exists that attempt to explain the dynamic mechanisms of dimerization, most of which are 
based on some assumptions to arrive at a parametric conclusion [102]. One such is based 
on the 3D structures of the extracellular ligand binding domains of the EGFR and proposed 
as a mathematical model for the receptor-induced or ligand-induced dimerization and 
activation of ErbB3 [103], which is grouped as the receptor-mediated dimerization (RMD) 
[104] and ligand-mediated dimerization (LMD) [105, 106]. Ligand binding with the receptor 
is said to be a ligand-induced monomer-dimer transition [107] or ligand-induced 
conformational change with pre-formed dimers [102, 108]. In the case of the EGF-EGFR 
interaction, one method is the intramolecular mechanism, whence the EGF has induced a 
conformational change in the extracellular region that is transmitted via the transmembrane 
helix to activate the tyrosine kinase in a cis conformation, which mediates the 
autophosphorylation in the cytoplasmic region on multiple tyrosine residues [109]. The 
other is the intermolecular mechanism where information is transferred from the 
extracellular region to the cytoplasmic region because there is a lateral contact between the 
two receptors initiated by the ligand for dimerization to occur [110]. While the role of the 
ErbB4 may be unclear in oncogenesis those of EGFR, ERBB2 and ERBB3 are all implicated in 
the development and progression of cancer, and heterodimerization of the receptors plays 
a crucial part in their function [111]. Dimerization of the EGFR remains complex, therefore, 
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the need of models that offers closest explanation is required. Figure  10 is based on the 
LMD and RMD [112, 113]. 
 
 
 
 
 
 
 
 
 
 
1.5.2 The key aa residues involved in the dimerization of EGFR 
EGFR suits structure-based drug design (SBDD) for its current information [114, 115]. The 
extracellular structure of the dimerized EGFR was elucidated in 2002 [101] using x-ray 
crystallography and identified as PDB ID: 1IVO in the RCSB Protein Data Bank [46, 101]. The 
Figure 10. RMD and LMD model topologies. RMD occurs through direct extracellular 
receptor–receptor interactions that are stabilized by the binding of monovalent ligand to 
receptors. LMD occurs through indirect receptor–receptor interactions facilitated by an 
interposed bivalent ligand, around which the receptors dimerize. In both cases, receptor 
dimerization promotes phosphorylation (P) of a representative tyrosine (Y) present in the 
cytoplasmic tail of the receptor. Where K
L, f 
= Ligand association, K
L, r
 = Ligand dissociation, 
Kd,f = Receptor coupling, Kd.,r  = Receptor uncoupling, Kcat = phosphorylation and Kdp = 
Dephosphorylation. Revised source:  Monast et al. (2014). 
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four domains (I - IV) in the extracellular region of the dimer surface are mostly affiliated with 
domain II where a beta-hairpin arm of aa residues PRO242-GLY259 in this domain are said 
to be essential to maintaining the oligomeric structure [116]. This group of aa residues at 
the tip overlay ASN86, PHE230, PHE263, GLY264, ALA265, TYR275, THR278, CYS283, 
ARG285, and ALA286 set of aa residues in the cleft [116] through hydrophobic bonds (HYs) 
formation. The tip and cleft aa residues interact in such a predictive manner to form the HYs 
hexagonally sketched through the aa residues highlighted in Figure 11 (section 2.1). This β-
hairpin loop structure is canonized as the ‘dimerization) arm’, and referred to as the 
‘dimerization or oligomerization region’ for a dimer or an oligomer. However, the 
‘oligomerization region’ is defined here as the region that embraces the binding aa residues 
in the backbone chain & side chain of the tip and the cleft of the oligomer. This is a feature 
that exists in all the subfamily members to enable formation of homodimers or homo-
oligomers [92] & heterodimers or hetero-oligomers [117], particularly, as tetramers [118]. 
The key functions of the ‘oligomerization arm’ are to hold together the dimerizing 
(oligomerizing) receptors and thus, provide a sequential peptide framework for subsequent 
biological functions. 
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The active participation of some of the ligands in realizing dimerization and carcinogenesis 
is already mentioned (section 1.3). Each cognate ligand plays a unique role in the 
dimerization of their canonical receptors. Thus,  ligands are classified as mono -, bi - and tri 
– specific, exemplified by EGF, BTC, NRG2β, respectively, for HER1, HER1 & HER4, HER1, 
Figure 11. EGFR model of the ‘oligomerization region’ showing the aa residues.  
The aa residues at the tip ‘monomeric arm’ (the left scroll) overlay or are linked to those below 
in the cleft (right scroll) by the HYs (represented in hexagonal shapes). The eight key aa 
residues at the tip of the ‘dimerization arm’ involved in binding those in the cleft of another 
EGFR during dimerization (oligomerization) are shown in yellow colour [A] while [B] describes 
the side chain aa  residues in the ‘monomeric arm region’. It is important to recognize that 
each monomer has its own [A] and [B]. Modified source: Ferguson et al., 2008. 
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HER3 & HER4, in that order [116], since members in the subfamily share one or more ligands  
[119, 120] as shown in Figure 12 that is responsible for inducing the formation of their 
homodimers, heterodimers or their higher oligomers [121]. However, this excludes the 
ErbB2 (HER2) for lack of a definite ligand despite its dominant participation in formation of 
hetero-oligomers with others in the group [122]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Model of the canonical ligands of the ErbB - RTK subfamily.  The canonical ligands 
are unique to or shared among some of the receptors HER1, HER2, HER3 and HER4. The blue 
color square with BTC, HB-EGF and ER are ligands shared by HER1 & HER4, red color square 
containing NRG1α, NRG1β and NRG2α are ligands shared by HER3 & HER4 and cyclic tan 
color containing NRG2β is a ligand shared by HER1, HER3 & HER4. HER2 has no 
representative ligand. Oligomerization results from these interactions. 
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1.5.3 Dimerization is becoming insufficient to explain EGFR activation  
EGFR is beheld as a critical super-node in cellular signaling pathway mechanisms pathways 
[123, 124] (sections 1.2 & 1.3). The oligomerization process includes forming higher 
numbers of monomers than just the traditional two [125, 126] . It is now clearer that the 
ErbB-RTK subfamily members  activate each other through forming tetrameric molecules 
such as heterotetramers [127] and homotetramers [128], although EGFR trimers have been 
reported as well [121]. Schlessinger and coworkers in 1976, however, initiated a 
transforming perspective from the traditional dimerization mechanisms when they used 
fluorescence microscopic studies to achieve direct visualization of ErbB binding, aggregation 
and internalization of EGF on living fibroblast cells when suitable fluorescent derivatives of 
EGFR ligands and antagonists were developed [129]. This is the classic work that connected 
EGFR oligomerization, mobility, and internalization [130]. Further structural details were 
obtained when fluorescence microscopy and Förster Resonance Energy Transfer (FRET) 
were combined to elucidate the architectural and clustering of the subfamily RTKs [131]. For 
instance, an evidence that EGFR activation may not just occur within an EGFR dimer but 
depends also on interactions among EGFR dimers, a type of secondary dimerization, which 
is claimed to be modulated by multiple ligands and / or crosstalk with other receptors, which 
then propagates their activation [132, 133]. Thus, the principle of tetramerization is through 
transmodulation or transactivation of the heterodimers or homodimers [37]. Formation of 
higher oligomers (larger than dimers) is recognized among subfamily members, as shown 
for EGFR [106] with ErbB2 [134] and ErbB3 [135] in Figure 13  (section 1.5.3). However, 
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EGFR/ErbB2 and ErbB2/ErbB3 oligomers were proposed [136]. EGFR multimerization has 
been reported to be an important feature in regulation of its activities [137].The unresolved 
EGF-binding heterogeneity structurally displayed by the EGFR on the surface of cell lines 
shown on Scatchard plots depict negative binding cooperativity that is said to be  linked 
primarily to high-affinity receptors involved in the mitogenic signaling process [132], which 
indicates a defense to oligomerization process. Queries such as ‘are we missing a trick in 
cancer therapy’ [138] or ‘finding the missing links in EGFR’ [139] can be answered on the 
basis that oligomerization, and not dimerization, mechanisms generate the EGFR-activated 
signals [140, 141].Furthermore, microscopic, image correlation spectroscopy and 
phosphorylation (western blots) using a model of mass-action chemical kinetics have been 
used to define the higher-order ligand-induced receptor-mediated EGFR oligomerization or 
clustering and its influence on signaling outputs, which proved to be distinct from EGFR 
dimers  [142]. The ongoing investigations on tetrameric structures of the ErbB subfamily 
members [136] (depicted in Figure 13) using modified forms of FRET and microscopic 
imaging such as cited [34, 143, 144] makes the object of our study relevant.   
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1.6 Aims/Objectives 
EGFR activates its signal transduction through hetero-tetramer structures (Section 1.5.3). 
Trial and proven anti-EGFR approaches discussed in section 1.4 are summarized in Figure 14 
to illustrate fundamental mechanisms that bring about the anti-EGFR. Other specific 
examples are combinations of mAbs [49] and RTKIs / mAbs [145], decoy receptors [146], 
DNA aptamers [147] and anti-ATP binding sites [148] agents. The circles overlap to indicate 
anti-EGFR activity, howbeit, from   dissimilar mechanisms. Our focus area is arrowed. 
Figure 13. ErbB-RTK activates its members by hetero-tetramerization. B
1
: EGFR, B
2
: ErbB2, B
3
: 
ErbB3; solid arrows (black color) = auto-phosphorylation (aY) between homodimerized moieties; 
solid arrow (blue color) = unidirectional transphosphorylation of B
3
 by B
1
 since B
3
 is devoid of 
tyrosine kinase domain; broken arrows (red color) = potential transphosphorylation (tY) between 
two EGFRs, two ErbB2s, i.e., between heterodimers where tyrosine kinase domain exists. (i) EGF-
induced EGFR homodimer 2[B
1
] and two molecules of [B
2
] to form a heterotetramer complex. 
The two B
2
 molecules dimerize through binding to an activated B
1
 dimer. Arrows mark aY between 
B
1
 / B
1
 and B
2
 / B
2
 & tY between B
1
 / B
2
 and B
2
 / B
1
. Note that no ligand is indicated for B2 and the 
purple color single bond shows it has been activated by homodimer 2[B1]. This is expected to be 
similar in B
2
 & ErbB4 heterotetramer formation. (ii) EGF-induced EGFR homodimer 2[B
1
] and a 
NRG-induced 2[B
3
] homodimer to form the heterotetramer complex. Arrows mark aY between B
1
 
/ B
1
 only & tY of B
3
 by B
1
. This is expected to be similar when B
3
 & ErbB4 form a heterotetramer. 
Source: modified from Schlessinger, 2000. 
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The aims/objectives of this piece of work are: 
a. To design novel small molecules that inhibits the oligomer formation in EGFR by targeting 
the monomeric arm in the ‘oligomerization region’ as defined. 
Figure 14. Aims/objectives defined based on Anti-EGFR mechanism.  
These entire agents share in interfering with EGFR dimerization subsequently, 
however, through different mechanisms. For instance, the mAbs act at the 
extracellular domain but the RTKIs in the cytoplasmic domain, inhibiting the EGFR 
activity subsequently. The ‘Focus area’ points to our aims/objectives as we design, 
bioevaluation, and synthesis small molecules that target the ‘oligomerization region’ 
of EGFR to be novel anticancer agents on successful development.    
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b. To bioevaluate the hit (s) in an in vitro bioanalysis using colorimetric and western blotting 
in order to investigate the hit (s) influence on the i) EGF-induced pY-Akt activation, ii) EGF-
induced pY-ERK1 and 2, and ii) EGF-induced pY-EGFR. 
c. To optimize successful lead (s) as well as generate a library (or libraries) of potentially 
active compounds using the v3.9CombiGlide for further bioanalysis rounds. 
d. To synthesize and / or design synthetic methods of individual and / or groups of 
compounds with clear potential anti-EGFR anti-oligomeric activities.  
1.7 The approach to achieve the aims / objectives 
Programs of the Schrödinger Release 2015-4 shall be used throughout the drug design 
procedures. Schrödinger is a leading provider of advanced molecular simulations and 
enterprise software solutions and services for life sciences and materials research [149]. Two 
EGFR 3D crystals of different domains - Crystal structure of the complex of human epidermal 
growth factor and receptor extracellular domains (ectodomain), 1IVO (PDB ID 1IVO)  [101]  
and Crystal structure of EGFR kinase domain in complex with AEE788, 2J6M (PDB ID 2J6M) 
(endodomain) [150] shall be imported from the RCSB Protein Data Bank and prepared. Grids 
of these crystals shall be generated and subsequently docked with 3D ligands sourced from 
Chemical Data Banks. The emerged ‘hits’ would be purchased and / or synthesized for 
bioevaluation. The lead candidate (s) will be optimized using the v3.9CombiGlide tool to 
generate a biased library (or libraries) of anti-EGFR anti-oligomeric compounds for bioassays. 
Synthesis shall apply to compounds of ‘best’ GlideScores (Gscores) not purchasable or 
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synthesizable. All synthesized compounds shall be bioevaluated and optimized again as lead 
candidates. The cycle of design, bioevaluation, and synthesis of lead candidates may 
continue, varying the physicochemical properties to obtain potentially more active anti-
oligomeric compounds preparatory for drug development (Figures 28 & 45). Figure 15 
shows the reductionist bow-tie model that attempts to simplify the complexity of the EGFR 
influence on biological systems. The input of a growth factor that functions through the 
EGFR receptor to achieve hetero- or homodimers activates common signaling cascades that 
are defined through a core collection process of biochemical interactions which are tightly 
coupled to each other and interfaced by the oligomerized EGFR, i.e., dimers such as 
2[EGF:EGFR] or tetramers represented as |2[EGF:EGFR]:2[ErbB2.ErbB2]| [151] (Figure 13). 
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Figure 15. The bow-tie model simplifies the 2[EGF:EGFR] network.  
The model is modified to show the dimer axis or symmetry of the EGFR crystal (1IVO), the 
appearance of the overlapping aa residues shown in the space-filled crystal, its β-hair loop, and 
a possible show of the aa residues in the cleft and at the tip. The output of the core process 
following gene transcription is shown in cell proliferation, survival, etc. as inscribed. Source: Citri 
and Yarden, 2006; Ogiso et al., 2002; Ferguson et al., 2000 & 2008. 
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Chapter Two  
Molecular docking, scoring, and modeling 
 
 
 
 
 
 
 
 
Figure 16. Full and partial representations of the EGFR crystal (1IVO).  
Top left is the 1IVO, in ribbon of a 2[EGF:EGFR] dimeric ectodomain structure without 
protein backbone chain; top right is the monomeric arm without the protein 
backbone; bottom left shows the interface of the two dimeric (oligomeric) arm 
region and their prominent interacting aa residues TYR251, ASP279,HIS280, and 
ARG285, and bottom right is the dimeric (oligomeric) arm showing most of the 
protein backbone chain residues and a few of the aa residues in the cleft are also 
noticeable, e.g., ASN86, PHE230, PHE263, TYR275, CYS283, ALA286, etc.  
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2.0 Introduction 
Computer-aided drug design (CADD) is a rational technique [152] in search of novel 
biomolecular sites using known ligands or termed ligand-based drug design (LBDD) [153], 
or search for novel ligands using known biomolecular sites or termed structure-based drug 
design (SBDD) [154], although the duo can complement each other in drug discovery 
development [155, 156]. LBDD depends on the knowledge of the 3D ligand and SBDD relies 
on the information of the 3D target molecular structure. The design of small molecules 
that target the ‘oligomerization region’ of the EGFR is a SBDD style that envelops molecular 
docking, structure-based virtual screening, and molecular dynamics methods [157]. The 
use of molecular docking and scoring (in silico screening) and modeling methods has 
enhanced search for new therapeutic drugs [158] for its relative cheapness , fastness, and 
information-driven [159]. Some EGFR details are shown in Figure 16 and explained in 
section 2.1. The crystal structures of EGFR PDBID1IVO (Figure 17) and PDBID2J6M (Figure 
18) were obtained from the RCSB PDB. 
 
 
  
 
 
Figure 17. Ribbon structure of 
1IVO crystal. 
The oligomerization region is 
enclosed in the red ring and the 
target aa residues in yellow cubes. 
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The 2J6M crystal prior to preparation showed it had several interactions  involving water bridges, 
π-cation contacts between LYS754, H-bond (Hb) with MET793 carbonyl oxygen on the main side 
chain and another Hb from MET793 amino group to the the  nitrogen on the pyrimidine moiety. 
The H-bonds (Hbs) and HYs are shown in Figures 19.  
 
 
 
 
 
 
Figure 18. Ribbon structure of 2J6M 
crystal. 
The cytoplasmic kinase site in complex 
with the RTKI, AEE788 in green ball & 
stick shown. 
Figure 19. 2J6M crystal interfaced with Hbs and HYs in dotted yellow line. 
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2.1 Targeting the ‘oligomerization region’ of the EGFR-RTK 
Section 1.5.2 has defined the oligomerization region. The protein  backbone is absolutely 
necessary in anchoring and aligning the frontline aa residues to form the HYs and Hbs that 
effect oligomerization on binding with native ligands [160]. The ligand that binds induces 
a monomer–oligomer transition from an untethered  monomeric receptor on  exposure of 
a dimerization arm which partners with another induced receptor to cause their 
oligomerization, kinase activation and signaling [141]. The repositioned allosteric EGFR 
enhances the activity of the so-called eight key aa residues in the tip monomeric arm (T for 
‘at the tip or top’) that associated with the second or underlying monomeric arm (B for 
‘below or in the receptor cleft’) (Figure 11). This is described as:  
a) TYR246, PRO248 and TYR251 [T] form hydrophobic bond (HY) with PHE230, PHE263, 
ALA265, TYR275, and ARG285 [B] in the cleft  
b) PRO248 [T] forms selectively HY with PHE230 and ALA265 [B] 
c) TYR246 side chain oxygen atom [T] forms Hb with CYS283 carbonyl oxygen and GLY264 
nitrogen [B] in the cleft 
  d) THR249 [T] forms Hb with ASN86 in domain 1 
e) TYR251 [T] oxygen on side chain forms Hb ARG285 nitrogen atom on side chain as well 
as HY with PHE263, GLY264 and TYR275 [B] in the cleft 
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f) GLN252 [T] amide main side chain forms Hb with ALA286 [B] carbonyl oxygen in the cleft 
and  
g) MET253 [T] forms HY with THR278 [B] in the cleft [101, 161] (Figures 20 & 21).)  
The interception prior to the dimerization is what we seek to achieve since interfering with 
any or all of these hydrophobic - bond & H – bonding - forming aa residues (Figure 22) 
imperils native processes. Our grids were generated based on this knowledge. 
2.1.1 Descriptions of the 1IVO for grid design before and after. 
Figure 20 shows the [T] and [B] aa residues on a monomeric arm with the line of symmetry 
between them. The purpose would be to examine the ligand impact on the [T] aa residues, 
the [B] aa residues, combinations of [T] and [B] aa residues, and some of the side chain and 
backbone aa residues (some observations not reported) associated with the anti-
dimerization process [87]. Figure 21 shows that all the aa residues on [T] and [B] are located 
on each monomeric arm but must require another of its kind to dimerize.  Figure 22 shows 
the hydrophobic / hydrophilic surface map on the [T] and in [B] of the receptor. 
It is necessary to note that [T] from Chain A or B overlaps [B] only on its Chain B or A 
accordingly [99, 101, 161].  
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Figure 20. The 8 [T] and 10 [B] key aa residues in 1IVO.  
[T] & [B] responsible for the oligomerization highlighted in green are shown cropped for |A| 
& |B|. |A| is symmetrical to |B| as delineated and parted by the symmetric line. ASN86 
(shown) is in domain 1, thus way out of the apparently clustered residues. 
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Figure 21. The oligomerization 
residues on a monomeric arm of 
1IVO. The monomeric arm (in red 
ring) [T] (aa residues in ball & stick) 
overlays [B] (aa residues in white 
rectangle) of 2nd monomeric arm 
during oligomerization process. Note 
the cleft & ASN86 (in white). 
Figure 22. Hydrophobic / 
hydrophilic surface map of 1IVO. 
 The symmetric structure of 1IVO 
showing the hydrophobic / 
hydrophilic surface map within 5Å. 
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2.2 Modifications on the imported 1IVO and 2J6M crystals from the RCSB PDB  
The 2[EGFR:EGF] dimer crystal structure, 1IVO (extracellular domain), and AEE788:EGFR 
(cytoplasmic tyrosine kinase domain),  2J6M, were individually imported from the RCSB 
PDB (Research Collaboratory Structural Bioinformatics Protein Data Bank) and prepared 
with the Protein Preparation Wizard (ppw) with v3.4Epik, v4.2Prime and v6.9Impact 
(Schrödinger, LLC, New York, NY, 2015-4). The workspace structure was preprocessed to 
achieve the removal of water molecules of crystallization and other non-essential waters, 
the addition of hydrogen atoms, creation of disulfide bonds and filling of missing side 
chains and loops. Following the analysis of the workspace, hets such as N-acetyl-D-
glucosamine (NAG) ligands were removed within 5Å by default during proton and metal 
charge generation. Optimization of the proteins for Hb, ASN, GLN and HIS states were 
achieved automatically using the Epik during protein preparation, which assigned the 
protein orientations for the minimization to follow for unrestrained frozen heavy atoms. 
The program was run at pH 7.0 ± 3, convergence RMSD of 0.30Å and Force Field 
OPLS_2005, all at default values [162].  
2.2.1 2j6M crystal after protein preparation  
The RTKI (AEE788) is now removed for a new ligand occupation (Figure 23). 
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2.2.2 1IVO after protein preparation 
  
 
 
 
 
 
 
 
 
 
 
Figure 23. 2J6M grid with ligand 
AEE removed. The cropped area 
would be occupied by a new 
ligand (cf. Figure 16). 
Figure 25. A prepared monomeric 1IVO 
crystal for grid generation. 
  A monomeric structure of 1IVO & its 
monomeric arm in the yellow ring.  The side 
chain aa residues are removed for clarity.  
Figure 24. A prepared dimeric 1IVO crystal 
for grid generation.  A dimeric structure of 
1IVO and its dimers in place. The side chain 
aa residues are removed for clarity, set for 
grid generation. 
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2.3 Grid generation from the prepared 1IVO and 2J6M crystals 
2.3.1 2J6M Grid 
The grid of the 2J6M was generated using v6.9Glide (Schrödinger, LLC, New York, NY, 2015-
4). The ligand AEE788 was picked to define the grid box (Figure 26). 
 
 
 
 
 
 
 
2.3.2 The generated grids from 1IVO 
2J6M helped to furnish us with helpful information about our focused receptor, 1IVO. 
Unlike 2J6M, several grids were generated from the 1IVO crystal for docking, as either 
probes and / or attempts to improve on the Gscores. The grids generated for docking were 
not only from the essential aa residues directly involved in the HY during oligomerization 
of EGFR but the grids extended to a combination of side chain and backbone aa residues. 
Among the grids generated were a) |246-253|S or W, comprising amino acid residues 
Figure 26. 2J6M grid at 10Å view. 
Grid generation removed AEE788. 
The green cube shows the 
molecular center of the incoming 
ligand while the purple envelopes 
the entire structure of the ligand.  
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TYR246, ASN247, PRO248, THR249, THR250, TYR251, GLN252 & MET253 [88], b) |TYR246 
TYR251|S, c) |TYR 246 MET253|S, d) |ASN86 PHE230 PHE263 GLY264 ALA265 TYR275 
THR278 CYS283 ARG285  ALA286|S or W and e) |TYR246 PHE230 TYR275  ALA286|W and 
f) |200-300|W, i.e., (ARG200, GLY201, LYS202, SER203, PRO204, ASP206, CSY207, CYS208, 
HIS209, ASN210…ASP290, SER291, TYR292, GLU293, MET294, GLU295, GLU296, ASP297, 
GLY298, VAL299 & ARG300) (Figure 11). Grids from aa residues of the ‘monomeric arm’ 
are tagged S (for single or one arm), dimeric region are described as W (for whole or 
complete dimer). Grids of W emphasized the symmetry of the dimer [163] (Figures 20 & 
22). Grid 1IVO |246-253|S remained the most biased throughout the experiment unless 
stated otherwise. The numbers within the two vertical lines reflect the aa residues used to 
define the centroid of the grid which defines that of the docked ligand. 
2.3.3 Similes of some generated 1IVO grids   
The grids generated aimed at obtaining ‘best’ Gscores as well as for investigation. Figures 
27A-27E show some of these grids ably used throughout the search for anti-oligomeric 
novel compounds against cancer. However, docked grids with very poor Gscores are not 
reflected in this report. 
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Figure 27A. 1IVO grid |246-253|S. 
Grid of the single arm of the 1IVO 
crystal. The green cube defines the 
centroid of any docked ligand while the 
purple box (10Å) its entire structure. 
 
Figure 27B. 1IVO grid |246-
253|W. 
A dimeric grid of 1IVO crystal. 
The green cube describes the 
molecular center of any docked 
ligand while the purple box (10Å) 
encloses its entire structure.  
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Figure 27C. 1IVO grid |86 230 263 264 
265 275 278 283 285 286|S. 
1IVO monomeric arm grid of the key aa 
residues in the cleft. The green cube 
articulates the molecular center of any 
docked ligand while the purple box 
(10Å) encloses its entire structure. 
 
Figure 27D. 1IVO grid |86 230 263 264 265 275 278 283 285 286|W. A dimeric grid from 
two different aa residues of two clefts. The green cube contains the molecular center of any 
docked ligand while the purple box (10Å) encloses its entire structure. 
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2.4 The ligand sources and preparation  
The chemical databases we obtained our ligands and their figures in brackets in ready-to-
dock format (3D) were ZINC (www.zinc.docking.org) [4,439,415], Ambinter 
(www.ambinter.com) [5,053,503], SPECS (www.specs.net) [25,030], Cayman 
(www.caymanchem.com) 4,376], ChEBL (www.ebi.ac.uk) [34,383], Chembridge 
(www.chembridge.com) [24,971]   and Mcule (https:/mcule.com) [5,000] [164]. Thirty one 
(31) known RTKI ligands  were also constructed using v10.4Maestro GUI (graphic user 
interphase) which effected a 2D to 3D format atructures and minimized with v3.6LigPrep 
(Schrödinger, LLC, New York, NY, 2015-4). A total of >9 x 106 compounds were imported 
and docked, however, only a significantly low figure had an average of ≥ - 5.0 Gscores . 
Figure 28 shows a description of the role docking process plays in drug discovery and 
Figure 27E. 1IVO grid |200-300|W. 
A complete or whole aa residues 200 – 300 that included residues from both side 
and backbone chains. The green X, Y & Z are coordinates that define the molecular 
center of any docked ligand while the purple box (10Å) encloses its entire structure. 
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development [165]. Tables 4, 5, 6 & 13 and 8, 9, 10 & 12 show the top 20 ligands of docked 
1IVO and 2J6M, respectively, with respective ligands. Table 13 gives examples of the RTKIs, 
curcumin, P and Y compounds docked into 1IVO |246-253|S showing their Gscores. 
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Figure 28. Drug design itinerary model Glide-based. 
1IVO and 2J6M grids were ligand-docked on premeditation. 1IVO grids used often were 
|246-253|S, |246-253|W, |86,230,263,264,265,275,278,283,285,286|W, and |200-
300|W. Total number of hits 124: 86 from Ambinter and 7 from Cayman chemical 
databases and 31 built ligands (RTKIs, curcumin, P and Y) docked into 1IVO |246-253|S, 
whose results alone are shown here. The number of ligands used from each source are 
shown. The 2J6M docked results with the built RTKIs and chemical databases are not 
reflected in the Table but are found in Section 2.5.3. In addition to considering Lipinski‘s 
“Rule of Five” (Ro5) filter Lipinski-like filters were theoretically instrumental in the 
hierarchical Glide screening of the ligands Table 2). While Table 3 contains DPT1 1, DPT2 
2, DPT3 3, DPT4 4, DPT5 5 & DPT6 6 as ligands that emerged as hit leads, Tables 6 & 10 
show that the basis of DPT1 1, DPT2 2, DPT3 3 & DPT4 4 selection was in their potential 
inhibition at the ectodomain (1IVO) and endodomain (2J6M) regions represented by 
these crystals, and not necessarily on Gscores. DPT5 5 & DPT6 6 are hit leads from 2J6M-
ZINC docked ligands, and thus RTKI-like in activity. Enumeration and docking of core leads 
was achieved with 3.9CombiGlide in order to generate potentially more active anti-EGFR 
anti-oligomeric agents. CombiGlide offers a continuous method of generating more 
potentially active compounds for designed libraries of anti-oligomeric discovery and 
development. Modified from: Hughes et al., 2011 & Kalyaanamoorthy and Chen, 2011.  
Yi-Ping Phoebe Chen 
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2.4.1 Modeling and selection of the ‘best hit leads’   
We saw it important to test-run our generated grid (s) from 1IVO with known compounds 
such as the RTKIs, cucurmin, P and Y (already described) in addition to the ligands from the 
chemical data bases, despite known and unknown mechanism differences. Docking of 
these compounds into 2J6M revealed their possible activities in the endodomain or 
cytoplasmic region.  Since v6.9Glide allows the choice of filters during the docking process, 
the Lipinski’s “Rule of Five” (Ro5), alongside other Lipinski-like filters have been considered 
(as Ro5 fails to predict pharmacological properties of an active compound that leads to 
drugs with higher MW, more rings, more rotatable bonds, and higher lipophilicity, 
following its molecular structural modification) were applied. The refining of Ro5 had led 
to development of more empirical rules that almost itemized the biological and 
physicochemical properties any potential active drug should feature. Among such are  
Bioavailability filters (BF) [166], Ghose filters (GF) [167], Lead-likeness filters (LLF) [168] , 
Muegge filters (MF) [169], and Veber filters (VF) [170]. Table 2 shows the Lipinski-like filters 
and their key features. The potential activities of of the ‘hit-to-lead-candidates’ were based 
on the MTS cytotoxicity assay and western blotting, however, the rules assist extra guide.  
 
 
 
 
 
Table 2. The Lipinski’ Ro5 and other Lipinski-like filters. 
In addition to the Ro5, there other empirical rules that predict  absorption (A), 
distribution (D), metabolism (M), excretion (E), and toxicity level (T) (ADMET)  of 
potentially active agents and their main features in drug discovery and development, 
which been described here.  
Source modified from Bose et al., 2012.  
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SASA (MSA): solvent-accessible surface area or molecular surface area, PSA: polar surface area; other 
abbreviations have been suggested for space and use only) 
 
2.4.2 Importance of the Glide-guided R-L bonding  
Glide (grid-based ligand docking with energetics) is designed to perform an in-depth search 
for the positional, orientational, and conformational space available to the ligand as 
practicable as possible while considering enough computational speed to screen large 
libraries, [162], however, this was querried during this modeling process. This is 
accomplished via the use of a series of hierarchical filters (section 2.4.1, Table 2). Glide has 
three operational stages in the whole docking process: the high-throughput virtual 
screening (HTVS) wherein all compounds are screened rapidly with both ligand and 
Lipinski-like filters Lipinski’s 
rule (Ro5) 
Bioavailability 
filters 
(BF) 
Ghose filter 
(GF) 
Lead 
likeness 
(LLF) 
Muegge 
filter (MF) 
Veber 
filter 
(VF) 
Mass (MW) ≤500 ≤500 ≥160≤480 ≥450 ≥200≤600 - 
logP ≤5 ≤5 ≥0.4≤5.6 ≥7.4≤30 ≥-2≤5 - 
Hb donor (HBD) ≤5 ≤5 - ≤5 ≤5 - 
Hb acceptor (HBA) ≤10 ≤10 - ≤10 ≤10 - 
Rotatable count 
(RotC) 
- - - ≤10 ≤15 ≤10 
PSA - - - - ≤150 ≤140 
MSA (SASA) - ≥200≤800 - - - - 
Fused ring count 
(FRC) 
- ≥5≤6 - - - - 
Atom count (AC) - - ≥20≤70 - ≥5 - 
Refractivity (R) - - ≥40≤130 - - - 
logD - - - ≥-4≤4 - - 
Ring count (RC) - - - ≤4 ≤7 - 
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receptor being held rigid. The next stage is the Standard Precision (SP) which allows the 
flexibility of the ligand alone, and Extra Precision (XP) is only for the best scoring states. A 
pose was saved per ligand in 1000 poses  permitted to pass to the in situ energy 
minimization (within the active site). Docking accuracy was assessed by redocking ligands 
from 150 – 300 cocrystallized PDB complexes starting from conformationally optimized 
ligand geometries that bear no memory of the correctly docked pose. A notable feature in 
compounds is their ability to display their rotamers, which are form a number of isomers 
of a molecule that can be interconverted by rotation of part of the molecule about a 
particular bond, can influence docking values as well. Geometrical errors are reportedly 
less than 1 Å for the top-ranked pose in nearly half of the cases and are greater than 2 Å in 
only about one-third of them [171]. For this reason drug modeling using Glide is currently 
ranked better among similar techniques [172, 173]. The flexible docking method was 
preferred to rigid or none (refinely only) or none (score in place only). Glide primary scoring 
function is Gscore (abbreviated as Gscore) or  docking scores (abbreviated as DScores). All 
predicted binding affinities were within the default root mean square deviation (rmsd) of 
0.3 kcal/mol. Although the Gscores should be identical to the DScore, a slight discrepancy 
was observed when 2J6M was docked with ZINC (Table 9). The docked outcomes were 
encouraging. Figure 29 illustrates the key functions in the Glide docking hierarchical 
pattern.  
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2.4.3 The ‘hit leads’ in the light of the Glide parameters  
Gscore is used to predict binding affinity and rank-ordering ligands in database screens, 
and in conjunction with the ligand - receptor molecular mechanics interaction energy and 
the docked ligand strain energy [162], the correct ligand pose (relative orientation) can be 
selected. However, Friesner and coworkers observed that Emodel (glide energy model or 
model energy, ME), which is the composite scoring function in Glide, is much better at 
selecting the correct pose than is either the molecular mechanics energy or Gscore alone. 
This supports our choice of ME for our comparison of data in Canvas or Script analysis from 
the Project Table. Glide is designed to offer an effective high-throughput virtual screening 
of potential ligands based on the mode of binding affinity for a given receptor 
Figure 29. The Glide docking hierarchy. 
Stage 1 defines the HTVS, Stages 2a – 2d 
define the SP and Stage 3 defines the XP. It 
is notable to know that each stage has its 
scores, the poorest occurring at the HTVS 
when grid conformers have maximum 
energy. Basic source Friesner et al., 2004 
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macromolecule. It allows studies and comparisons of scores and geometries of both test 
and reference ligands (where the two exist), as well as generates conformers that produce 
‘best’ binding modes at lowest free energy (ΔG) possible for newly designed ligands. 1IVO 
does not have a reference ligand, unlike 2J6M. Ligand and protein preparation optimized 
as well as minimize structural requirements for a successful docking. The generation of 
receptor grid supported a rigid protein structure for ease of docking and scoring. Glide 
then allows the analysis and comparison of ligand binding affinities and their geometries, 
which can be used to predict ligand features. Sections 2.5.2 and 2.5.6 show some of these 
features. The Maestro GUI functions principally to facilitate the set up and submissions of 
jobs to Schrodinger’s computational programs through the designing and simplification of 
modeling tasks, like molecular building and data analysis using v10.4Maestro (Schrödinger, 
LLC, New York, NY, 2015). Other Glide parameters that waved among themselves to make 
the docking a success or a failure include the docking score (DS) which defines the Gscore 
(GS) supplemented by Epik state penalties; Gscore (GS) is composed of the van der Waals 
(vdW), Coul (Coulomb), Lipo (lipophilicity), Hb, metal rewards, RotBonds and site; glide 
energy (GE), is the Modified Coulomb-van der Waals interaction energy; glide ligand 
efficiency (GLE), expresses the relationship between the docking score and number of 
heavy atoms represented mathematically as (docking score)/(number of heavy atoms); and 
glide ligand efficiency surface area (GLESA), is the efficiency metric approximates of the 
effect of surface area by relating the docking score to the heavy atoms in this manner 
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(docking score)/(number of heavy atoms)2/3. Another important is ME (already mentioned) 
is expressed as: 
 Gscore + internal ligand strain (Einternal) + Coulomb + van der Waals energy energies 
ME is insightful for analytical purposes. LowMW is an example of Glide XP term, which 
defines the rewards for ligands with low molecular weights [162, 171]. A few of these 
metrics were employed to show if any correlation existed among selected compounds, 
particularly the lead candidates DPT1 1, DPT2 2, DPT 3 3 and DPT4 4, as a level top best 
were utilized, which has been done for some compounds prior to and after their structural 
modifications with the v3.9CombiGlide (Section 2.5.8). We also used this information to 
view our compounds in the face of known compounds, with or without similar 
mechanisms. The scatter plot platform was also used to correlate structurally some of 
these properties using v2.6Canvas (Schrödinger, LLC, New York, NY, 2015) (Figures 50 – 54 
and values were tabulated in Tables 24 – 28 for to view the relationship. The hierarchical 
disposition of Glide predisposes its program to high accuracy in the prediction of the 
binding mode of the ligand [171] and therefore analyses and views suitable. 
2.5 The Docking outcomes, optimization and additional analyses 
Although 124 ligands were considered to have emerged, including the 31 built RTKIs, 
curcumin and P & Y, only compounds DPT1 1 – DPT4 4 in Table 3 have met our selection 
criteria for further investigation as already explained. Compounds DPT5 5 and DPT6 6 are 
ZINC ligands that had no score with 1IVO |246-253|S but when docked with 2J6M had the 
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highest Gscores (Table 9). These shall be studied biologically. The lead candidates were 
optimized to improve potential potency (Tables 20-23). Scatter Plots was to check 
relationships using their correlation values as explained: if R2 = 1.00, it is said to be a unique 
link; if R2 = 0.00, no link exists; if R2 = ≥ 0.50, fairly good link exists; R2 = ≤ 0.50, poor link 
exists.  
 
2.5.1 In silico results for the 1IVO |246-253|S 
Grid |246-253|S prepared from 1IVO monomeric arm was first docked with each of the 
chemical databases. 2J6M grid was handled the same way. Table 3 shows a summary of 
the selected and coded hit molecules (section 2.4.3). 
 
 
 
 
  
Compound Structure (2D) Gscore Code  name 
ZINC 65372018 
 
-2.7 
 
 
DPT  1 1 
Table 3. The six codified selected hits. The selection of DPT1 1-DPT4 4 is based on 
inhibition of both 1IVO and 2J6M. DPT5 5 and DPT6 6, in orange, inhibited only 2J6M 
but for their ‘best’ scores and availability, would be bioevaluated.  
NB: Ambinter used the coding as ZINC at the time of docking.  
1 
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ZINC 67919965 
  
-1.9  
 
 
DPT2 2 
ZINC 67851668 
 
 
2.1 
 
DPT3 3 
ZINC 20537922 
 
 
-3.5 
 
DPT4 4 
ZINC56992273 
    
 
 
-10.6 DPT5 5 
ZINC59454528 
 
     
 
-10.3 DPT6 6 
 
2.5.2 The 1IVO docking outcomes 
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The Gscores for known RTKIs are shown in 4. The Gscore values were generally low (a 
typical good Gscore range is -8 to -15). Similar observations occured in other docked 
ligands (cf. Tables 5 & 6). Tables 4, 5 & 6 show the Gscores and interacting aa residues for 
the top 20 ligands of RTKIs, Chembridge & Ambinter, respectively, when docked with 1IVO 
|246-253|S. 1IVO |246-253|S-ZINC ligands did not yield result (cf. Table 9). Figures 34 & 
39A -39D show Scatter Plot analyses of Tables 4 & 5.  
 
 
 
Ligand Gscore Associated residues 
CUDC-101 -4.3 TYR246 TYR251 
WZ4002 -4.27 TYR246 
WZ8040 -3.77 MET253 GLN252 ASP279 
Lapatinib -3.7 TYR246 
Tyrphostin AG 478 -3.59 TYR246 MET244 
AG-490 -3.47 MET244 
WZ3146 -3.33 TYR261 ASP279 
PD153035 -3.19 ASP279 
AST-285 -3.08  
Mubritinib -2.98  
Table 4. Top 20 docked 1IVO |246-253|S -Built RTKI ligands. 
 Low Gscores a likely indication of different mechanisms (cf. Table 8).   
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The most featured aa residue (s) linked to a ligand is shown in the pie chart in Figure 30.   
 
2% 5%
12%
10%
5%
8%1%
34%
14%
9%
% Featured interacting residues  from the three 
1IVO-docked ligands 
TYR261
ASP 279
MET 244
MET 253
HIE280
GLN 252
LEU 243
TYR 246
TYR 251
VAL255
Dasatinib -2.92 HIS281 
Gefitinib -2.68 MET244 TYR246 
Dabrafenib -2.67  
AZ8931 -2.63 TYR251 
Canertinib -2.6 TYR246 
Sunitinib -2.52 TYR246 TYR251 
Neratinib -2.51 TYR246 
Dacomitinib -2.45 GLN252 
Pelitinib -2.45  
ARRY-380 -2.42 TYR246 TYR251 
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(a) (b) 
Figure 30. Predominant aa residues in 1IVO |246-253|S-RTKI complexes. The first 
four residues noticed in most of the interactions were TYR246 (34%), TYR251 
(14%), MET244 (12%) and GLN252 (8%) despite low Gscores in the first 20. 
MET253 was absent. LEU243, HIS280, MET244, and VAL255 were protein side 
chain residues with unknown contributory mechanism to oligomerization. The 
information assisted in knowing more about the aa residues from other 
mechanisms. 
y = 5.17x + -22.99 (R2 = 0.21) y= 0.02x + -0.03 (R2 = 0.01) 
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(c) (d) 
Table 5. Top 20 docked 1IVO |246-253|S - Chembridge ligands. 
 Low Gscores and their interacting residues are shown (cf. Table 9). 
Figure 31. Scatter Plots for top 20 1IVO |246-253|S-RTKI ligands.  The selected docking 
properties are shown. (a) A poor link in DS & ME, (b) A poor link in DS & LowMW exists, and (c) 
A poor link in DS & GE exists, (d) A fairly good link in DS & GLESA independent of GE. 
 
 
y = 4.95x + -16.39 (R2 = 0.28) y = 0.10x + 0.01 (R2 = 0.71) 
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Ligand Gscore Associated residues 
ZINC72131899 -4.04 TYR246 
ZINC67458838 -4 TYR246 
ZINC65425691 -3.4 HIS280 MET244 
ZINC67847696 -3.3 TYR246 PRO248 
ZINC65461424 -3.04 MET244 THR239 
ZINC72457980 -3 MET253 LEU243 
ZINC67955977 -2.9 MET253 GLN252 
ZINC67847695 -2.79 TYR246 THR239 CYS240 
ZINC72457966 -2.74 HIS280 MET244 
ZINC65425691-2 -2.71 TYR246 MET244 
ZINC67446719 -2.7 TYR246 CYS240 THR239 
ZINC23116769 -2.66 GLN252 
ZINC72457976 -2.53 TYR261 ASP279 
ZINC65461432 -2.47 VAL255 ASN247 
ZINC67920036 -2.2 MET253 
ZINC02897937 -2.16 MET253 
ZINC72131820 -2.05 TYR251 
ZINC55271940 -1.92 HIS280 
ZINC65425691-3 -1.8 MET253 GLN252 
ZINC67847708 -1.74 MET253 
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The Scatter Plot from the Project Table v10.4Maestro (Schrödinger, LLC, New York, NY, 
2015-4) was used to analyze 1IVO |246-253|S – Chembridge complexes in Table 5 based 
on selected properties of DS, GE, GLESA, ME and LowMW [171]. These properties depicted 
a varying relationship with each other. Scatter Plots 32A to 32D give an insight into some 
of them. 
   
 
 
 
 
Figure 32A. DS v GE.   
DS & GE show poor link. 
Figure 32B. DS v ME.  
DS & ME show poor link. 
y = 1.86x + -20.57 (R
2
 = 0.09) 
y = 1.95x + -24.44 (R
2
 = 0.03) 
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Table 6. Top 20 docked 1IVO |246-253|S - Ambinter ligands. 
Low Gscores and their interacting residues are shown. 
Colored rows indicate selected hits (cf. Table 10). 
Figure 32C. DS v LowMW.  
DS & XP LowMW show poor link  
Figure 32D. DS v GLESA.  
DS & GLESA show strong link. 
y = 0.07x + -0.15 (R
2
 = 0.11) 
y = 0.12x + 0.00 (R
2
 = 0.92) 
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Ligand Gscore Associated residues Hit code 
ZINC72131821 -3.82 TYR246   
ZINC20537922 -3.53 TYR246 MET244 DPT4 4 
ZINC20322301 -3.35  TYR251  
ZINC72131820 -3.3 TYR246 MET244  
ZINC67847695 -3.1 TYR246 MET253 GLN252 
ZINC67847694 -2.8 TYR246  
ZINC65372018 -2.73 TYR246 TYR251 DPT1 1 
ZINC71771450 -2.66 TYR251  
ZINC67741022 -2.61 TYR246  
ZINC67955954 -2.3 TYR246  
ZINC67851668 -2.07 TYR246 TYR251 DPT3 3 
ZINC72457948 -2.07   
ZINC67774117 -2.03 HIS280  
ZINC02887281 -1.96 MET244  
ZINC00052413 -1.95 TYR246  
ZINC67919965 -1.92 TYR246 TYR251 DPT2 2 
ZINC20907761 -1.81   
ZINC67955955 -1.71 TYR246  
ZINC39515547 -1.59 TYR251  
ZINC22926613 -0.63   
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The Gscores from the monomeric arm are low as mentioned. The v2.6Canvas program 
(Schrödinger, LLC, New York, NY, 2015-4) was used to study a few of the properties of the 
four selected hits (Tables 6 & 10) utilizing a scatter plot of the GLE (y – axis), GE (in color of 
diamond), ME   (size of the diamond) and DS (x – axis). A linear relationship was observed 
between the DS & GLE (Figure 33). All other experimental properties were within the 
calculated values shown in Table 7.  
 
 
 
 
 
 
Figure 33. Top 20 1IVO |246-253|S - Ambinter ligands displaying DPT1 1 - DPT4 4. 
Using v2.6Canvas Program, the following were studied – DS, GLE, GE (color intensity 
of the square) and ME (size of the square). The details of the Scatter Plot are 
contained in Table 7. 
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2.5.3 The 2J6M docking outcomes 
The docking protocol was repeated with 2J6M and selected scores shown in Tables 8, 10 
& 11. The Tables show the scores and type of interacting residues for the first 20 docked 
ligands.  
 
 
 
 
Ligand 
Docking 
score 
(x-axis) 
Glide 
ligand 
efficiency 
 (y-axis) 
Glide Emodel (size) 
Fixed = 16points 
Glide Energy (color) 
Fixed = Dark blue 
Minimum 
(12 
points) 
Maximum 
(48 
points) 
Minimum 
(blue) 
Maximum 
(Red) 
-36.075 -12.213 -28.944 -16.433 
DPT1 
(ZINC65372018) 
-2.735 -0.105 -28.606 -22.308 
DPT2 
(ZINC67919965) 
-1.917 -0.083 -23.493 -19.821 
DPT3 
(ZINC67851668) 
-2.070 -0.083 -18.387 -16.432 
DPT4 
(ZINC20537922) 
-3.531 -0.136 -36.075 -27.684 
Table 8. Top 20 docked 2J6M-Built RTKI ligands. 
Gscores 3 – 4x higher than their counterparts in 1IVO |246-253|S and their 
interacting residues are shown (cf. Table 4).  
Table 7. Detailed values for the selected properties of DPT1 1 - DPT4 4. These 
estimated values shown are from Figure 33. The observed values were within range. 
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Ligand Gscore Associated residues 
CUDC-101 -9.24 MET793 ASP855 ASN842 
Pelitinib -9.19 THR854 
Gefitinib -8.95 MET793  
Erlotinib -8.92 MET793 CYS797 
Dacomitinib -8.56 MET793 CYS797 
AEE788 -8.48 MET793 
Tyrphostin AG 1478 -8.43 MET793 
AZ8931 -8.41 MET793 
PD153035 -8.28 MET793 
Canertinib -7.99 MET793 
BMS 599626 -7.53 MET793 ASP855 LYS745 
WZ3146 -7.1 MET793 ARG841 
Lapatinib -6.99 MET793 ARG841 ASP855 
ARRY-380 -6.65 GLU804 ARG841 
Mubritinib -6.61 MET793 THR854 
AG-490 -6.58 MET793 GLU762 
WZ4002 -6.49 MET793 
Suramin -6.47 ARG841 ASP855 GLU758 GLU804 
Dasatinib -6.26 MET793 ASN842 
AST-285 -6.13 MET793 
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The most linked residues on for 2J6M were MET793, GLN791, ASP855, and LYS745 shown 
in the pie chart in Figure 32. 
 
 
 
 
 
 
 
 
 
 
16%
5%
3%
1%
10%
4%
1%2%1%
7%
45%
5%
% Featured interacting residues  from the three 2J6M-
docked ligand sources 
GLN 791
ARG 841
ASN 842
ASP 800
ASP 855
CYS 797
GLU 758
GLU 804
GLU 762
LYS 745
MET 793
Figure 34. Predominant aa residues in 2J6M-RTKI complexes. The first four residues noticed 
in most of the interactions were MET793 (45%), GLN791 (16%), ASP855 (10%) and LYS745 
(7%). These residues had the ‘best’ Gscores among the first 20 in ranking. Other amino acid 
residues formed bonds with the protein side chain residues of the kinase domain.  
Table 9. Top 20 docked 2J6M-ZINC ligands. 
Gscores are 4 - 5x higher than their counterparts in 1IVO |246-253|S 
and their interacting residues are shown.  
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Ligand GScore DSocre Interacting residues 
ZINC12301510 -10.58 -9.36 MET793 GLN791 
ZINC12302594 -10.33 -9.21 MET793 GLN791 
ZINC12302594-2 -10.3 -9.18 MET793 GLN791 
ZINC12301510-2 -9.72 -9.14 MET793 GLN791 LYS745 
ZINC19774030 -9.71 -8.9 MET793 GLN791 
ZINC12298615 -9.19 -8.78 MET793 GLN791 
ZINC12298615-2 -9.18 -8.76 MET793 GLN791 
ZINC19760143 -9 -8.59 MET793 GLN791 
ZINC19760143-2 -8.96 -8.54 MET793 GLN791 
ZINC12301510-3 -8.97 -8.39 MET793 GLN791 
ZINC12301510-4 -9.59 -8.36 MET793 GLN791 
ZINC19800528 -8.73 -8.32 MET793 GLN791 
ZINC12301510-5 -8.9 -8.32 MET793 LYS745 
ZINC12301510-6 -8.87 -8.29 MET793 LYS745 
ZINC12302594-3 -8.84 -8.22 MET793 GLN791 
ZINC12301510-7 -8.78 -8.2 MET793 GLN791 
ZINC12301510-8 -8.77 -8.19 MET793 
ZINC19760143-3 -8.55 -8.14 MET793 GLN791 
ZINC11839243 -8.13 -8.12 MET793 ASP855 
ZINC12302594-4 -8.74 -8.11 MET793 GLN791 
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Ligand Gscore Associated residues Hit code 
ZINC71771450 -7.69 MET793 GLN791 LYS745   
ZINC72131820 -7.4 MET793   
ZINC67847694 -6.95 MET793 ASN842   
ZINC72131821 -6.77 CYS797 ASP800   
ZINC67847695 -6.45 ASP855 LYS745   
ZINC20537922 -6.21 MET793  DPT4 4 
ZINC67741022 -5.81 MET793 THR854   
ZINC65372018 -5.63 MET793  DPT1 1 
ZINC67955954 -5.62 MET793 ASP855   
ZINC67955955 -5.55 ASP 855 THR854   
ZINC67919965 -5.41 LYS745 DPT3 3 
ZINC72457948 -5.16 CYS797   
ZINC20322301 -4.82 PRO794   
ZINC02887281 -4.58 MET793 ARG841   
Table 10. Top 20 docked 2J6M-Ambinter ligands. 
Gscores 2 - 3x higher than their counterparts in 1IVO |246-253|S their 
interacted residues shown (cf. Table 6). Colored rows are selected hits based on 
their antagonistic effects on both 1IVO and 2J6M (cf. Table 6). 
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ZINC39515547 -4.31 THR854 ASP855   
ZINC67774117 -3.99 ASP855   
ZINC22926613 -3.76 MET793   
ZINC20907761 -3.71 ASP855   
ZINC67851668 -3.35 - DPT3 3 
ZINC00052413 -1.82 MET793   
 
 
The v2.6Canvas program (Schrödinger, LLC, New York, NY, 2015-4) was used to study a few 
of the properties of the four selected hits (Tables 6 & 10) utilizing a scatter plot of the GLE 
(y – axis), GE (in color of cross), ME (size of cross) and DS (x – axis). A linear relationship 
was observed between the docking score and glide ligand efficiency (Figure 35). All other 
experimental properties were within the calculated values (as shown in Table 11) 
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Figure 35. Top 20 2J6M-Ambinter ligands displaying DPT1 1 - DPT4 4. Using 
v2.6Canvas Program, the following were studied – DS (x – axis), GLE (y – axis), GE 
(color intensity of the diamond) and ME (size of the diamond). The details of the 
scatter plot are contained in Table 11. 
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Ligand 
Docking 
score (x-
axis) 
Glide 
ligand 
efficiency 
 (y-axis) 
Glide Emodel (size) 
Fixed = 16points 
Glide Energy (color) 
Fixed = Dark blue 
Minimum 
(12 
points) 
Maximum 
(48 
points) 
Minimum 
(blue) 
Maximum 
(Red) 
-36.075 -12.213 -28.944 -16.433 
DPT1 
(ZINC65372018) 
-5.631 -0.217 -52.000 -38.000 
DPT2 
(ZINC67919965) 
-5.409 -0.235 -44.851 -33.520 
DPT3 
(ZINC67851668) 
-3.352 -0.134 -44.651 -34.883 
DPT4 
(ZINC20537922) 
-6.213 -0.239 -56.230 -36.609 
Table 11. Detailed values for the selected properties of DPT1 1 - DPT4 4.  These 
estimated values shown are from Figure 35. The observed values were within range. 
 
Table 12. Top 20 docked 2J6M-Chembridge ligands. 
 The Gscores 4 -5x those observed in 1IVO |246-253|S showing their linked 
residues and Gscores (cf. Table 5). 
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Ligand GScore Interacting aa residues 
ZINC00064952 -9.09 
ALA743 LEU788 MET793 
ZINC00309912 -9.07 
GLN791 
ZINC17489032 -8.6 
MET793 
ZINC04812637 -8.26 
MET793 
ZINC16677424 -8.26 
GLN791 MET793 
ZINC19774030 -8.06 
PRO794 LEU1001 
ZINC19774030-2 -8 
PRO794 LEU1001 
ZINC12202453 -7.62 
PRO794 
ZINC19799281 -6.96 
MET793 PHE997 PHE795 
ZINC19791293 -6.85 
GLU804 PHE997 
ZINC12302594 -6.83 
ASP994 
ZINC19791293-2 -6.4 
LEU1001 
ZINC12302087 -6.37 
LEU1001 
ZINC19787192 -6.26 
LEU1001 
ZINC11788575 -6 
LEU1001 
ZINC09012972 -5.86 
LEU1001 
ZINC05041707 -5.79 
LEU1001 
ZINC12302736 -5.77 
ASP800 CYS797 
ZINC19772740 -5.67 
PRO794 
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2.5.4 Selected docking properties for top 18 Built compounds for analysis 
Fifteen RTKIs (sections 1.4.4 & 1.4.5), curcumin (sections 1.4.2 & 1.4.4) and two reportedly 
active anti-dimer agents P & Y (section 1.4.7) were built using the v10.4Maestro GUI, thus 
the conversion of 2D to 3D structures  by LigPrep was accomplished. The ligands were 
prepared with the v3.6LigPrep (Schrödinger, LLC, New York, NY, 2015-4). These were 
docked into the monomeric 1IVO grid |246-253|S and a selected docking and non-docking 
properties of these compounds were examined. Curcumin had the highest Gscore (-9.3), 
however, P and Y surprisingly had Gscores of -4.8 and -4.3 respectively, similar to some of 
the docked RTKIs with 1IVO |246-253|S  (Tables 4, 5 & 6). This offered a broader view for 
comparative purpose with the evolving anti-oligomeric agents. The docking properties 
were DS on the x-axis and ME, LowMW, GE on the y-axis as illustrated in Figure 34 (a), (b) 
and (c), respectively. However, (d) is scatter plot of three docking properties of DS (x-axis), 
GLESA (y-axis), GE (in rainbow color). There is no clear correlation between the DS and ME 
shown in (a). The (b) plot exhibits no relationship between the DS and LowMW while (c) 
shows a slight relationship between the DS and GE. The plot in (d) shows a correlation 
exists between the DS and the GLESA, however, with GE having no clear effect (Figure 34).  
 
 
 
 
Table 13. 1IVO |246-253|S-Built ligands. These Built ligands were selectively 
built RTKIs (tan color), curcumin (olive green color), P (blue color) and Y (orange). 
Gscores, MW, HBD/HBA, PSA, MSA and structures are shown (cf. Tables 4, 5, 6 & 
29).  
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Ligand structure Gscore⃰ MWα HBD/HBAβ PSA (Å2)† MSA (Å2)‡ 
 
--4.3 434.488 3/8 106 762.93 
 
-4.3 494.973 3/6 91.85 686.15 
 
-3.8 481.013 2/7 99 717.29 
 
-3.2 360.205 1/5 56.57 425.65 
 
-3.7 581.057 2/6 106.35 776.04 
 
-3.6 315.754 1/5 56.27 421.44 
 
-3.5 294.305 3/4 93.35 389.46 
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-3.3 464.947 2/8 82.62 638.59 
 
-3.0 468.471 0/3 65.97 636.19 
 
-2.9 488.005 3/6 106.51 665.66 
 
-2.7 446.902 1/7 68.74 623.66 
 
-2.7 519.562 3/7 110.86 658.92 
 
-2.6 473.928 2/8 88.61 649.86 
 
-2.6 485.938 2/8 88.61 651.65 
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⃰ =Docking score, α = molecular weight, β = HBD (hydrogen bond donor) and HBA (hydrogen bond 
acceptor), † = polar surface area, and ‡ = molecular surface area (solvent accessible surface area) 
 
-2.5 398.474 3/6 77.23 597.95 
 
-9.3 368.380 2/6 93 509.73 
 
-4.8 448.475 2/7 112.29 733.59 
 
-4.2 376.518 0/3 43.60 684.91 
P 
Y 
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(a) (b) 
(c) (d) 
Figure 36. Scatter Plots of top 20 1IVO |246-253|S-Built ligands. (a) DS & ME show poor 
correlation, (b) DS & LowMW show poor correlation, (c) DS & GE show poor correlation, (d) DS, 
GLESA & GE show unique correlation. 
 
 
y = 0.04x + 0.01 (R2 = 0.10) y = 4.23x + -24.71 (R2 = 0.49) 
y = 0.12x + 0.05 (R2 = 0.95) y = 3.32x + -20.34 (R2 = 0.49) 
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2.5.5 Visuals of DPT1 1-DPT4 4 in complex with 1IVO |246-253|S 
Visualization of the nature of Hbs / HYs formed between DPT1 1-DPT4 4 and 1IVO |246-
253|S through their complexing aa residues in Figures 37, 38, 39 & 40, respectively.  
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2.5.5.1 1IVO |246-253|S in complex with DPT1 1 
 
 
 
 
 
 
 
(a) (b) 
(c) 
(d) 
Figure 37. Screens of DPT1 1 - |246-253|S complex. (a): DPT1 1 formed Hb with primary 
residues, TYR246 and TYR251, at T; (b): an expanded 2D structure of DPT1 1 showing the 
mechanism of the Hb and contribution of the π-π interactions formed between the TYR246 
aromatic ring and that of the pyrazole ring of DPT1 1; (c) a mesh binding site surface created for 
the receptor and ligand, showing the Hb; and (d) the HY ≈ 10x denser than Hb. 
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2.5.5.2 Screens of the 1IVO in complex with DPT2 2 
(a) (b) 
(c) (d) 
 
 
 
 
 
 
Figure 38. Screens of DPT2 2 -|246-253|S complex. (a): DPT2 2 formed Hb with primary 
residues, TYR246 and TYR251 at T; (b): an expanded 2D structure of DPT2 2 showing the 
mechanism of the Hb that occurred between the residues; (c) a mesh binding site surface 
created for the receptor, showing the Hb; and (d) the HYs ≈ 10X denser than the Hb. 
 
   
 
100 
 
 
2.5.5.3 Screens of the 1IVO in complex with DPT3 3 
 
 
 
 
 
a) (b) 
(c) 
(d) 
Figure 39. Screens for DPT3 3-|246-253|S complex. (a): DPT3 formed Hb with primary residues, 
TYR246 and TYR251 at T; (b): an expanded 2D structure of DPT3 showing the mechanisms of 
the Hb and π-π interactions between the TYR246 aromatic ring and the quinoline ring of the 
ligand; (c) a mesh binding site surface created for the receptor, showing the Hb, and (d) the HY 
is ≈ 10X denser than Hb. 
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2.5.5.4 Screens of the 1IVO in complex with DPT4 4 
(a) (b) 
(c) (d) 
 
 
 
 
 
 
Figure 40. Screens for DPT4 4-|246-253|S complex. (a): DPT3 formed Hb with primary residues, 
TYR246 and TYR251 at T; (b): an expanded 2D structure of DPT3 3 showing the mechanisms of 
the Hb with the TYR246 and MET244 residues; (c) a mesh binding site surface created for the 
receptor, showing the Hb, and (d) the HY ≈ 10X denser than Hb. 
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2.5.6 Molecular interactions of DPT1 1-DPT4 4  
Glide assists in showing the molecular interactions between the binding residues and 
candidate compounds. An insight into how the lead candidates interact with the aa 
residues is useful in studying their mechanisms of action and structural modifications for 
improved potency. Figures 41A/B, 42A/B, 43A/B & 44A/B show some of these basic 
properties for DPT1 1, DPT2 2, DPT3 3 & DPT4 4, respectively. 
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2.5.6.1 The 1IVO |246-253|S-DPT1 1-aa residues molecular interactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41A. The 3D picture of the interacting residues with DPT1 1. 
The key residues are TYR246 and TYR246, their distances from the ligand 
and the Hbs in yellow-dotted lines within a space of 4Å are shown. Details 
in 2D format are shown in Figure 41B. 
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Figure 41B. Analysis of the interacting residues with DPT1 1.  
TYR246 and TYR251 form Hbs (purple) and a π-π interaction (green) with DPT1 1. TYR246 protein 
side chain displays i) Hb between its H hydroxyl phenyl function and the N in N-20  of the 2,4,5,7-
tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one moiety of DPT1 1 & ii) π-π interactions between its 
phenyl ring and pyrazolo- moiety of DPT1 1; TYR251 protein backbone chain-a displays a Hb 
between its O carbonyl group and the H on N-19 pyrazolo-pyridin-6-one moiety of DPT1. These 
predict the mechanisms of DPT1 1 as an anti-oligomerization agent within these approximate 
distances and angles summarized in Table 14.  
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2.5.6.2 The 1IVO |246-253|S residual interactions with DPT2 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42A. The 3D picture of the interacting residues with DPT2 2. 
The key residues are TYR246 and TYR251, distances away from the ligands, and 
the Hbs in yellow-dotted lines within a space of 4Å. Details in 2D format are 
shown in Figure 42B. 
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Figure 42B. Analysis of the interacting residues with DPT2 2.  
The interacting residues with DPT2 2 are TYR246 and TYR251. The Hb (in purple) 
is as a protein side chain (as with TYR251 in purple line) or protein backbone (as 
with TYR246 in purple line). These predict the mechanisms of DPT2 2 as an anti-
oligomerization agent within these approximate distances and angles 
summarized in Table 14. 
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2.5.6.3 The 1IVO |246-253|S residual interactions with DPT3 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43A. The 3D picture of the interacting residues with DPT3 3. 
The key residues are TYR246 and TYR251, distances away from the ligands, and 
the HBs within a space of 4Å are shown. Details in 2D format are shown in Figure 
43B. 
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Figure 43B. Analysis of the interacting residues with DPT3 3.  
TYR246 and TYR251 form Hbs (purple) and a pair of π-π interactions (green) with DPT3.  
TYR246 protein side chain – a displays i) Hb between its H hydroxyl group and the O hydroxyl 
group on C-6 naphthyl ring of DPT3 3 & ii) a pair of π-π interactions ((i) & (ii) as labeled in the 
diagram) between its phenyl ring and the naphthyl rings of DPT3 3; TYR251 protein side chain 
– b displays Hb between its H hydroxyl function and N-19 of the oxadiazole ring of DPT3 3. These 
predict the mechanisms of DPT3 3 as an anti-oligomerization agent within these approximate 
distances and angles summarized in Table 14.  
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2.5.6.4 The 1IVO |246-253|S residual interactions with DPT4 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44A. The 3D picture of the interacting residues with DPT4 4. 
The key residues are TYR246 and TYR251, distances away from the ligands, and 
the Hbs within a space of 4Å are shown. Details in 2D format are in Figure 43B. 
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Figure 44B. Analysis of the interacting residues with DPT4 4.  
MET244 and TYR246 form Hbs (purple) and a π-π interaction (green) with DPT4 4. MET244 
protein backbone chain – b displays Hb between its O carbonyl group and the H of N-22 of the 
pyrazole ring of DPT4 4; TYR246 protein backbone chain – a displays Hb between its H amide 
group and N-21 of the pyrazole ring of DPT4 4; TYR246 protein side chain displays i) Hb between 
its H hydroxyl function and N-6 pyrrole ring of DPT4 4 ii) a π-π interaction between its phenyl 
ring and thiol ring of DPT4 exists. These predict the mechanisms of DPT4 as an anti-
oligomerization agent within these approximate distances and angles summarized in Table 14.  
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The summary of the residual interactions of DPT1 1, DPT2 2, DPT3 3, and DPT4 4 are shown 
in Table 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 14. A précised molecular studies of DPT1 1-DPT4 4 within 4 Ǻ.  
Figures 40B, 41B, 42B, and 43B show that the mode of aa residual interactions with the ligands 
in terms of their distances and angles within a specified space, in this case 4Å, can be predicted. 
There are two types of Hbs formed - those with the protein backbone chain and those with the 
protein side chain. The protein side chain lacks an acceptor angle while the protein backbone 
chain possesses both acceptor and donor angles. The π-π interacts in a manner unique to the 
ligand, thus DPT2 2 does not have any, DPT4 4 interaction is face-to-face, DPT3 3 exhibits both 
face-to-face and edge-to-face, and DPT1 1 shows edge-to-face at the different distances with 
the face seemingly having shorter distance than the edge-to-face. Only DPT2 2 lacks protein 
backbone chain. The largest acceptor angle 168.59
0
 from DPT4 4 that already exhibits two 
donor angles 94.95
0
 and 137.59
0
 show its high potential for structural optimization. DPT2 2 
exhibits the highest donor protein side chain angle, 156.72
0
 and only DPT3 3 shows two 
different protein side chain angles, 97.81
0
 and 118.50
0
. These parameters render the binding 
affinities, hence their anti-EGFR, individually unique. 
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The role of MET 244 has an unknown anti-dimerization activity.   
 
2.5.7 Docking outcomes of some 1IVO complete (W) grids  
An initial no Gscore when |246-253lS was docked with ZINC ligands through obtaining low 
Gscores to deliberate investigational reasons prompted the need to generate 1IVO grids 
that spanned the entire ‘oligomerization region’ (already defined). Tables 4, 5 & 6 show 
Feature DPT1 1 DPT2 2 DPT3 3 DPT4 4 
Interacting residue (s) 
TYR246 
TYR251 
TYR246 
TYR251 
TYR246 TYR251 TYR246 MET244 
Hb to protein side 
chain 
Distance from 
ligand (Å) 
2.210 1.667  (a) 2.016, (b) 
2.078  
2.169 
Donor angle (0) 96.15 156.72 (a) 97.81, (b) 
118.50  
117.69 
Acceptor angle (0)     
Hb to protein 
backbone chain 
Distance from 
ligand (Å) 
1.997 2.192  (a) 2.062, (b) 
1.829  
Donor angle (0) 130.14 149.98  (a) 94.95, 
(b)137.32  
Acceptor angle (0) 151.51 133.76  168.59  
π-π interactions 
Nature of 
interaction 
Edge to 
face 
   Edge to face (i), 
Edge to face (ii) 
Face to face 
Distance (Å) 4.974  4.819 (i), 5.307 (ii) 3.818 
Angle (0) 76.40  67.75 (i), 68.48 (ii) 11.17 
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some of the low Gscores when docked with the monomeric arm. The opposite was 
observed when the same compounds were docked with 2J6M as 3 – 5x Gscores of the 
1IVO monomeric grids were obtained (Tables 8, 9 & 10), particularly Table 9 of 2J6M-ZINC 
ligand complexes, whereas no score was observed with the 1IVO |246-253|S-ZINC ligand 
docking. The viable dimeric grids generated include |246-253|W and |86, 230, 263, 264, 
265, 275, 278, 283, 285, 286|W, representing T and B residues, respectively. Another 1IVO 
grid that reflected the entire ‘oligomerization region’ was 1IVO |200-300|W since its aa 
residues were from both the side chain and backbone chain of the 1IVO. All these grids 
were docked with the same chemical databases with outcomes very encouraging since 
average cutoff Gscores ≥ -6.0, which is still 3 – 4x those of DPT1 1 – DPT4 4. Only a selected 
few dimeric docking outcomes are shown in Tables 15 – 18. 
 
2.5.7.1 1IVO |246-253|W-Chembridge ligands  
 
 
 
 
 
 
Table 15. Top 4 of docked |246-253|W-Chembridge ligands. 
Gscores of 3 - 4x higher than those from the |246-253|S and their aa residues are 
shown (cf. Table 5) (where L-R, ligand-receptor complex).  
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Ligand Gscore Interacting residue (s) 2D L-R complex 3D L-R complex 
ZINC04661187 -8.1 TYR246 HIS280  
  
ZINC00784489 -7.6 CYS240 SER262 
HIS280 
  
ZINC22018488 -7.6 GLY281 SER262 
 
 
ZINC05682347 -7.2 CYS240 HIS280 (B) 
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2.5.7.2 1IVO |246-253|W -ZINC ligands  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16. Top 4 of docked |246-253|W-ZINC ligands. 
Gscores are 2-3x higher than those from the|246-253|S and their aa residues are 
shown. There was no Gscores with the |246-253|S-ZINC ligands. 
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Ligand   Gscore   Interacting  residue (s)   2D L - R complex   3D L - R complex   
ZINC08441257   - 6.12   
HIS280   
CYS240   
  
  
ZINC02062178   - 5.98   
HIS280    
LEU243   
  
  
  
ZINC08441846   - 5.03   
HIS280   
    
ZINC20031600   - 5.03   
HIS280   
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2.5.7.3 1IVO |86 230 263 264 265 275 278 283 285 286|W -Chembridge ligands  
 
 
Ligand Gscore Interacting 
residues 
2D L-R complex 3D L-R complex 
ZINC00297549 -7.7 CYS240 
LYS260 HIS280 
 
 
ZINC004784489 -7.3 CYS240 
HIS280 
 
 
ZINC00784489 -7.3 TYR246 
SER262 
PHE230 
HIS280 
 
 
 Table 17. |86 230 263 264 265 275 278 283 285 286|W-Chembridge complexes.  Gscores and 
their interacting aa residues are shown. Monomeric grid was not docked.  
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ZINC00406587 -7.3 CYS240 
LYS260  
SER282 
HIS280 
GLY281 
 
 
 
2.5.7.4 1IVO |86 230 263 264 265 275 278 283 285 286|W-Ambinter ligands  
 
Ligand Gscore Interacting 
residues 
2D L-R complex 3D L-R complex 
ZINC00661065 -8.6 TYR246 LYS260 
LEU243 
 
 
ZINC08432896 -8.5 CYS240 SER262 
HIS280 (π-cat) 
 
 
Table 18. |86 230 263 264 265 275 278 283 285 286|W -Ambinter complexes. 
 Gscores and their interacting aa residues are shown. Monomeric arm was not docked.   
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These results are yet to be exploited due to time constraint. 
 
2.5.8 Optimization of the lead hits (DPT1 1-DPT4 4)  
The four lead candidates, DPT1 1-DPT4 4, having passed through the bioassay positively, 
were structurally modified using the v3.9CombiGlide (Schrödinger, LLC, New York, NY, 
2015-4). Library design is one of the four methods used in in silico screening for drug 
design, besides the well-known structure-based, ligand alignment, pharmacophores, QSAR 
and the de novo approaches. Here, almost all were in place. By allowing flexible docking, 
each conformer for each candidate was generated and docked into the rigid active site of 
the receptor and binding affinity of each was assessed based on their final Gscore or DS, 
ZINC18153302 -7.1 CYS240 HIS280  
 
ZINC16972974 -6.9 CYS240  
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which are invariably the same. Approximately   2.3 x 109 structurally modified compounds 
were generated from cores of each lead candidate, different fragment collections and with 
or without use of linkers, which are a collection of representative functional groups 
commonly found in pharmaceuticals and permits the user to effectively explore an active 
site and to identify types of functional groups that are likely to interact with the binding 
site in an energetically favorable manner, and only ≥100 had ≈ -7.0 Gscores. Five core 
structures were prepared from each lead candidate (DPT1 1-DPT4 4) preparatory for 
optimization with the fragment collection by the v3.9CombiGlide, which first enumerates 
the 2D core and fragment structures with or without linkers, transform the new 
‘synthesized’ to 3D structures and dock them into the receptor grid of choice. The 
illustration in Table 19 is for DPT1 1 only for space. 
 
2.5.8.1 Model for optimization of lead candidates (DPT1 1-DPT4 4) 
Figure 45 shows the model designed to highlight some key stages the v3.9CombiGlide 
utilizes to enumerate and dock. Addressing conformation at all stages of ligand sampling is 
core in Glide-docking. The Glide docking and scoring procedure permitted four approaches 
(already mentioned). Flexible ligand docking by default was used for the in silico screening 
throughout the SBDD, which allowed the conformer with optimum binding affinity (lowest 
energy) to dock and be reflected as a Gscore.  
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Table 19. Optimization method for DPT1 1-DPT4 4: DPT1 1 exemplified.  
 The arrows indicate the departing fragment (s) and where the new fragment (s) will be 
attached. The different colors define the positions of the outgoing and would-be fragment (s) 
on enumeration. The more the linkers the more compounds are enumerated and docked. 
Figure 45. An Iterative model for optimization of DPT1 1-DPT4 4. 
The v3.9CombiGlide first enumerates, synthesize using one or more linkers that bond the 
selected fragments from the fragment collection [indicated by the plus cross arrow] to the 
core structure. The enumerated is docked to the receptor grid hierarchically. The ‘best’ are 
purchased and/or synthesized for bioevaluation. The cycle A→B & B→A continues until a 
focused library of potentially active agents is generated for further drug development through 
the relevant transforming connections of the new modified structure (s), which are then 
purchased / synthesized→bioevaluation. Table 19 shows some of the core structures 
generated from DPT1 1 only for space while Tables 20-23 & 28 show the top newly modified 
products of DPT4 4 in the first cycle. However, zm1 and zm2 were found synthesizable (chapter 
three). The emerged leads can further be modified or made a fragment collection for a new 
or old core molecule in the second cycle to obtain more potent compounds predicted by their 
Gscores after bioevaluation. The Program is also suitable for a de novo structure-based drug 
design. Table 30 shows some of the synthesizable yields from the optimization. Modified 
source: Cavasotto et al., 2011.  
 
   
 
123 
 
Cores generated for DPT1 1 The v3.9CombiGlide Information display 
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2.5.8.2 Optimized compounds from DPT1 1 
DPT1 1 (ZINC 65372018) had a Gscore of -2.7, but it has generated compounds with 
Gscores -7.0 following optimization, an indication binding affinity is 3x improved. 
 
 
 
 
 
 
R1 R2 
Code 
name 
Linke
r (if 
any) 
Gscor
e 
 
Interactin
g residues 
Potentia
l Energy 
 
 
Table 20. Top 10 optimized 1IVO |246-253|S-DPT1 1 with their DS & aa residues.  
R1 and R2 are points of new attachments on the scaffold for the labeled moieties. The number of 
linkers used (if any), the Gscore, interacting residues, code name, and potential energy are 
reflected accordingly. The number of structures enumerated and docked by the v3.9CombiGlide 
is shown right to the scaffold. 
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DPT1A None -7.34 
CYS240 
GLY264 
HIS280 (π-
Cat) 
161.55 
  
DPT1B None -7.08 
GLY264 
CYS240 
192.61 
 
 
DPT1C None -6.74 
CYS240 
GLY264 
259.70 
 
 
DPT1D None -6.71 
CYS283 
CYS240 
HIS (π-Cat) 
169.74 
 
 
DPT1E None -6.6 
CYS240 
SER282 
GLY264 
PHE230 
(π-Cat) 
197.52 
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DPT1F None -6.58 
CYS240 
GLY264 
HIS280 (π-
Cat) 
197.52 
 
 DPT1
G 
None -6.56 
CYS240 
GLY264 
266.41 
 
 DPT1
H 
None -6.53 
CYS240 
GLY264 
SER262 
HIS280 (π-
Cat) 
127.29 
 
 
DPT1I None -6.31 
ASP238 
CYS240 
GLY264 
227.65 
  
DPT1J None -6.27 
CYS240 
GLY264 
174.22 
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2.5.8.3 Optimized compounds from DPT2 2 
DPT2 2 (ZINC 67919965) had a Gscore of -1.9, but it has generated compounds with 
Gscores  -7.0 following optimization, indication binding affinity is about 4x improved. 
 
 
 
(a) (b) 
(c) 
 
Figure 46. Top 10 ligands from optimized 
DPT1 1 scaffold plot. 
 (a) No correlation in DS & potential 
energy (PE), (b) poor link in DS & ME, 
and (c) most abundant DS is -6.6. 
y = 5.04x + 228.05 (R
2
 = 0.00) y = 1.64x + -41.17 (R
2
 = 0.01) 
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R1 R3 
Code 
name 
Gscore 
Linkers 
(if any) 
Interacting 
residue (s) 
Potential 
energy 
  DPT2A -7.59 1 
SER262 HIS280 
SER282 LYS260 
cys240 
11.60 
  DPT2B -7.41 1 
SER262 LYS260 
TYR261 (π-Cat) 
GLY281 
PRO241 HIS280 
16.73 
 
 DPT2C -7.13 2 
SER282 SER262 
CYS240 LYS260 
HIS280 (π-Cat) 
47.00 
  
DPT2D -6.97 2 
CYS283 CYS240 
HIS280 SER262 
27.61 
Table 21. Top 10 optimized 1IVO |246-253|S-DPT2 2 with their DS & aa residues.  
R1 and R3 are points of new attachments on the scaffold for the labeled moieties. The number 
of linkers used (if any), the Gscore, interacting residues, code name, and potential energy are 
reflected accordingly. The number of structures enumerated and docked by the v3.9CombiGlide 
is shown right to the scaffold. 
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PHE230 (π-Cat) 
 
 
DPT2E -6.94 2 
CYS240 SER262 
LYS260 HIS280 
HIS280 (π-Cat) 
19.20 
 
 DPT2F -6.92 2 
CYS240 SER262 
LYS260 
73.30 
  DPT2G -7.09 2 
SER262 SER282 
LYS260 CYS240 
HIS280 (π-Cat) 
10.33 
  
DPT2H -6.91 None 
SER262 CYS240 
HIS280 GLY264 
PHE230 (2 π-
Cats) 
104.94 
  
DPT2I -6.87 1 
GLY264 SER262 
CYS240 HIS280 
PHE230 (π-Cat) 
62.90 
  
DPT2J -6.84 2 
CYS240 SER262 
SER282 
158.17 
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2.5.8.4 Optimized compounds from DPT3 3 
DPT3 3 (ZINC 67851668) had a Gscore of -2.1, but it has generated compounds with Gscores  -7.0 
following optimization, an indication binding affinity is more than 3x improved. 
 
 
 
 
(a) 
(b) 
(c) 
 
Figure 47. Top 10 ligands from optimized 
DPT2 2 scaffold plot. 
 a) Poor link in DS & PE, (b) poor link in DS 
& ME (c) Most abundant DS is -6.90. 
y = -3.11x + -72.30 (R2 = 0.01) y = 110.31x + 832.65 (R
2
 = 0.33) 
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R7 R8 
Code 
name 
GScore 
Linkers 
(if any) 
Interacting 
residues 
Potential 
energy 
 
 
 
DPT3A -8.5 1 
TYR246 
CYS240 
GLY281 
246.25 
 
 
DPT3B -8.07 
1 TYR246 
SER282 
HIS280 
191.48 
 
 
DPT3C -8.02 
1 TYR246 
LYS260 
HIS280 
191.11 
Table 22. Top 10 optimized 1IVO |246-253|S-DPT3 3 with their DS & aa residues. 
R7 and R8 are points of new attachments on the scaffold for the labelled moieties. The number of 
linkers used (if any), the Gscore, interacting residues, code name, and potential energy are 
reflected accordingly. The number of structures enumerated and docked by the v3.9CombiGlide is 
shown right to the scaffold. 
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DPT3D -8.01 
1 TYR246 
CYS240 
150.07 
  
DPT3E -8 
1 TYR246 
HIS280 
168.31 
 
 
DPT3F -7.99 
1 
GLY281 
CYS240 
HIS280 
HIS280 (π-
Cat) 
PHE230 (π-
Cat) 
125.16 
  
DPT3G -7.82 
1 
TYR246 176.86 
 
 
 
DPT3H -7.75 
1 ASP279 
CYS302 (A) 
CYS302 (B) 
THR278 
313.10 
 
 
DPT3I -7.69 
1 
GLN252 
MET253 
178.86 
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ASP279 
LYS303 
 
 
DPT3J
  
-7.52 
1 CYS240 
GLY281 
PRO241 
LYS260 
174.89 
(a) (b) 
(c) 
 
Figure 48. Top 10 ligands from optimized 
DPT3 3 scaffold plot. 
a) Poor Link in DS & PE, (poor link in DS 
& ME, and (c) most abundant DS is -8.0. 
y = 17.08x + 88.13 (R2 = 0.15) y = -18.63x + 43.67 (R2 = 0.01) 
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2.5.8.5 Optimized compounds from DPT4 4 
 DPT4 4 (ZINC 20537922) had a Gscore -3.5, but it has generated compounds with Gscores  
-8.0 following optimization, an indication binding affinity is about 3x improved.  
 
 
Table 23. Top 10 optimized 1IVO |246-253|S-DPT4 4 with their DS & aa residues. 
 R3 and R4 are points of new attachments on the scaffold for the labeled moieties. The 
number of linkers used (if any), the Gscore, interacting residues, code name, and potential 
energy are reflected accordingly. The number of structures enumerated and docked by the 
v3.9CombiGlide is shown right to the scaffold. 
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R3 R4 
Code 
name 
Gscore 
Linker
s (if 
any) 
Interactin
g residues 
Potentia
l energy-
OPLS-
2005 
  
DPT4A -10.4 1 
ASP238 
CYS240 
SER282 
TYR246 
100.45 
  
DPT4B -9.68 
1 ASP238 
CYS240 
SER282 
TYR246 
76.98 
 
 
DPT4C -9.52 
1 ASP238 
CYS240 
TYR246 
SER282 
83.40 
  
DPT4D -9.34 
1 
ASP238 
CYS240 
77.49 
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HIS280 
SER282 
TYR246 
  
DPT4E -9.11 
1 TYR246 
CYS240 
ASP238 
LYS229 (π-
Cat) 
57.20 
 
 
DPT4F -8.95 
1 
Tyr246 
SER262 
113.51 
  
DPT4G -8.92 
1 TYR246 
MET244 
CYS240 
LYS229 (π-
Cat) 
282.38 
  
DPT4H -8.92 
1 VAL255 
TYR246 
MET244 
CYS240 
172.03 
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These structurally optimized compounds await more analyses as most of them were neither 
purchasable nor synthesizable. Therefore a complete approach to their chemical and biological 
  
DPT4I -8.88 
1 
 64.35 
  
DPT4J -8.88 1  154.09 
(a) (b) 
(c)  
 
Figure 49. Top 10 ligands from optimized 
DPT4 4 scaffold plot. 
(a) Poor link in DS & PE, (b) poor 
correlation in DS & ME, and (c) most 
abundant DS is -8.90.  
y = -4.48x + -102.47 (R
2
 = 0.09) y = 48.56x + 567.81 (R
2
 = 0.12) 
 
   
 
138 
 
handling is required. However, a core of DPT4 4 was modified using Cayman chemical fragments 
to obtain two synthesizable compounds zm1 7 & zm2 8 (Table 30).   
 
2.5.8.6 Canvas studies of the optimized & docked DPT1 1 – DPT4 4 complexes 
Lead optimization involved enumeration and docking of the selected potentially active 
compounds as described. The parameters involved in the docking contribute to the final 
‘best’ binding affinity of the compound since binding energy is lowest. Using v2.6Canvas 
(Schrödinger, LLC, New York, NY, 2015-4), we can investigate more about these lead 
candidates on selected parameters of the docked 1IVO |246-253|S-Optimized DPT1 1 – 
DPT4 4 structures plus 1IVO |246-253|S-RTKI ligands for an observation. For each lead 
candidate, molecules with lowest and highest DS within the first top 10 were picked for 
their merited qualities and analyzed based on DS (x-axis), GLE (y-axis), ME (symbol size) 
and GE (color of symbol). Figures 46 - 49 show their Scatter Plot views with structures of 
the DPTH’s lowest and highest DSs and other properties summarized in Tables 24 - 28, 
respectively. Data for the analyses were from Tables 20 – 23 & 4 in that order.  
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2.5.8.6.1 Top 10 1IVO |246-253|-DPT1 1 ligands 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. Top 10 optimized 1IVO |246-253|S-DPT1 1 analysis. The highest 
and lowest DS are shown. GE (color of star) and ME (size of star). Details in are 
contained in Table 24. Source: Table 20. 
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Ligand 
Docking 
score (x-
axis) 
Glide 
ligand 
efficiency 
 (y-axis) 
Glide Emodel (size) 
Fixed = 16points 
Glide Energy (color) 
Fixed = Dark blue 
Minimum 
(12 
points) 
Maximum 
(48 
points) 
Minimum 
(blue) 
Maximum 
(Red) 
-59.226 -44.271 -46.046 -37.600 
DPT1A 
(DPT1-
ZINC65372018) 
-7.337 -0.216 -48.257 -37.596 
DPT1J  
(DPT1-
ZINC65372018) 
-6.308 -0.166 -55.223 -43.304 
 
2.5.8.6.2 Top 10 1IVO |246-253|-DPT2 2 ligands  
 
 
 
 
 
 
 
 
 
Table 24. Detailed values for the selected properties of DPT1 1 from Figure 50.  
The observed values for the highest and lowest structures showing ME & GE within range.   
Figure 51. Top 10 optimized 1IVO |246-253|S-DPT2 2 analysis. 
Structures with the highest and lowest DS are shown. GE (color of round rectangle) and 
ME (size of round rectangle). Details in are contained in Table 25. Source: Table 21. 
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Ligand 
Docking 
score 
(x-axis) 
Glide 
ligand 
efficiency 
 (y-axis) 
Glide Emodel (size) 
Fixed = 16points 
Glide Energy (color) 
Fixed = Dark blue 
Minimum 
(12 
points) 
Maximum 
(48 
points) 
Minimum 
(blue) 
Maximum 
(Red) 
-61.537 -41.357 -45.721 -31.173 
DPT2A 
(DPT2-
ZINC67919965) 
-8.504 -O.387 -60.195 -42.483 
DPT2J (DPT2-
ZINC67919965) 
-7.523 -0.537 -25.924 -26.994 
 
 
 
 
 
 
 
 
 
 
 
 
Table 25. Detailed values for the selected properties of DPT2 2 from Figure 51.  
The observed values for the highest and lowest structures showing ME & GE within range.   
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2.5.8.6.3 Top 10 1IVO |246-253|-DPT3 3 ligands 
 
 
 
 
 
 
 
 
 
 
Figure 52. Top 10 optimized 1IVO |246-253|S-DPT3 3 analysis. 
Structures with the highest and lowest DS are shown. GE color of diamond) and 
ME (size of diamond). Details in are contained in Table 26. Source: Table 22.  
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2.5.8.6.4 Top 10 1IVO |246-253|-DPT4 4 ligands 
 
 Ligand 
Docking 
score (x-
axis) 
Glide 
ligand 
efficiency 
 (y-axis) 
Glide Emodel (size) 
Fixed = 16points 
Glide Energy (color) 
Fixed = Dark blue 
Minimum 
(12 
points) 
Maximum 
(48 
points) 
Minimum 
(blue) 
Maximum 
(Red) 
-60.195 -25.924 -46.520 -26.994 
DPT3A 
(DPT3-
ZINC67851668) 
-8.504 -0.387 -60.195 -42.483 
DPT3J (DPT2-
ZINC67851668) 
-7.523 -0.537 -25.924 -26.994 
Table 26. Detailed values for the selected properties of DPT3 3 from Figure 52.  
The observed values for the highest and lowest structures showing ME & GE within range.   
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2.5.8.6.5 Canvas analysis of 1IVO |246-253|S-Built RTKIs  
Ligand 
Docking 
score 
(x-axis) 
Glide 
ligand 
efficiency 
 (y-axis) 
Glide Emodel (size) 
Fixed = 16points 
Glide Energy (color) 
Fixed = Dark blue 
Minimum 
(12 
points) 
Maximum 
(48 
points) 
Minimum 
(blue) 
Maximum 
(Red) 
-48.320 -70.980 -55.993 -23.260 
DPT4A 
(DPT4-
ZINC20537922) 
-10.404 -0.385 -57.708 -46.522 
DPT4J (DPT4-
ZINC20537922) 
-8.877 -0.269 -49.837 -47.099 
Table 27. Detailed values for the selected properties of DPT4 4 from Figure 53.  
The observed values for the highest and lowest structures showing ME & GE within range.   
 
Figure 53. Top 10 optimized 1IVO |246-253|S-DPT4 4 analysis. 
Structures with the highest and lowest DS are shown. GE (color of circle) and ME 
(size of circle). Details in are contained in Table 27. Source: Table 23. 
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Figure 54. Top 10 optimized 1IVO |246-253|S-RTKI analysis. 
Structures with the highest and lowest DS are shown. GE (color of star) and ME (size of star). 
Table Details are expressed in Table 28. Source: Table 4. 
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 Ligand 
Docking 
score 
(x-axis) 
Glide 
ligand 
efficiency 
 (y-axis) 
Glide Emodel (size) 
Fixed = 16points 
Glide Energy (color) 
Fixed = Dark blue 
Minimum 
(12 
points) 
Maximum 
(48 
points) 
Minimum 
(blue) 
Maximum 
(Red) 
-54.393 -25.487 -42.196 -21.224 
CUDC-101 -4.301 -0.134 -46.371 -38.752 
AEE788 -2.002 -0.061 -31.393 -25.406 
Gefitinib -2.685 -0.087 -34.090 -26.195 
Erlotinib -0.354 -0.012 -37.660 -30.437 
Canertinib -2.600 -0.076 -31.975 -25.641 
Lapatinib -3.700 -0.095 -54.393 -42.196 
 
2.6 Some observed challenges in molecular docking processes  
The design of the active constituents against specific targets has its challenges, some which 
are i) handling the unexpected results such as no scores as observed in 1IVO |246-253|S 
docking, ii) unsure of the limits of your docking software, iii) managing false positives and 
false fails, iv) validation of unliganded target biomolecules, especially when it requires 
developing such, v) failed structural enumerations and subsequent docking as noticed 
Table 28. Detailed values for the selected properties of RTKIs from Figure 54.  
The observed values for the highest and lowest structures showing ME & GE within range.   
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during the combinatorial synthesis using CombiGlide, vi) enumerated and docked 
‘compound forests’ that yielded no scores, vii) enumerated and docked molecules that 
yielded very low docking scores defiant to expectations, viii) optimized products major 
microspecies at pH 7.4 exist as ionic as obtained with DPT2 2 in Table 21, ix) delayed 
deliveries from chemical vendors on order for those purchasable, x) enumerated and 
docked compounds that yielded good glide scores but hard to synthesize and / or 
purchase, and xi) anxiety if high scored ligands synthesized and / or purchased ‘hits’ to 
translate into ‘lead’ candidates following bio-evaluation fail. The whole process of the 
modeling is punctuated with real uncertainties, therefore to finally emerge with results is 
encouraging amidst the staircases ascended [174]. 
Tables 29 and 30 contained purchasable and synthesizable hits of coded DPT5 5 and DPT6 
6 & optimized zm1 7 and zm2 8, respectively. 
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Ligand Gscore Linked aa residues   Code name 2D L-R Complex 
ZINC56992273 
    
 
-10.6 GLN791, MET793 DPT5 
5 
 
ZINC59454528 
 
     
-10.3 GLN791, MET793 DPT6 
6 
 
Ligand Gscore Linked aa residues 2D L-R complex  
Zm1 7 
 
-8.0 GLY281, LYS260, 
HIS280, SER282 
 
Zm2 8 
 
-9.2 CYS240, HIS280, 
CYS283, GLY264, 
SER264 
 
Table 29. 2J6M- DPT5 5 & DPT6 6 showing their Gscores and aa residues. 
Table 30. 1IVO |200-300|W-zm1 7 & zm2 8 showing their DS and aa residues. 
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2.7 The docking computational details  
The 2-D ligand structures of the known RTKIs were built using v10.4MaestroGUI, since it 
provided many viewing options to accommodate the varied needs of different 
applications. Thus, it gave the small molecules and large biomolecular complexes a wide 
range of clarity of modeled systems with full-featured 3D visualization and enhanced 2D 
ligand interaction diagrams. V3.6LigPrep generated accurate, energy minimized their 3D 
molecular structures on conversion from the 2D, and corrected the Lewis structures to 
eliminate mistakes in the 31 ligands in order to reduce downstream computational errors. 
The geometry minimizations of all the ligands constructed was by the OPLS_2005 force 
field. Optimizations were converged to a gradient RMSD at 0.05kj/mol with a maximum 
iterations of 2500 with an extended cutoff thus with minimal changes in RMSD gradients. 
These compounds were then docked into the grids generated from the prepared 1IVO and 
2J6M with the Prep Wizard (v3.4Epik, v4.2Prime & v6.9Impact) using v6.9Glide 
hierarchically through a number of Lipinski’s Ro5 embedded and Lipinski-like filters and / 
or on choice. The shape and properties of the binding site were characterized using some 
selected docking out properties of the top 4, 10 or 20 as the case warranted. An 
accomplished docking would be reflected in the glide ligand efficiency, emodel that 
combined the energy grid score, the binding affinity predicted by Gscore, and (for flexible 
docking) the internal strain energy for the model potential used to direct the 
conformational-search algorithm on one hand while the glide energy efficiency related to 
the glide score and the heavy atoms of the protein. The application of the v2.6Canvas 
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established the correlation of these properties. The v3.9CombiGlide enumerated as well 
as well docked newly generated compounds and their shape and properties of the binding 
site were characterized using the selected docking out properties for further 
characterization. 
 
2.8 Drug-likeness of DPT1 1-DPT6 6 and zm1 7, zm1a 7 and zm2 8 
 Sections 2.5.2, 2.5.6, 2.5.7, 2.5.8 and 2.9 reflect properties of DPT1 1-DPT4 4 as our major 
focus as explained. The examination of the drug-likeness of these selected hits is assertive. 
Drug-likeness is a complex balance of various molecular properties and structural features, 
requiring that a molecule intended for therapy should resemble known drugs, where they 
exist. Properties common to drugs include hydrophobicity, electronic distribution, 
hydrogen bonding (Hb) characteristics, pharmacophoric features, and molecule size and 
flexibility are commonly identified as influential factors of the behavior of the small 
molecule in a living organism. The ChemAxon (http://www.chemicalize.org/)  and its 
EGFRpred Software  (http://crdd.osdd.net/oscadd/egfrpred/draw.php)  predicted the 
Lipinski-like filters [175] and the  anti-EGFR activity [176]  of DPT1 1-DPT6 6, zm1 7, zm1a 
7 and zm2 8. The results of their predictions are shown in Table 31. 
 
 
 
Table 31. Lipinski-like filter predictions: DPT1 1-DPT6 6, zm1 7, zm1a 7 and zm2 8.  
ChemAxon Software was used for their Lipinski-like filters and anti-EGFR predictions. ‘Yes’ = 
requirements met; ‘No’ = requirements unmet. All abbreviations are fully clarified in Table 2. 
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Structure/properties of hit Ro5 BF GF LLF MF VF EGFR-inhibition 
 
Yes Yes Yes No Yes Yes 1. Probability 
score = 3 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
 
Yes Yes Yes Yes Yes Yes 1. Probability 
score = 3 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
 
Yes Yes Yes Yes Yes Yes 1. Probability 
score = 3 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
 
Yes Yes Yes Yes Yes Yes 1. Probability 
score = 0 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
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No Yes No No No Yes 1. Probability 
score = 1 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
 
N0 Yes Yes Yes No Yes 1. Probability 
score = 1 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
 
Yes Yes Yes Yes No Yes 1. Probability 
score = 1 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
 
Yes Yes Yes Yes Yes Yes 1. Probability 
score = 1 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
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All the compounds meet the Ro5 requirements except DPT1 1, DPT5 5, DPT6 6 & zm1 7 
which failed in one or two Lipinski-like filters as indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
Yes Yes Yes Yes Yes Yes 1. Probability 
score = 1 
2. Prediction = 
Non-inhibitor 
3. Prediction on 
EGFR-10 
model 
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Chapter Three 
Syntheses of zm1 7 (1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbohydrazide), zm1a 
7 (N'1,N'2-dicyclopentylideneoxalohydrazide) and zm2 8  (2-hydroxy-N-(4-
hydroxybenzyl)-2-(4-hydroxyphenyl)acetamide) 
3.0 Introduction 
The structural optimization of a prepared DPT4 4 core with Cayman fragment collection 
without a linker produced two synthesizable compounds: zm1 7 (Gscore -8.0), zm1a 7 and 
zm2 8 (Gscore -9.2) when docked into 1IVO |200-300|W that are synthesizable (Table 30). 
However, in the process of synthesizing zm1 7 compound zm1a 7 (N'1,N'2-
dicyclopentylideneoxalohydrazide) crystalized out and x-crystallographic information 
obtained. The generation of these first two compounds against a validated targeted for 
cancer therapy such as EGFR [177] is encouraging, despite chemical state. Figure 56 shows 
their structures, however, Table 30 shows only zm1 7 and zm2 8 since these are optimized 
docked compounds and their DS values. Table 31 shows the Lipinski-like filter properties 
of these compounds, introducing them as having passed the drug-likeness and lead-
likeness based on the predictions by the ChemAxon Software [175]. The prediction of their 
anti-EGFR activities by the Software  in Table 31 and elaborated on in Table 32 is based on 
statistical principles of random forest regression described by Singh and coworkers [176]. 
Singh and his group generated QSAR models using single scaffold-based analogues along 
with data collected experimentally. The group asserted that a dataset of approximately 
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3500 diverse molecules was used to generate the QSAR-based prediction models. Random 
forest is machine-learning software that envisages the inhibition strength of a potential 
anti-EGFR candidate drug. Random forest was first developed by Breiman [178] with a wide 
application for various statistical purposes in cellular studies [179]. Tables 31 & 32 are 
based on this information, wherein both zm1 7, zm1a 7 and zm2 8 are active inhibitors of 
EGFR with probability scores of 20, 28 and 23, respectively, on Prediction Model EGFR-
1000. Figures 55 & 56 show the 3D structures of zm1 7 and zm2 8 and associated aa residue 
interactive properties. 
 
 
 
 
 
 
 
 
 
 
Table 32. DS & full anti-EGFR features of zm1 7, zm1a 7 (in view) and zm2 8. 
No docked or bioevaluated metrics for zm1a 7. Zm1 7 found IC50 was not established since 
its slope was negative when bioevaluated. Anti-EGFR predictions were done with ChemAxon 
Software based on statistical models (nM) of IC50 ≤ 10, 100, and 1000. Their binding energy 
estimates (BEs) as defined by the molecular mechanics and implicit solvent energy were 
calculated using the prime energy for an optimized receptor-ligand complex. For zm1 7 total 
tautomers is 7, zm1a 7 224, and zm2 8 4, however, only the dominant is shown. 
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Agent Major tautomer 
shown 
aa residues Gscore Anti-EGFR 
model† 
10 100 1000 
 
bee: -38.23; pred. IC50: 4.6 
µM; calc. IC50: ? 
Total: 7 
 CYS240, MET244, 
LYS260, HIS280, 
GLY281, SER282 
-8.0 1 5 20 
 
 
Total: 224 
 
Yet to be docked  5 14 28 
bee: -
28.13; 
 
CYS240, SER262,  
GLY264, HIS280, 
CYS283 
-9.2 1 4 23 
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predict. IC50: 4.30 µM; 
calc. IC50: 0.63 µM 
Total: 4 
† = values are probability scores, all scores in EGFR-10 & EGFR-100 predict tag compounds non-inhibitors but as active 
inhibitors on EGFR-1000; bee = binding energy estimate; predict. = predicted; calc. = calculated; zm1a 7 (in orange 
filled) crystalized out while synthesizing zm1 7 and yet to be docked or bioevaluated  
 
 
 
 
 
  
 
 
 
 
 
Figure 56. 3D structure of zm2 8 in bonds with aa 
residues. Zm2 8 (in ball & stick) and its linked aa 
residues show the distances (in purple dashed 
lines). The Hbs (yellow dashed lines) and the 
hydrophobic bonds (green dashed lines). 
Figure 55. 3D structure of zm1 7 in bonds with aa 
residues. Zm1 7 (in ball & stick) showing its linked 
aa residues the distances (in purple dashed lines). 
The Hbs (yellow dashed lines) and the 
hydrophobic bonds (green dashed lines). 
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3.1 General instrumentation procedure for the syntheses of zm1 7 & zm2 8 
The reagents were obtained from Sigma-Aldrich, Australia, and used as such without 
further treatment. The Buchi rotary evaporator was used to achieve an efficient and gentle 
(gradual) evaporation of solvents from samples performed under vacuum. The products 
were purified by recrystallization and / or column chromatography, which were all carried 
out using prepacked silica gel columns provided by Grace RevelerisR on the Grace 
Automated column using favorable separating systems earlier guided by thin layer 
chromatography (TLC). The TLC was performed on Merck aluminium plates, silica gel 60 
F264. Components spotted on the TLC were visualized by observation under ultraviolet 
light (UV) 254 and/or 365 nm. Elemental analysis was carried out at Campbell Micro 
analytical Laboratory, Department of Chemistry, University of Otago, New Zealand. The IR 
was recorded on a Shimadzu FTIR–8400S apparatus. The melting points were determined 
on a Shimadzu SRS MPA100 OptiMelt Automated Melting Point apparatus. Proton and 
carbon nuclear magnetic resonance (1H and 13C NMR) spectra were recorded on a Varian 
400MR using DMSO-d6 as solvent. Chemical shifts were measured in parts per million 
(ppm) downfield from an internal tetramethylsilane (TMS) standard, and the residual 
solvent was used as a signal. Coupling constants are reported in Hz. NMR abbreviations 
used are s = singlet, d = doublet, dd = double doublet, q = quartet, m = multiplet, t = triplet 
and br = broad. The mass spectroscopy was performed on ESI Q1MS for low and high 
resolution.  
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3.1.2 Zm1 7 and [zm1a 7] syntheses 
 
 
 
 
Square brackets indicate an unintended product. Although the duo had the same starting 
materials their mechanisms are different. Zm1 7 is a 5,5-fused pyrazole carbohydrazide 
derivative but zm1a 7 an aliphatic hydrazide. Reactions of carbonyl-containing compounds 
with hydrazides and semicarbazides have extensively been investigated via versatile 
synthetic methods and for specific use in structural elucidation by infrared (IR) 
spectroscopy [180]. An earlier synthetic approach for hydrazides was by Szmuszkovicz and 
Greig in 1961 formed hydrazone-hydrazide compounds such as aliphatic and aromatic 
hydrazides  by reacting suitable oxalic acid derivatives with the hydrazine hydrate to yield 
oxalic acid bishydrazide on hydrazinolysis [181]. Since then, similar reactions have 
appeared in literature such as described [182-184]. We adopt a modified method by 
Semple et al., 2008 [185], to synthesize zm1 7 and [zm1a 7] which emerged as a crystal. 
An appropriate reagent to start with is cyclopentanone 9, which was acylated with diethyl 
oxalate 10, which on cyclization gives diketo ester 11. This reacts with H2NNH2.H2O 12 yield 
the bicyclic pyrazole ester 13. Excess H2NNH2.H2O yields both zm1 7 and [zm1a 7], howbeit, 
by different mechanisms (Scheme I). 
Figure 57. Structures of zm1 7 and zm1a 7. 
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Figure 58. Scheme I:  Syntheses of zm1 7 and zm1a 7. 
The mechanisms for zm1 7 and zm1a 7 synthesis are distinct due mainly to altered conditions. The 
conditions, reagents and/or process are (a) NaOET, EtOH, (EtOCO)2, all mixed at room temperature 
(rt) before mixture was heated at 75 0C; (b) H2NNH2.H2O, 75 OC, ≥ 2hr, cyclization; (c) excess 
H2NNH2.H2O required; (d) Hydrazinolysis; (e) (EtOCO)2, condensation. Zm1 7 is a product of 
hydrazinolysis via the hydrazine hydrate process. First, EtO- nucleophile extracts H from the active α-
methylene C to the carbonyl ketone, the carbanion readily reacts with the carbonium generated by 
the leaving EtO- , to form a new bond (in red colour) to get 11. A two equivalent H2NNH2.H2O is 
required to first form the transition product 13, and subsequently zm1 7. Zm1a 7 followed a different 
path, as an excess of H2NNH2.H2O was required to first form 14, and in condensation with (EtOCO)2 
to yield the product. 
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Figure 59. Scheme II: mechanisms for zm1a 7 synthesis over imine formation. 
Summary: (i) Protonation of 9 by a H donor, (ii) 9 becomes more electrophilic for a [1,2] addition 
with the amine, hydrazine, (iii) proton transfer, (iv) a [1,2] elimination of [-H2O] to form an iminium 
ion moiety, (v) deprotonation [-HX] with a proton acceptor to yield the imine 14, (vi) a condensation 
reaction of 14 & 10 and removal of [-CH3CH2OH]2 to produce zm1a 7. Reaction starts with stirring 
the dissolved 9 with a proton-donating moiety H-X, e.g., some acid, which weakens the C=O, 
making the carbonyl carbon more electrophilic since it binds to the carbonyl oxygen. The H2NNH2, 
an amine & a nucleophile, then attacks the carbonyl electrophilic carbon whence a [1,2] addition 
occurs. The proton transfer is an intramolecular event that protonates the [OH] to give [H2O
+
], 
which is an excellent leaving group. This transfer also frees the lone pair on the amine nitrogen, 
which attacks the neighboring carbon, leading to eliminating the [H2O] and iminium formation, 
considered the most positively charged organic molecules. A proton-accepting moiety, e.g., some 
base, deprotonates [-HX] the iminium to have 14. Further condensation of this product in 10 yields 
zm1a 7, which is a better alternative path to its synthesis.       
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3.1.3 Experimental details: syntheses of zm1 7 and [zm1a 7]  
Square brackets indicate an unintended product. Cyclopentanone 9 (4 g, 47.55 mmol) was 
dissolved in ethanol (230 mL). Diethyl oxalate (7.75mL, 47.55 mmol) 10 was added with 
stirring, followed by the addition of sodium ethoxide (3.56 g, 47.55 mmol), at room 
temperature. The mixture was heated at 75 0C for 2hr and cooled to 4 0C in an ice bath, to 
give ethyl 2-oxo-2-(2-oxocyclopentyl) acetate 11, as a pale yellow liquid product, which was 
neither isolated nor extracted. Aqueous hydrazine 12 (4.61 mL, 47.55 mmol) was added to 
11 and heated at 75 0C for 2 hours in the ethanolic medium. Its cyclization yielded the 
bicyclic pyrazole ester, 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate 13. The 
resulting aqueous crude product was extracted with dichloromethane (3 x 30 mL). The 
organic portion was dried over Na2SO4 and the DCM removed under reduced pressure. 
The brown fluffy solid obtained was purified by column chromatography on silica eluting 
with 50% EtOAc/n-hexane. Samples showing the same spot by TLC observed under UV light 
(254 nm) were pooled and evaporated under pressure and product recrystallized from 
EtOAc to obtain a white fluffy solid 7 of weight 208mg, 5.2%). 1HNMR data revealed that 
the isolated solid was a mixture of zm1 7 and zm1a 7; mp = 205-210 0C, no literature report 
on melting point; 1H NMR (400 MHz, DMSO-d6,) 1.62 - 1.76 (2H, m, CH2, C-5), 2.16 - 2.25 
(2H, m, CH2, C-4), 2.37 (2H, dd, J=7.1 Hz, C-6); 13CNMR (400 MHz, DMSO-d6,) 24.6 (C-5), 
28.8 (C-4), 33.58 (C-4), 156.2 (C-3a), 164.3 (C-3), 166.99 (C-6a), 174.21 (C-7); vmax, KBr/cm, 
3264 (-N-H), 1683 (C=O), 1653 (-CONH-; [M + H]+ = 167.09. 
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 3.2 Zm2 8: synthetic approaches 
  
 
 
 
Zm2 8 is a new chemical entity that emerged when DPT4 4 was optimized using Cayman 
fragment collection. Zm2 8, a hydroxylated benzoic acid amide derivative, was docked in 
1IVO |200-300|W as a proceed of the optimized DPT4 4 in search of anti-EGFR anti-
oligomeric agent. The polyhydroxylated benzoic acid amide derivatives are known 
anticancer agents [186], bitter-masking compounds [187] as well as antioxidants and non-
metal stabilizers essential in organisms, particularly, human skin [188]. Tables 29, 30 & 31 
show its docked results, Lipinski filter-like properties and anti-EGFR inhibition prediction 
using ChemAxon Software, respectively. The synthesis of the agent will add to the new 
drug group with a defined mechanism against cancer when successfully achieved and 
bioevaluated. 
 
3.2.1 Synthesis of zm2 8 
The direct conversion of a carboxylic acid to an amide is difficult as amines are basic and 
tend to convert the carboxylic acids to their highly unreactive carboxylates. The addition 
Figure 60. Structure of zm2 8.  
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of the carboxylic acid to DCC (dicyclohexylcarbodiimide) 17 (EDC, (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide) can also be used) creates a good leaving group that 
can be displaced by an amine during nucleophilic substitution. Complete removal of 
moisturized air requires the dissolution of reagents in 1,4-dioxan under nitrogen. There are 
known synthetic approaches to obtain hydroxylated benzoic acid amide or phenolic amide 
derivatives [189], however, the Ley and Bertram method [186] is adopted with 
modifications [190, 191] for the zm2 8 synthesis. Ley and coworker used the non-classical 
coupling of phenolic acids with acid chlorides and amines in basic mixtures since they 
observed the phenolic acids self-condense, to synthesize polyhydroxylated phenolic acid 
amides. The unprotected phenolic acid derivatives are generated using an activating agent 
such as DCC that induces coupling to form an unstable filterable precipitate amine-reactive 
O-acyl isourea intermediate from (2-(4-Hydroxyphenyl)acetic acid 15. The addition of NHS 
stabilizes the amine-reactive intermediate in converting it to an amine-reactive NHS-ester, a semi-
stable esterified 4-hydroxysuccinimide (NHS). This increases the efficiency of DCC-mediated 
coupling reactions to yield 8 when reacted with phenolic acid amine 19 through the formation of 
an amide bond (in red color in Scheme III).  This non-classical coupling approach is shown in 
Scheme III in Figure 60. Scheme IV shows the synthesis of zm2 8 in Figure 61.   
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Figure 61. Scheme III: the non-classic coupling synthetic mechanism of zm2 8. 
DCC–NHS chemistry: DCC reacts with a carboxylic-acid group to form an amine-reactive O-acyl isourea 
intermediate. This intermediate reacts with the amine to yield a conjugate of the two molecules joined 
by a stable amide bond. The addition of NHS stabilizes the amine-reactive intermediate in converting it 
to an amine-reactive NHS-ester, thus increasing the efficiency of DCC-mediated coupling reactions to 
yield 8 when reacted with phenolic acid amine 19.   
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Zm2 8 is synthesizable both in the non-classical (Scheme IV, mechanisms in Scheme III), 
which requires no protection of the phenolic acid amide –OH group (s) and the classical 
coupling methods using DCC (Scheme V, Figure 62, for mechanisms). This requires 
protection of the –OH group (s).  
3.2.2 Synthesis of zm2 8 – Experimental details 
2-(4-hydroxyphenyl)-2-oxoacetic acid (4-hydroxymandelic acid) 15 (2 g, 11.9 mmol) and 1-
hydroxypyrrolidine-2,5-dione 16 (1.40 g, 11.9 mmol) were dissolved in 100 mL of dioxan 
(12.3 mL/mmol) and N,N'-dicyclohexylcarbodiimide (DCC) 17 (2.5 g, 11.9 mmol) was added 
with stirring, under N2, at room temperature and left overnight (≥16 hr). The precipitated 
Figure 62. Scheme IV: Conditions for 
zm2 8 synthesis. 
(i) 1,4-Dioxan, NHS (1 equivalent), 
DCC (1 equivalent), rt, ≥ 16hr; (ii) 
H
2
O, NaHCO
3, (1 equivalent), HCl 
(calc. 5%), ≥ 2hr. 
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by-product 18 was filtered off and 4-(amino methyl) phenol 19 (1.5 g, 11.9 mmol) dissolved 
in 100 mL of water was added to the filtrate. The resulting product was acidified using HCl 
(calc., 5%) and extracted with ethyl acetate (3 x 30 mL). The organic layer was evaporated 
under reduced pressure and dried over Na2SO4 to give  (2-hydroxy-N-(4-hydroxybenzyl)-2-
(4-hydroxyphenyl)acetamide) 8  which was recrystallized from EtOAc to give an off-white 
solid (1180 mg, 59%), after drying in the desiccator; mp = 196.5-197.3 0C; 1HNMR (400 
MHz, DMSO-d6,) 4.1- 4.2 (2H, m, CH2, H-1’), 4.78 (1H, br. s., H-2’), 5.89 (1H, d, J=3.9 Hz, 
CH-OH), 6.65 (2H, dd, J = 8.5 Hz, H-2’, H-6’); 6.99 (1H, d, J = 8.6 Hz, 2 x H-3’, 2 x H-5’), 7.15 
(1H, d,  J = 8.6 Hz, H-3’, H-5’), 8.2 (1H, t, J = 6.16 Hz, N-H), 9.25 (1H, br. s., H-4’); 13CNMR 
(400 MHz, DMSO-d6,) 41.7 (CH2, C-2H), 73.7 (CH-OH, C-2), 115.3 (CH: C-3, C-5, C-3, C-5), 
128.3 (CH, C-2), 129 (CH, C-6), 130.20 (C-1’), 132.0 (C-1), 156.56 (C-4’), 157.0 (C-4), 173 (C,  
CO); vmax KBr/cm-1 3369.6 Ar-OH, 2504 O-H (OC-OH), 1545 (amide), 1512 (ArC=C); (ESI 
MS): 273.1 Found 274.0 [M + H]+; found elemental analysis (%): C 65.7, H 5.59;  N 5.1, calc. 
(%): C, 65.9; H, 5.5; N, 5.1 
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Figure 63. Scheme IV: a classical coupling for zm2 8 synthesis with DCC. 
The direct conversion of a carboxylic acid to an amide is difficult because amines are 
basic and tend to convert carboxylic acids to their highly unreactive 
carboxylates. When the carboxylic acid is added to the DCC molecule, a good leaving 
group is formed that is easy to be displaced by an amine during nucleophilic 
substitution.  DCC - induced coupling to form an amide linkage is an important reaction 
in the synthesis of peptides or where an amide (-N-C-) is required. Reaction requires 
protection of vulnerable groups such as –OH (in purple colour) as in phenolic acid 15. 
The stable amide bond is shown in red color.  
 
   
 
170 
 
Chapter Four 
Bio-evaluation of the selected hits 
  4.0 Introduction 
The screening of antitumor compounds utilizes a number of methods as in vitro or in vivo, 
for cytotoxicity, associated with some terms as named. For instance, a ‘cytotoxic’ 
compound is toxic to cells regardless whether they are normal or abnormal ones, and may 
be cytostatic (stops cell growth reversibly or irreversibly) or cytocidal (kills cells); an 
‘antitumor’ compound is active in an in vivo tumor system and shows selectivity against 
the tumor cells; and an anticancer refers to an effective agent against human cancers. All 
viability screening assay methods have limitations. Typical examples of viability assays are: 
a) membrane integrity assays - which determine cell membrane integrity via dye exclusion 
from live cells, e.g., Exclusion dyes, Fluorescent assays or lactate dehydrogenase (LDH) 
leakage; b) functional assays - which examine metabolic components that are growth 
essentials, e.g., (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) (MTS), crystal sulphate  /acid phosphatase or neutral red 
assay; c) Deoxyribonucleic acid (DNA) labeling assays- these carry out simultaneous cell 
selection and viability, e.g., Fluorescent  conjugates; d) morphological- which determines 
any morphological change, e.g., microscopic observation; and e) reproductive- which 
defines rate of growth, e.g., colony formation. The functional assays using MTS, a 
colorimetric-based sensitivity, cytotoxicity, and quantitative assay of viable cells in 
proliferation shall be used. The reduction of MTS tetrazolium compound by viable cells 
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generates a colored formazan dye product that is soluble in cell culture media, a 
conversion effected by nicotinamide adenine dinucleotide (phosphate) hydrogen 
(NAD(P)H)-dependent dehydrogenase enzymes in metabolically active cells. The formazan 
dye produced can be quantified by measuring the absorbance at 490-500 nm with the 
microplate reader. It is rapid, non-radioactive, safe, easy to use, flexible, accurate, permits 
high-throughput analysis under reduced medium and plastics costs, and allows volume 
miniaturization in 96-well microliter plates [192]. The prepared MTS solution (MTS and an 
electron-coupling reagent (phenazine methosulfate) PMS) is added directly into the wells 
of the cell culture media without intermittent steps, making MTS to have an edge over its 
group members like 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
[193].        
4.1 Some parametric terms used in the growth inhibition studies 
The cellular response parameters applied are the median growth inhibitory concentration 
(dose) or growth inhibition of 50 % (IG50), total growth inhibition (TGI) and half-maximal 
inhibitory concentration or concentration (dose) of inhibition of 50% (IC50). They are 
incorporated values that represent the concentrations at which the term percentage 
growth (PG) is +50, 0, and -50, for IG50, TGI and IC50, respectively [194-196]. 
4.1.1 Data generation and treatments 
This is termed the measured effect of the compound on A431 wild type (A431wt) cell line 
premeditated in this work as follows: 
a. If (Mean AH – Mean AC) ≥ 0, then  
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PG = 100 x (Mean AH – Mean AC)/(Mean AC – Mean AB) 
b. If (Mean AH – Mean AC) < 0, then  
PG = 100 x (Mean AH – Mean AC)/Mean AC,  
c. If (Mean AH – Mean AC) = 0, then PG = TGI = 0, which implies AH = AC 
 where: Mean AH = the average absorbance (A) of hit dose; Mean AB = the average A of 0.1 
% DMSO + A431wt; Mean AC = the average A of the blanks (100 µM 0.1% DMSO or 
complete medium minus cells) [197] (Table 33). Concentrations are expressed by log10 µM. 
The values for mean ±SD of data from the triplicate wells are calculated using the GraphPad 
Prism and adds the error bars automatically (GraphPad-Prism Software Inc., San Diego, CA). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 33. The 96-well microliter plate format for colorimetry. 
Letters A –H and Nos. 1 -12 represent the microliter plate map. Six rows (A – F) were used for the 
two different concentrations (e.g., 5000 cells  in A – C & 8000 cells in D – F) as divided by the 
colors orange for one and dark blue for another concentration. The 12 columns are as labeled 
the blank column 1 (complete medium, for AB), control column 2 (0.1% DMSO & cells, for AC) and 
concentration or dose columns 3 - 12 (test drug or ‘hit’, A431wt cells & medium, for AH). The mean 
absorbance values for A
B
, A
C
 and A
H
 for the first cell concentration, e.g., 5000 cells, are each (A + 
B +C)/3 & for, e.g., 8000 cells, (D + E + F)/3. The mean absorbance value in each column for 
different A431wt cell concentration reflects the hit dose, which can be normalized to percentage 
(0% - 100%) in GraphPad Prism for calculation of IG50 and IC50. Section 4.3 and Figures 65 – 72 
show the dose –response curves (DR) of the analyzed compounds.  
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4.1.2 PG 
This term measures the effect of the compound (hits) on (A431wt) cell line in percentile 
[197] and a useful parameter that defines other predictions [198]. 
4.1.3 IG50 
GI50 value defines the concentration for which PG = +50, and demonstrates that a drug 
effect of this intensity is interpreted as primary growth inhibition, i.e., the drug 
concentration that gives a 50% reduction in the net protein increase. GI50, a T/C-like 
parameter, where T = test growth (H, ‘hit’) & C = control growth, is capable of having values 
from +100 to -100, which makes it an acceptable measure of the growth inhibitory power 
of the tested compound (s) [197].  
4.1.4 IC50  
This half-maximal inhibitory concentration measures the effectiveness of a substance that 
inhibits a specific biochemical function (minimal inhibition can be estimated as well), i.e.,  
Row 1 2 3 4 5 6 7 8 9 10 11 12 
  Blank Control Hit concentrations (µM) used all through 
A 100μL medium 10μL(.1%v/v DMSO) + 90μL (cells)  1 2.5 5 7.5 10 15 25 50 80 100 
B 100μL medium 
10μL(.1%v/v DMSO) + 90μL (cells)  
1 2.5 5 7.5 10 15 25 50 80 100 
C 100μL medium 
10μL(.1%v/v DMSO) + 90μL (cells)  
1 2.5 5 7.5 10 15 25 50 80 100 
D  100μL medium 
10μL(.1%v/v DMSO) + 90μL (cells)  
1 2.5 5 7.5 10 15 25 50 80 100 
E 100μL medium 
10μL(.1%v/v DMSO) + 90μL (cells)  
1 2.5 5 7.5 10 15 25 50 80 100 
F 100μL medium 
10μL(.1%v/v DMSO) + 90μL (cells)  
1 2.5 5 7.5 10 15 25 50 80 100 
G                         
H                         
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the molar concentration of inhibition that specifically reduces the response by 50% of the 
maximum attained in a biological or biochemical function [199]. It is equivalent to the 
concentration for which the PG = -50 [20]. 
4.1.5 TGI 
This value shows that absorbance (number or mass of cells) in the hit dose well when an 
experiment ends equals the absorbance (number or mass of cells) in the control well. A 
drug with such intensity is cytostatic. In order words T (or H, hit dose) = C [197]. 
             4.2 Hits for bioevaluation  
 DPT1 1 – DPT6 6 and zm1 7 & zm2 8 (Tables 5, 9 & 27) are slated for bioassay. However, 
zm1 7 and zm2 8 are the optimized products. Zm1 7 had been bioevaluated following its 
spectral details before the unexpected crystallization of zm1a 7 from regular dimethyl 
sulfoxide (DMSO) (70 % by volume) and distilled water (30 %), and therefore yet to be 
assayed. Zm2 8 is synthesized and characterized. The predicted drug-likeness, lead-likeness 
and a few other Lipinski-like filters of these compounds (DPT1 1 – DPT6 6 and zm1 7, zm1a 
7 & zm2 8) using ChemAxon Software are shown in Table 31. Table 32 shows the predicted 
anti-EGFR of compounds zm1 7, zm1a 7 and zm2 8, using the EGFRPred, a ChemAxon 
Software, though the mechanism is not defined by the Software [176]. The downstream 
cascade resulting from the autophosphorylation of the tyrosine kinase aa residues requires 
more protein scaffolds and adapters to attain biochemical outcomes [200]. Akt [201] and 
ERK1/2 [202] are such key adaptor pathways among others. Anti-oligomerization activity 
is presumed to have occurred when phospho-Akt and phospho-ERK1/2 are missing and / 
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or smaller than the control, which are quantifiable [203, 204], which sets the pace for WB 
[205]. Figure 64 describes the model the bioassay is based. 
 
 
 
 
 
 
 
A431wt cell line, a human epidermoid carcinoma cell line, is chosen for its extremely high 
number of EGF receptors on its cell surface (3 x 106/cell, ≈ 0.2% of total protein) [206], 
which makes protein quantification and WB viable at very low determination levels.  
4.3 Experimental – Colorimetry results 
We adopted the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay protocol. 
Samples were solubilized in DMSO without filtration or sterilization of drug stocks at 100 – 
fold the desired final maximum ‘hit’ concentration and stored frozen prior to use. The 
A431wt cells were grown in DMEM-Dulbecco’s Modified Eagle Medium; 10 % FBS; 2mM 
glutamine; 100 IU penicillin & 0.1 mg/mL streptomycin in T75 Flasks at 37 oC, 5 % CO2, 95 
% Air and 100 % relative humidity Incubators. The 96-well microliter plates were seeded 
Figure 64. Model for the WB analysis. 
This is based on selecting the PI3K/Akt, 
Ras/Raf/MEKERK1/2, and EGF-induced 
EGFR activation as key signal 
transduction pathways to be blocked 
by DPTH, if active. 
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with the A431wt at cell strength range 4 x 103 - 1 x 104 cells/mL and incubated in a 100 % 
humidified 5 % CO2 Incubator over night at 37 oC. The old medium was removed and fresh 
medium added. 10.0 µL containing various prepared concentrations (not serially) of ‘hit’ 
or drug (DPT1 1 - DPT6 6 & zm1 7 or zm2 8) was added whereas positive/negative control 
has standard ‘hit’ and no ‘hit’, respectively (as illustrated in Table 33). Plates were 
incubated for 48hr at 37 oC in 100% humidified 5 % CO2 Incubator. The medium was 
removed from the wells at the end of incubation and 20 µL of combined MTS/PMS 
prepared solution pipetted into each of the 96 wells assay plate containing the 100 µL of 
cell line. Plates were incubated at 37 oC in humidified CO2, 5% atmosphere and 100 % 
relative humidity for 2 - 3hr and readings were taken at an absorbance of 490 nm using 
Bio-Rad Colorimetric Assay Plate Reader [207]. Each graph was plotted using the 
v6.0GraphPad Prism. GraphPad Prism makes provisions to statistically accommodate 
outliners for ‘best’ and reproducible curves for tested compounds, as well as it is fast, can 
express the results as fractions or percentages and the Software is easily manipulated, for 
instance, calculations can be made for concentrations of ‘hit’ agents giving a H/C value of 
10 %., or 10 % growth inhibition (IC90), H/C value of 25 %, or 75 % growth inhibition (IC75)  
and H/C value of 50 % and therefore growth inhibition 50 % (IC50) [197]. Figures 65 – 71 
show the dose – response curves (DR) of the compounds bioevaluated using the GraphPad 
Prism. Table 34 shows the summary of found and calculated dose-response curves (DR) 
and it is indicated where there is no observed result (nor). 
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4.3.1 Dose-response curves for DPT1 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
II 
Figure 65. DR of DPT1 1 vs cell line strength 
8 x 103 & 1 x 104 cell/mL.  
I: the concentration that gave 50% 
reduction in the net protein increase of 
A431wt cells in cell strength of 8 x 103 
cells/mL, IG
50
 = 3.980 µM, SD ±30.69; II: IG
50
 
of 1 x 104 cell/mL = 10.000 µM, ±25.25, for 
a triplicate determination per DPT1 1 
concentration; III:  Grouped sketched of I & 
II shows the difference between cell 
strengths.   
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4.3.2 Representative dose-response curves for DPT2 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
II 
III 
Figure 66. DR of DPT2 2 vs cell line strength 
8 x 103 & 1 x 104 cells/mL.  
I: the concentration that gave 50% 
reduction in the net protein increase of 
A431wt cells in cell strength of 8 x 103 
cells/mL, IG50 = 0.251 µM, SD ±34.36; II: IG50 
of 1 x 104 cell/mL = 1.585 µM, ±31.96, for a 
triplicate determination per DPT2 2 
concentration; III:  Grouped sketched of I & 
II shows the difference between cell 
strengths.   
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 4.3.3 Representative dose-response curves for DPT3 3 
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Figure 67. DR of DPT3 3 vs cell line strength 
8 x 10
3
 & 1 x 10
4 
cells/mL.  
I: the concentration that gave 50% 
reduction in the net protein increase of 
A431wt cells in cell strength of 8 x 103 
cells/mL, IG50 = 1.585 µM, ±36.45; II: IG50 of 
1 x 104 cell/mL = 0.681 µM, ±45.04, for 
triplicate determination per DPT3 3 
concentration; III:  Grouped sketched of I & 
II shows the difference between cell 
strengths.   
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 4.3.4 Representative dose-response curves for DPT4 4 
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Figure 68. DR of DPT4 4 on A431wt cell line 
strength 8 x 10
3
 & 1 x 10
4 
cells/mL.  
I: the concentration that gave 50% 
reduction in the net protein increase of 
A431wt cells in cell strength of 8 x 103 
cells/mL, IG50 = 1.585 µM, SD ±36.00; II: IG50 
of 1 x 104 cell/mL = 10.000 µM, ±30.89, for 
triplicate determination per DPT4 4 
concentration; III:  Grouped sketched of I & 
II shows the difference between cell 
strengths.   
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 4.3.5 Representative dose-response curves for DPT5 5 
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Figure 69. DR of DPT5 5 vs cell line strength 5 x 10
3
 & 8 x 10
3 
cells/mL.  
I: the concentration that gave 50% reduction in the net protein increase of A431wt cells in cell strength of 5 
x 103 cells/mL, IG50 = 1.250 µM, SD ±27.47; IGtc (threshold concentration) of 8 x 10
3 cells/mL = 6.25 µM, SD 
±19.71, for triplicate determination per DPT5 5 concentration; II: A survival sketch enables the sigmoid shape 
and calculation of the IG50. Grouped sketched of I shows the difference between cell strengths.   
I 
II 
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 4.3.6 Dose-response curves for DPT6 6 
 
 
 
 
 
 
 
 
  
 
 
 
 
I II 
Figure 70. DR of DPT6 6 vs cell line strength 5 x 10
3
 & 8 x 10
3 
cells/mL.  
I: the concentration that gave 25% reduction in the net protein increase of A431wt cells in cell 
strength of 5 x 103 cells/mL, IG75 = 40.460 µM, SD ±20.17; IG75 in cell strength of 8 x 10
3 = 40.46, 
SD ±21.40, in a triplicate determination per DPT6 6 concentration; II: Grouped sketched of I shows 
the narrow difference between cell strengths.   
0 51 0 - 1 11 0 0 21 0 0 21 0 0 31 0 0
0
1 0 0
1 5 0
% G I o f  D P T 6 6  in  5 0 0 0  &  8 0 0 0  A 4 3 1  c e ll lin e
L o g 1 0 [D P T 6 ] ( M )
%
 G
ro
w
th
 I
n
h
ib
it
io
n
 (
G
I%
) % G I (5 0 0 0  c e lls )
% G I (8 0 0 0   c e lls )
IG 50
IG 5 0  =  0  in  b o th  c a s e s
n  =  3
2
.0
0
0
0
.8
0
7
9
3
3
1
.0
5
0
2
0
4
1
.2
9
2
4
7
4
1
.5
3
4
7
4
5
1
.7
7
7
0
1
5
0
.8
1
3
9
6
0
1
.0
5
6
2
3
0
1
.2
9
8
5
0
1
1
.5
4
0
7
7
1
1
.7
8
3
0
4
1
0
1 0 0
1 5 0
% G I o f  D P T 6 6  in  5 0 0 0  &  8 0 0 0  A 4 3 1 c e ll lin e
L o g 1 0 [D P T 6 ]( M )
%
 G
ro
w
th
 I
n
h
ib
it
io
n
 (
G
I%
)
% G I (5 0 0 0   c e lls )
% G I (8 0 0 0  c e lls )
IG 5 0  =  0  in  b o th  c a s e s
n  =  3
% G I (5 0 0 0  c e lls )
% G I (8 0 0 0   c e lls )
G I50
 
   
 
183 
 
4.3.7 Representative dose-response curves for the mixed zm1 7 
 
 
 
 
 
 
 
 
 
I 
II 
Figure 71. DR of zm1 7 vs cell line strength 4 x 10
3
 & 8 x 10
3 
cells/mL.  
I: the concentration that gave 25% reduction in the net protein increase of A431wt cells 
in cell strength of 4 x 103 cells/mL, IG75 = 30.460 µM, SD ±4.14; IG75 in  cell strength of 8 
x 103 = 30.300 ±8.70, for triplicate determination per zm1 7 concentration; II: Grouped 
sketched of I shows the difference between cell strengths. Zm1 7 slopes are different 
from the rest.  
-4 -2 0 2 4
0
50
100
% G I o f z m 1 7  in  8 0 0 0  A 4 3 1  c e ll lin e
L o g 1 0 [zm 1 ] (n M )
%
 G
ro
w
th
 I
n
h
ib
it
io
n
 (
G
I%
)
4 0 0 0  A 4 3 1  c e lls
8 0 0 0  A 4 3 1  c e lls
n  =  3
IG 5 0 =  0  in  th e  tw o  c a s e s
4 0 0 0  A 4 3 1  c e lls
8 0 0 0  A 4 3 1  c e lls
-2
.3
5
9
3
5
9
-1
.0
2
8
0
2
8
0
.3
0
3
3
0
3
1
.6
3
4
6
3
4
-2
.0
3
9
0
3
9
-0
.7
0
7
7
0
8
0
.6
2
3
6
2
3
1
.9
5
4
9
5
5
0
50
100
% G I o f z m 1 7  in  8 0 0 0  A 4 3 1  c e ll lin e
L o g 1 0 [z m 1 ] (n M )
%
 G
ro
w
th
 I
n
h
ib
it
io
n
 (
G
I%
)
4 0 0 0  A 4 3 1  c e lls
8 0 0 0  A 4 3 1  c e lls
n  =  3
G I5 0 =  0  in  th e  tw o  c a s e s
4 0 0 0  A 4 3 1  c e lls
8 0 0 0  A 4 3 1  c e lls
 
   
 
184 
 
4.3.8 Representative dose-response curves for zm2 8 
 
 
 
 
 
 
The summary of the values described in the dose-response curves are shown in Table 34. 
The experimental IC50 and the predictive IC50 values are also included, in addition to other 
parametric information.  
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II 
Figure 72. DR of zm2 8 vs cell line strength 5 x 10
3
 & 8 x 10
3 
cells/mL.  
I: the threshold concentration (tc) required to initiate a reduction in the net protein increase of 
A431wt cells in both cell strengths of 5 x 103 IGtc (threshold concentration) = 0.130 µM, SD 
±3.32; the estimated threshold in cell strength concentration of 8 x 103 cells/mL, IGtc = 0.130 
µM, ±6.31, for a triplicate determination per zm2 8 concentration; II: Grouped sketched of I 
shows no difference between cell strengths.   
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Lead 
Candidate 
Gscore %GI50 or %GI75‡ (µM) TGIΔ IC50 (found)¤ (µM) IC50 (µM)  
(predicted)† 
[208] 
5000 
cells/mL 
8000 
cells/mL 
10000 
cells/mL 
 5000 
cells/mL 
8000 
cells/mL 
10000 
cells/mL 
Anti-oligomerization lead candidates 
DPT1 1 -2.70  3.98 10.00 0  8.90 28.90 3.98 
DPT2 2 -1.90  0.25 1.59 0  0.40 2.40  0.17  
DPT3 3 -2.10  1.59 0.68 0  1.50 0.70 6.61 
DPT4 4 -3.50  1.59 10.00 0  1.10 9.10  3.98 
Cytoplasmic Tyrosine kinase-Targeted (RTKI-like) 
DPT5 5 -10.60 1.25 6.25  0 0.3892 6.25 4.50 6.31 
DPT6 6 -10.30 40.46 
(IG75) 
40.458 
(IG75) 
 0 30.460 30.30 4.80 7.59 
Synthesized Anti-oligomeric anti-EGFR 
Zm-1 7† -8.00    0 0.3404‡ 0.1216 - 2.82 
Zm-2 8 -9.2 0.13 (tc) 0.13 (tc)  0 0.4053 0.0 4.20 5.01 
Table 34. Summary of found and calculated parametric DR values. 
The % GI50, % GI75, calculated & investigational IC50 for all screened hits in cell strength 
range 4 x 103 – 1 x 104 cell/mL used in the experiment are shown. Only zm1 7 used 4 x 103 
cell strength in the random cell strength sampling. The predicted IC50 for each candidate 
under consideration is indicated. The total growth inhibition (TGI) has a zero value since 
there are IG values. 
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‡ = GI50 or GI75 was used; Δ = total growth inhibition is zero once drug acts; ¤ = predicted from QikProp (Schrodinger 
LLC, New York, NY USA); nor = no observed result; tc = threshold concentration; † = zm1 7 is the crude mixture of zm1 
7 based on spectral information and zm1a 7 which crystallized out late and could not be assayed for time; ‡ = zm1 7 
was analyzed in cell strengths 4 x 103 & 8 x 103 only    
 
4.4 Experimental: Immunoblotting (WB) results  
The preliminary screening of the hits by MTS - colorimetric methods showed DPT1 1 – DPT4 
4 could further be investigated (Figures 65 – 72 and Table 34). Immunoblot analysis of 
EGFR have been reported [209, 210]. The protocol to set the activity profile for each of the 
compounds DPT1 1- DPT4 4 at selected concentrations of 1, 10 and 100 µM and Gefinitib 
10 µM in a 2 x 6 – well plate was adhered to (format shown in Table 35).  
 
 
 
 
 
 
 
Table 35. Format for activity profile of the ‘hits for WB. 
Where DPTH = the hits of DPT1 1 – DPT4 4 & A431wt = A 431 wide type. Hit was allowed an 
overnight contact with A431wt, however, only about minutes contact when EGF as added to 
cell well contents. 
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Each well had 2 x 106 cells grew to 80 % confluent, washed and serum-starved overnight 
in starving medium (0.1 % FBS/BSA, DMEM). The DPTH (hits of DPT1 1 – DPT4 4) and 
Gefitinib at said concentrations were added in complete medium (10 % FBS, 1 % PS, 
DMEM) and incubated at 100 % humidity, 37 °C, 5 % CO2 and 95 % Air for 1 hr. The cells 
were stimulated with 10ng/mL EGF for 3 minutes, washed with ice cold PBS and cells lysed 
with 200 µL lysis enriched buffer per well. The precipitates and lysates were resolved on 
7.5% SDS-PAGE, electrophoretically transferred to the polyvinylidene fluoride (PDVF) 
membrane, and blocked in 5% skim milk in Tris-Buffered Saline and Tween 20 (TBST) for 
1hr, to prevent interactions between the membrane and the primary antibody used for 
detecting target protein. This was washed 3x for 5 minutes with PBS-Tween 0.01% and the 
First six-well plate 
A431wt 1 µM DPTH 
1 
A431wt  10 µM  DPTH 
2 
A431wt  100 µM  DPTH 
3 
A431wt 1 µM  DPTH 
+EGF 
4 
A431wt 10 µM  DPTH 
+EGF 
5 
A431wt 100 µM  DPTH 
+EGF 
6 
Second six-well plate 
A431 WT 
1 
A431 WT 
+EGF 
2 
A431 WT 10 µM Gefitinib 
+EGF 
3 
 
4 5 6 
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membrane probed with the designated primary antibody [p-Akt, Rabbit (Host), dil.1:1000, 
Cat. No. 4685 (Cell Signaling Technology, Danvers MA 01923, USA); p-44/42 Map Kinase 
(ERK1/2), Rabbit (Host), dil.1:1000, Cat. No. 9101 (Cell Signaling Technology, Danvers MA 
01923, USA); or p-EGFR (tyrosine), EGFR (Cell Signaling Technology, Danvers MA 01923, 
USA)], in 5 % bovine serum albumin (BSA) and incubated overnight at 4 oC on a shaker in 
the cold room (or for 1hr at rt). This was washed with PBS-Tween 0.01 % for 5 minutes 3x 
and then probed with a secondary, HRP-linked Anti-rabbit, Goat (Host), dil.1:10000, Cat. 
No. 7074 (Cell Signaling Technology, Danvers MA 01923, USA) for 1hr at rt and washed 
again 3x for 5 minutes with PBS-Tween 0.01 %. Then proteins were visualized using 
Western Lightning® Plus-ECL substrates (Perkin Elmer, Waltham, MA, USA) according to 
manufacturer instructions. Membranes incubated in ECL were exposed to X-ray film 
(Fujifilm, Tokyo, Japan). Densitometry was carried out using v1.47ImageJ [211]. 
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4.4.1 Effects of DPT1 1-DPT4 4 on EGF-induced Akt activation 
  
 
 
 
 
 
 
 
  
Figure 73. Effects of DPT1 1 to DPT 4 4 on EGF-induced pY-Akt1/2 activation. 
The profile activity of the DPT1 1 – DPT4 4 was prepared according to the protocol at 
concentrations 1, 10 & 100 µM for each DPT. Cells were starved overnight in medium 0.1 
% FBS/BSA, DMEM, and on rinsing were incubated with the compounds in non-starving 
medium10 % FBS,1 % penicillin & streptomycin (PS) , DMEM. The cells were then 
stimulated with 10 ng/mL EGF. WB assessed cell lysates.    
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 4.4.2 Effects of DPT1 1-DPT4 4 on EGF-induced ERK1/ERK2 activation 
 
 
 
 
 
 
 
 
 
 
 
Figure 74. Effects of DPT1 1 to DPT 4 4 on EGF-induced pY-ERK1/2 activation. 
The profile activity of the DPT1 1 – DPT4 4 was prepared according to the protocol at 
concentrations 1, 10 & 100 µM for each DPT. Cells were starved overnight in medium 0.1 
% FBS/BSA, DMEM, and on rinsing were incubated with the compounds in non-starving 
medium10 % FBS,1 % penicillin & streptomycin (PS) , DMEM. The cells were then 
stimulated with 10 ng/mL EGF. WB assessed cell lysates.    
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4.4.3 Effects of DPT1 1-DPT4 4 on EGF-induced pY-EGFR activation and representative graph for all 
 
 
 
 
 
 
 
 
 
 
Figure 75. Effects of DPT1 1 to DPT 4 4 on EGF-induced pY-EGFR activation. 
The profile activity of the DPT1 1 – DPT4 4 was prepared according to the protocol at 
concentrations 1, 10 & 100 µM for each DPT. Cells were starved overnight in medium 
0.1 % FBS/BSA, DMEM, and on rinsing were incubated with the compounds in non-
starving medium10 % FBS,1 % penicillin & streptomycin (PS) , DMEM. The cells were 
then stimulated with 10 ng/mL EGF. WB assessed cell lysates.    
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Figure 76. Graph showing normalized data from Figures 72 – 74 using ImageJ. 
This was analyzed by densitometry using ImageJ Software program (available from 
http://imagej. nih.gov/ij/) that analyzed the selected image lanes on the film to measure the 
relative amount of the specific protein on the blot by comparing it with a control.  
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Chapter Five 
Result analyses and discussions 
5.0 Introduction 
There are two established types of ErbB-RTK subfamily inhibitors, viz, a) the mAbs and b) 
the RTKIs, which act at different domains of the receptors. For instance, the mAbs act at 
the ectodomain locale either by interfering with the ligand such as EGF [212] or the 
receptor such as EGFR [213], in each case interference with dimerization occurs, while the 
RTKIs act in the cytoplasmic tyrosine kinase  domain. However, little  has been done in the 
dimerization region as per developing specifically anti-EGFR anti-dimeric small molecules 
that inhibit the dimerization processes in spite the ligands bound to their canonical ErbB 
receptors [87]. In ‘Targeting the Oligomerization Region of the Epidermal Growth Factor 
Receptor’, we have attempted to design small molecules that act in the ‘oligomerization 
region’ (Section 1.5.2). Additionally, available data show dimerization is failing to respond 
to fundamental questions, for which the concept of oligomerization mechanisms, 
particularly heterotetramerization, has dared to, about the ErbB-RTK subfamily members 
(Section 1.5.3). Once more, this has polished the scope of our work. In this pioneering piece 
of the study, EGFR, a known validated cancer target was aimed, specifically the 
‘oligomerization region’ (already defined) using millions of small molecules from free and 
commercial chemical databases, however, only four were selected finally for purchase and 
preliminarily bioevaluated. One, zm2 8, obtained through the optimization of DPT4 4 
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molecule, was synthesized. It has undergone a preliminary colorimetric (MTS) bioassay 
with success, however, it still requires further bioanalysis. One more potentially active and 
synthesizable compound, zm1 7, awaits its synthesis and characterization for 
bioevaluation. A third synthesizable compound, zm1a 7, inadvertently crystallized out 
while synthesizing zm1 7, which, hopefully will further be characterized and bioevaluated. 
5.1 The Molecular modeling (MM) 
MM incorporates altogether the theoretical methods and computational techniques used 
to model or mimic the behavior of molecules [214]. Molecular docking (MD) is key in MM 
as it predicts the preferred orientation of one molecule to a second when bound to each 
other to form a stable complex [215]. The knowledge of the preferred orientation in turn 
can be used to predict the strength of association or binding affinity between two 
molecules using, for example, scoring functions. MD interprets MM, hence it is an 
optimization problem when optimized conformation for both receptor and ligand is 
achieved, thus making it central to computer-aided rational drug design [216]. Our 
molecular modeling appreciated these briefs and we went on to achieve as described.  
5.1.1 The Grids  
Following the modification of the proteins (Section 2.2), a grid was generated from the 
2J6M, which meant removal of AEE788 for new ligands to come in, however, five grids 
were generated from the 1IVO, namely, |246-253|S (Figure 27A), |246-253|W (Figure 
27B), |86 230 263 264 265 275 278 283 285 286|S (Figure 27C), |86 230 263 264 265 275 
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278 283 285 286|W ((Figure 27D) and |200-300|W (Figure 27E) (Section 2.3.3). A total of 
about six grids were generated. When |246-253|W was docked in a similar way as |246-
253|S, the Gscores were 2 – 3x higher as seen in section 2.5.7. Furthermore, |246-253|S 
did not show a Gscore when docked with ZINC ligands but |246-253|W had as shown in 
Table 9. The docking of |86 230 263 264 265 275 278 283 285 286|W with a number of 
different ligand sources yielded encouraging Gscores as contained in Tables 17 & 18 of 
section 2.5.7.  A number of grids were not utilized sufficiently such as |86 230 263 264 265 
275 278 283 285 286|S, |200-300|W & |86 230 263 264 265 275 278 283 285 286|W for 
time. For instance, the optimized lead DPT4 4 yielded zm1 7 and zm2 8 when docked with 
|200-300|W, showing high Gscores (Table 30). 2J6M docked outcomes had Gscores 
generally 3 – 5x those of the |246-253|S as shown in Tables 8, 9, 10 & 12 (cf. Tables 4, 5, 
& 6). These observations were insightful as our docking outcomes could possibly be 
influenced by the quality and / or nature of grid generated. A number of factors may be 
considered for these observations. 
5.1.2 The Ligands  
It is important to note that Ambinter, ChemBridge and the curated ZINC Chemical 
Databases shared the same coding system, ZINC, at the time this Project commenced. A 
total of about ≥ 9 x 106  ready-to-dock ligands from seven chemical databases were used 
in the docking, with focus on the |246-253|S and the subsidiary grid 2J6M (Section 2.4). 
Not all ligands docked properly with this grid, e.g., from the ZINC Chemical Database (see 
Figure 28). The  ligands, however, gave the ‘best’ scores with 2J6M (Table 9) which 
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ultimately led to selecting DPT5 5 & DPT6 6 as hit leads as well (Table 29), despite domain 
differences. Similarly, |246-253|S-ZINC ligands yielded but |246-253|W-ZINC ligands did 
as shown in Table 16. 2J6M generally excelled with most ligands docked and were used W 
(dimer) docking for time. These few observations indicate an adequate knowledge about 
ligand sources may save time and resources prior to docking. Moreover, there are specific 
or focused and general ligand sources. At the moment none is known for the 
oligomerization region.  
5.1.3 Glide docking 
Glide has been instrumental to the grid generation of the prepared receptors, ligand 
docking, and analyzing their parameters (Section 2.4.2). Glide can be set to dock flexibly or 
rigidly ligands into, usually, a rigid receptor structure as already explained and the nature 
of the grid matters as shown in Figures 28, 29 & 45 and reflective results in Tables 29 & 30. 
Glide in modeling stands out among others [172]. However, Glide can yield both false-
positives and false-negatives as well [158], which can be treated by post docking processes. 
Or better, values of 15% and 2% should be adapted depending on the library size and 
preparedness to wait. For instance, if the library is made of 10,000 structures or less it is 
alright to directly use the XP procedure to avoid false-positive and false-negative results 
(with 10 jobs with 1000 structures for example, each job will take 5,000 minutes i.e. 3-5 
days). However, Glide makes efforts to take care of the false-positives and false-negatives 
using its extra-precision (XP) mode that combines a powerful sampling protocol with a 
custom scoring function that is specifically designed to eliminate false positives [171], thus, 
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further improve enrichment. Time, size and nature of ligand and receptor were all 
observed to influence the verdicts of Glide. The fact that we have Schrödinger Release 
2015-4, suggests affirmatively Schrödinger (Schrödinger, LLC, New York, NY), the sole 
Proprietors of the Schrödinger Suite, is addressing some of these issues, and to remain 
competitive.  
5.1.4 Glide parameters for qualifying and quantifying docking outputs 
It is a status that we rate the success or failure of our docked outcomes by the final 
GlideScore (Gscore, GS) in Glide, which may be interpreted as the final quantification or 
scoring of the functions in the Program. However, it is important to note that several 
parameters entwined for a successful scoring function. “Which is the least or the most 
important parameter” seems to be a right query to dabble with. In this piece of work, we 
appreciated deeply what we obtained as final Gscores, however, we needed another 
approach to handle our docking outcomes, which finally led to the selection of the ‘hit 
leads’ DPT1 1 – DPT4 4 despite their very low Gscores (already explained), which 
subsequently became our ‘lead candidates’ on successful preliminary bioevaluation. There 
are twenty-two Maestro properties generated by HTVS and SP during docking runs and an 
additional fifteen Glide XP terms (plus their subdivisions) and their visualizations, for which 
it is expected that docking score (DS) (all the additional terms) and Gscore (sum of XP 
terms) should have an equal figure, as an instance [171]. Fails are expected as seen in Table 
9 where DS ≠ GS.   We deliberately chose docking properties such as DS or Gscore, GLE, 
ME and GLESA & a Glide XP term, LowMW, among other terms or parameters in v6.9Glide 
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program to characterize docked compounds. The Scatter Plots from the Project Table and 
v2.6Canvas Programs were used to see if correlations existed among a group of docked 
compounds (Section 2.5), the influence of the receptor (s), the docking software/scoring 
functions and ligand nature. The Scatter Plots for the lead candidate compounds were 
particularly focused on, with occasional comparison with known compounds. ME was the 
most featured for reason it appears to be the most intertwined with other parameters 
(Section 2.4.3). However, the use of v2.6Canvas showed that the comparison of DS, GLESA, 
ME and GE docking properties were within defined ranges Tables 7, 11, & 24 – 28. The 
Scatter Plots showed wide variations (Section 2.5 introduces correlation values). Figure 36 
shows those of known compounds (Built ligands from Table 13), which had poor 
correlation (R2 = ≤ 0.50) except in DS & GLESA independent of the GE; Figures 32A – 32D 
showed poor correlation except in DS & GLESA; Figure 36 had poor correlations in all 
except DS & GLESA independent of GE; Figures 46 – 49 showed poor correlations in all the 
optimized structures. The Canvas reports about the compounds tested with it were within 
the required range, as exemplified by Tables 7 & 11 containing the selected hit leads when 
Ambinter ligands were docked with 1IVO |246-253|S & 2J6M; Tables 24 – 28 show ME and 
GE are within range for the DPT1 1 – DPT4 4, respectively. There is also a similar 
observation in the Canvas analyses of 1IVO |246-253|S-RTKI ligands from Tables 4 shown 
in Table 28. It thus shows Canvas is more relax with Glide parameters than the Scatter 
Plots.  
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5.1.5 The CombiGlide enumerated and docked results 
We used v3.9CombiGlide to optimize the modified cores of DPT1 1 – DPT4 4 which enabled 
their synthetic feasibilities into designing a combinatorial libraries of the compounds. The 
workflow flow we harnessed was to instruct CombiGlide to enumerate, dock and analyze 
our results on a) submitting cores for each of the lead candidates in turn, b) made available 
the chemical fragment database, and c) chose whether to use a linkage (s) or not. It 
achieved this through the combination of accurate ligand-receptor scoring and an effective 
combinatorial docking algorithms (Section 2.5.8, Figure 45). We generated ≥ 2.3 x 109 
compounds, which actually overwhelmed the software, therefore more than three-
quarters could not be docked due mainly to designed properties because CombiGlide 
functions ‘best’ for small focused libraries. Only two grids were used, viz, 1IVO |246-253|S 
and |200-300|W, which were docked with optimized DPT1 1-DPT4 4. The results of docked 
|246-253|S are shown in Tables 20 – 23. Gscores improved 3-5x as shown in these Tables 
20-23 & 30. Table 30 in particular resulted 1IVO |200-300|W-optimized DPT4 4 core. 
Although, most of these new chemical entities were neither purchasable nor readily 
synthesized, the |200-300|W- yielded two synthesizable compounds zm1 7 & zm2 8 (Table 
30).  The ‘best’ optimized compounds were from DPT4 4 (Table 30) while DPT2 2 yielded 
the most ionized products (↑pKA) (Table 21). The physicochemical properties of the 
outcomes of the optimized lead candidates depended on the nature of the fragments and 
cores, some of which have been analyzed using Glide features as shown by their Scatter 
Plots in Figures 46 – 49, where variations in their DS were significant, though Canvas 
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analyses in Tables 24 – 27 depict their values as within range, which expressed a similarity 
with the known compounds in Table 28. 
5.1.6 Drug-likeness and lead-likeness of the lead candidates 
 Gscore is a relatively expensive calculation when Glide is ran.  In its virtual screening 
workflow, filtering requires an unconditional run of QikProp, prefiltration by Lipinski’s Rule 
and the removal of ligands with reactive functional groups. Glide has ≥ 70 properties, ≥ 18 
general attributes and close to 160 functional group counts to use in ligand filtering. This 
left us with the choice to design our compounds to our desires. Lipinski’s Ro5 is the most 
popular filter, however, its limitations are known (Section 2.4.1). This weakness in Ro5 
demanded a search for new empirical rules, commonly referred to as Lipinski-like filters 
shown in Table 2. These empirical rules have been used to predict some basic drug-likeness 
and lead-likeness of the lead candidates DPT1 1-DPT4 4, the RTKI-like DPT5 5 & DPT6 6, 
zm1 7, [zm1a 7] & zm2 8, although their selection procedures were manual. Table 31 shows 
that all the compounds made the Ro5 and only a few missed it with the Lipinski-like filters, 
as predicted by ChemAxon Software (already mentioned).     
5.1.7 Other physicochemical properties of DPT1 1-DPT4 4  
We started the visualization of the physicochemical properties of the four lead candidates 
in Section 2.5.5 subsections 2.5.5.1 -2.5.5.4 (Figures 37 – 40), where the emphasis was on 
the mechanisms on how each lead interacted with its bonding aa residues to form the key 
noticeable linkages, namely, i) hydrogen bonds, ii) hydrophobic bonds and iii) the π – π 
 
   
 
201 
 
interactions. The densest were the hydrophobic bonds which seemed to be influenced by 
the structure of the compound (section 2.1). Only DPT1 1 & DPT3 3 demonstrated their π 
– π interactions which occurred between the TYR246 aromatic ring and the pyrazole of 
DPT1 1 and the quinoline ring of DPT3 3. The hydrogen bonds were formed mostly with 
TYR246 & TTYR251 aa residues. Section 2.5.6 subsections 2.5.6.1 – 2.5.6.4 expanded on 
the section 2.5.5 to offer a more detailed molecular interactions that occurred between 
the aa residues and the lead hits. Table 14 shows a summary of the aa residual hydrogen 
bond, hydrophobic and π – π interactions exhibited by the leads, and following carefully 
Figures 41A/B, 42A/B, 43A/B & 44A/B. This showed the uniqueness in these compounds as 
anti-EGFR anti-oligomers, which is can be manipulated chemically to improve potency. The 
function of MET244 is unclear in the oligomeric arm of the β-hair loop, however its 
significance in the ‘oligomerization region’ is predictable.   
5.1.8 Limitations and challenges in protocols contributory to docking outcomes 
In addition to those already mentioned  (Section 2.6), a few factors could have influenced 
the docking outcomes in either way (poor or good docking), some of which are explained 
as follows: a) since glide docks flexible ligands into a rigid receptor structure by a rapid 
sampling of the conformational, orientation, and positional degrees of freedom of the 
ligand of the receptor, this could suggest that the rigidity and the interacting space could 
have been interfered with, leading to the poor outcome; b) further evidence to this is the 
increase in ligand-receptor interaction space and therefore Gscores increase in the 
oligomeric grid docking (Tables 15-18 & 30) as compared to 1IVO |246-253|S in Tables 4, 
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5, & 6; c) the software version could be a contributor to poor result, for instance, the 
maximum number of atoms in a ligand is 500 and the maximum number of rotatable bonds 
is 100 for the 2015-1 release v6.8Glide but our Project commenced with the limits of 300 
atoms and 50 rotatable bonds, whereas, for a rigid docking and score-in-place, there is no 
limit on the number of rotatable bonds; d) Glide concerns mainly with generating an 
accurate pose for each ligand and docking enrichment (the separation of actives from 
inactives), however, the task of accurately estimating binding for a set of ligands, 
particularly if they are diverse in structure, remains a herculean challenge and an active 
area of research for Schrödinger, which could have influenced our outcome; e) Glide is 
slow and somewhat poor in handling very large chemical databases, a disposition that 
could have influenced the outcomes following the millions of compounds  docked; f) 
opposed to undruggability is a good docking target, which should be deep with well-
defined pocket as shallow pockets have too many options that guarantee no docking 
altogether. This is explained this way: the T (|246-253|S) is a shallow site and this could 
cause ligands to bypass docking, a feature that is seen in the wide differences in the 
Gscores of W and S; g) the target site for specific interactions should have well-ordered 
side chains as well as having their backbone chains in place, which was weak situation in 
the monomeric arm (S), and therefore could impact negatively on docking requirements; 
h) many positive charge-charge or Hb and less hydrophobic interactions, particularly, a 
minimized vdW bad interactions are conditions that assist in effective docking, a lack of 
these can lead to poor docking, which could be absent in S when 1IVO |246-253|S-ZINC 
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ligand docking was done;  i) the mechanism of drug action matters, for instance, 1IVO |246-
253|S, which resulted from excising its bonding partner in the cleft, did not only dock 
poorly, but there could have been a form mechanisms, for instance, docked 2J6M-ZINC 
ligands had Gscores 3-5x those obtained with other ligand sources, as shown in Tables 8, 
9 & 12; and j) on the overall, docking and scoring algorithms are currently challenged with 
several limitations, some of which have been mentioned, which do affect effective docking 
leading to unexpected outcomes. Docking is a stair case that depends on so many factors 
to ascend successfully. Attempts to study some docking properties of known drugs vis-à-
vis the same selected chemical properties, exemplified by the RTKIs, curcumin and anti-
dimeric anti-EGFR P & Y), when docked with 1IVO |246-253|S, revealed that docking 
properties for these compounds fluctuate as well which is noticeable in Tables 3, 12 & 28 
and Figures 36 & 54) despite differences  in mechanisms. The Gscores and a few other 
physicochemical properties were observed to be close to each other, curcumin, though its 
mechanism of inhibition is unknown, had a Gscore of -9.3, which was 2-4x higher than the 
rest. These observations affirm our believe that DPT1 1 – DPT4 4, in particular, will make 
good anti-EGFR anti-oligomeric agents.  
5.1.9 Summary of drug modeling 
The detailed analyses of DPT1 1, DPT2 2, DPT3 3 and DPT4 4 for their inhibition at the 
ectodomain (1IVO |246-253|S) and endodomain (2J6M) regions of the EGFR, supported 
by their predicted anti-EGFR, and their general successful passage of the Lipinski-like filter 
tests, prepared these potential pioneering anti-oligomeric compounds for bioevaluation. 
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The work lends credence to the report that ‘good ligands’ are hard to find’ [217], for 
instance, ≥ 2.3 x 109 compounds were enumerated and only ≤ 4.4 x 10-8 % had Gscores ≥-
6.50 and DPT4 4 yielded the ‘best’ Gscore hits following its optimization (Table 30). 
Nevertheless, zm1 7 and zm2 8 from DPT4 4 and Cayman fragment collection were found 
to be synthesizable. Emodel used as analytical tool of these compounds for reasons 
explained. DPT5 5-DPT6 6 were chosen for their ‘good’ Gscores although they have RTKI-
like activity, as they were 2J6M docked yields, which can be bioassayed. 
 
5.1.10 Future work 
a) The ‘oligomerization region’ remains a complex site to explore in the development of 
novel anti-cancer drugs, despite current approaches. This is because it is still being 
accurately defined [218]. 
b) The future of anti-oligomers is seemingly set vis-à-vis the emergence that dimerization 
mechanisms are giving way to oligomerization mechanisms, and we depend more on 
biomolecular information for improved drug designs, particularly, in SBDD. 
c) The compounds that have been identified whether during docking with monomeric or 
dimeric grids are gold mines to this Project, in search for ways to synthesize and / or 
purchase them for preliminary bioassay in the drug discovery and development process. 
d) DPT1 1-DPT4 4 from 1IVO |246-253|S docking, DPT5 5 & DPT6 6 from ZINC chemical 
database docking, thus reflecting RTKI-like compounds, and zm1 7 & zm2 8 from the 
optimized core of DPT4 4 with anti-EGFR anti-oligomeric activities, we believe have 
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unlocked their extensive studies in the nearby further using both computer-based and 
biologically-based approaches to obtain their ‘best’ as anti-EGFR ‘anti-oligomeric’ in cancer 
therapy.    
 
5.2. Compounds zm1 7 & zm1a 7 and zm2 8 
5.2.1 Compounds zm1 7 and zm1a 7 
The code zm1 7 and zm1a 7 show the duo had proceeded the same synthetic path until 
the later crystallized unexpectedly, making zm1 7 a confirmed mixture of at least itself 
zm1a 7. The synthesis of zm1 7 was challenging, requiring a repeat of more than five times. 
First, our final yield was insoluble in most available solvents. The chromatographic (TLC, 
Column) processes and spectral (m/z, 1HNMR and 13CNMR) observations had z1 7 as a 
single entity. The elemental results further showed zm1a 7 as the compound, however, 
there was no spectral data to confirm it. For instance, the elemental analysis of zm1 7, 
calculated (%) - C, 50.59; H, 6.07 & N, 33.71 [219], found (%) – C, 57.28; H, 42 & N, 22.70. 
The crystallization occurred on dissolution in a mixture of regular DMSO (70% by volume), 
distilled H2O (30% by volume), and left over night. The crystallographic report on zm1a 7 
indicated its elemental analysis as follows: calculated (%) - C, 57.6; H, 7.2 & N, 22.4, found 
(%) – C, 57.3; H, 7.4 & N, 22.70 [181], which aligned with those intended for zm1 7. Time 
and its quantity did not permit its further chemical characterization and bioevaluation, 
however, predictive information about it are shown in Tables 30 & 31. The mechanisms to 
obtain zm1 7 and zm1a 7 showed that hydrazinolysis and condensation were required to 
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yield them, respectively. This was not clear at onset. Additionally, the quantities were 
infinitesimal and left to proceed despite a slight pale yellow color change when 11 was 
formed. The multi-component reactions (MRCs) approach utilized has its pros and cons as 
well. MRC is defined as the process where three or more reactants are combined in a single 
chemical step to produce products that incorporate substantial portions of the reactants 
[220]. One of its demerits the mechanisms of certain types of reactions may not be feasible 
while for infinitesimal quantities reactions leading to by-products may unnoticed. While 
zm1 7 possesses the 1o, 2o & 3o amine functionalities and an aromatic ring zm1a 7 has 2o 
and 3o, we therefore expect zm1 7 to fragment more. Scheme I in Figure 58 shows the 
synthesis of zm1 7 without excess use of hydrazine monohydrate and, instead of obtaining 
zm1a 7 as a by-product it can be synthesized an entity according to Scheme II in Figure 59. 
Although the 1H NMR, 13C NMR and IR data for zm1 7 & zm1a 7 are expressed in Section 
3.1.3 and included in the Appendix further discussion on this shall be suspended until the 
chemistry of these two potentially active anti-EGFR and anti-oligomeric compounds are 
resolved.  
5.2.1.1 Summary on zm1 7 and zm1a 7 syntheses: ‘divided and lost’ 
a) The syntheses of zm1 7 and zm1a 7 may be described as a form of ‘divided and lost’ 
because of the inconclusive resolution of the two compounds.  
b) Schemes I & II show that the compounds are preferentially synthesizable as zm1 7 & 
zm1a 7, respectively. 
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 5.2.1.2 Future work on zm1 7 and zm1a 7 
a) Zm1 7 and zm1a 7 should be synthesized vis-à-vis their potential anti-EGFR ant-
oligomeric activity for which literature has asserted to. Indeed, these are new chemical 
entities whose structures are easy to easy to manipulate to achieve more potent 
compounds. 
b) Zm1 7 and zm1a 7 should be synthesized separately noting their clear separate 
mechanisms as shown in Schemes I and Schemes II, respectively. 
c) The bioevaluation of these compounds, zm1 7 & zm1a 7, is important because of their 
potential claims, and should therefore be pursued.   
             5.2.2 Discussion on zm2 8 synthesis 
Zm2 8 is a new chemical entity with potential anti-EGFR anti-oligomeric activity according 
to its predictive results in Table 30 and other properties in Table 32. We used a mono-p-
hydroxy substituted mandelic acid instead of the disubstituted o- & p- compound. The 
room-temperature intermediate active semi-stable NHS-ester obtained when DCU has 
been filtered out, is a two-step reaction [191, 221]  as shown in Schemes III & IV, Figures 
61 & 62, respectively. Its synthesis is conveniently a simple preparation method, which is 
a basic requirement in drug discovery. NHS is a commonly used activating agent for 
carboxylic acids, basically esters, with a good leaving group that reacts with amines to form 
amides, otherwise the carboxylic acid would just form salt with the amines. It did not need 
protection of the available –OH functionality and is not harsh either as no heat was 
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required. It represents a typical non-classical coupling in amide formation [221] as shown 
by Scheme III Figure 61. The classical coupling is illustrated in Scheme V in Figure 63, which 
is a multi-step mechanisms. This approach is an alternative method to synthesis zm2 8 
without requiring NHS, however, the –OH species in the phenolic carboxylic acid must be 
protected [222, 223]. The spectral and chemical data of the compound are shown in 
Section 3.2.2 as well as included in the Appendix that affirmed zm2 8 as a new chemical 
entity.  
5.2.2.1 Summary on the synthesis of zm2 8 
a) Zm2 8 is synthesized. 
b) Since two synthetic methods are available for exploitation, the two can be explored to 
improve yield as well as reduce cost and time to obtain zm2 8. 
c) Zm2 8 is set for bioevaluation. 
5.2.2.2 Future work 
The easiness in synthesizing zm2 8 offers the opportunity to develop its analogs for a high 
throughput bioassay screening as anti-EGFR anti-oligomers.  
5.2.3 Summary on Compounds zm1 7 & zm1a 7 and zm2 8 
Zm2 8 has been synthesized but not zm1 7. Mechanistically, there are two methods zm2 8 
can be synthesized (Scheme III, Figures 61 or Scheme V, Figure 63). Since zm1 7 is likely a 
mixture of zm1 7 and zm1a 7 based on crystallographic reports, these compounds can be 
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independently synthesized following Scheme I, Figure 58 and Scheme II, Figure 59, 
respectively. 
5.3 Bioevaluation of hit leads (DPT1 1 – DPT4 4) 
The lead hits have been grouped into three sets following assays by the colorimetric 
methods: i) potentially active anti-EGFR anti-oligomeric compounds, DPT1 1 – DPT4 4; ii) 
potentially active RTKI-like compounds , DPT5 5 & DPT6 6; and iii) the synthesized 
potentially active anti-EGFR anti-oligomeric compounds, zm1 7 & zm2 8. Compound zm1 
7 can only be mentioned accordingly and referring to it occasionally, since it was an impure. 
The bioevaluation of impure compounds can be misleading even when results are 
tolerable, although the same could serve as a guide as well. The elemental analysis, melting 
point and the last minute inadvertent crystallization qualified zm1 7 to be a mixt chemical 
entity.  
5.3.1 MTS –Colorimetric analyses of the compounds 
We observed the following when two different cell strengths were used: a) only DPT6 6 
and zm2 8 showed a single IG values, b) DPT1 1 and DPT4 4 had the widest variation as 
indicated by their SD and expressed by IG values of between 6.00 – 8.00 , and c) DPT2 2 
and DPT3 3 had close IG values. These points highlighted show cell strength used can 
influence outcomes in functional assays.  Furthermore, different cell concentrations were 
used in each set. For instance, cell strengths used for DPT1 1 – DPT4 4 were 8 x 103 & 1 x 
104 while the rest used 5 x 103 & 8 x 103 except zm1 7 that used 4 x 103 & 8 x 103 cell/mL. 
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This assisted further to appreciate if variations could occur, which did as shown in some 
parametric differences in Figures 70– 72 where graph shapes and / or IG & IC estimations 
were difficult, however, DPT1 1 –DPT4 4 results in Figures 65 -68 were easy to estimate. 
Furthermore, for compounds in 1 x 104 cell/mL A431wt cell strength expressed a IC50 at 
lower µM concentration levels such as DPT3 3, 0.70 µM; DPT2 2, 2.40 µM; DPT4 4 9.10 
µM; and DPT1 1, µM28.90, although this is a subjective explanation. IG50 calculations for 
some compounds was again difficult despite manipulations of the GraphPad Prism, thus 
the threshold values was resorted to as for zm2 8  cell strength of 5 x 103 cell/mL. A 
significant observation also is the high IG75 values DPT6 6, indicating a 25 % concentration 
of their doses is enough to inhibit EGFR activity. This is important because these ZINC 
ligands (Table 9) had no prior anti-oligomeric activity when initially docked with 1IVO |246-
253|S. The synthetic compound zm2 8 expressed only threshold IG values, beckoning for 
more work on it. The found IC50 values for DPT1 1 – DPT4 5, zm1 7 & zm2 8 are significantly 
lower than the calculated, indicating these compounds have noteworthy potential anti-
EGFR anti-oligomeric activities, though  DPT6 6 showed about 5x the predicted value 
indicating higher doses are required to elicit activity. All the compounds expressed a zero 
value for TGI, signifying all have some measurable activities against the cell line and 
therefore, almost all (except zm1 7) can be modified structurally to have compounds that 
are more potent. Table 34 shows a summary colorimetric results. These observations could 
not have been without the influence of some of the protocols and instrumentation. For 
instance, it is known that colorimetric methods are not without limitations despite their 
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highlighted merits [224]. GraphPad Prism plotted DRs (drug response curves) that had 
anticipated formazan quantity produced and measured at 490nm absorbance was 
proportional to the number of living cells in the sample. However, this is a clean 
assumption since other colored metabolites can be produced in living systems in the 
presence and / absence of a substance at any time, capable of influencing the absorbance 
at the said λ nm (wavelength) [225]. This is true because it is noticed on a number of 
occasions where the actual cell number did not agree with assay reading. Formazan 
amplification by the commonly used culture media in large uncorrectable proportions is a 
common feature when microplate reader reads results, which do affect analyses in the 
end. Cell handling protocols can be stressful on the cells before commencement of 
experiment despite initial ‘best’ confluent cells. Production of the formazan had been 
dependent on the MTS concentration; however, the kinetics and degree of saturation of 
the composite metabolic processes are dependent on both cell type and form, which 
absorbance at λ 490 nm may not quantify. Assay becomes less effective as proliferation of 
cells slows down by increasing amount of dye and other metabolites, which goes on to 
influence analysis outcomes. Another limitation is that individual cell numbers are not 
quantitated and results are expressed as a percentage of control absorbance. This is in 
recognition that individual cancer cells in the same medium are not all equal. Finally, it 
requires a different experimental method to distinguish cytocidal from cytostatic activity 
of a compound even though a TGI = 0. However, the prescreening clues obtained from 
MTS assay do offer a helpful guide in bioevaluation processes. The inherent weakness in 
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colorimetric methods has shown that MTS can underestimate the anti-proliferation of a 
compound [226]. Some of these points only stress a fact that our result could be highly 
commendable. A key to obtaining a ‘good’ sigmoid DR curve in GraphPad Prism is to 
normalize a datum between 0 and 100 % with mathematically defined baselines. The 
results shown in Figures 69 – 72 had a challenge to normalize, as attempts to achieve 
normalization affected both shape and concentration designation. A case at hand is zm1 7 
in Figure 71 having a negative slope. Nonetheless, this can be explained on the basis that 
zm1 7 was a crude product. Getting a ‘good’ dose-response curve still faces challenges, 
especially in biological assays [227]. Besides, neither cell culture nor animal model systems 
have provided reliable predictions of drug efficacy or toxicity [228].  Despite these 
limitations, almost all these compounds assayed by MTS seemed to have made our 
minimum requirements to proceed to the precipitation and immunoblotting analysis, 
except for zm1 7. DPT1 1 – DPT4 4, in particular, as already mentioned, seem to align their 
predicted drug-likeness and lead-likeness features with their IG50 and IC50 values, to 
become promising anti-EGFR anti-oligomers. Similarly, zm2 8  expressed an equal 
threshold concentration (0.130 µM)  in both cell strengths and did meet all the drug-like, 
lead-like and anti-EGFR predictions in Tables 29, 30 & 31. Threshold concentration 
obtained can be used to measure other effects or toxicity concentrations, such as the 
concentrations at which a substance, not necessarily toxic, becomes detectable or 
noticeable by instruments, a human, or an animal. Threshold concentrations have been 
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used extensively in anticancer drug discovery and development [229, 230]. This 
emphasizes the need to explore zm2 8 beyond its present look.  
5.3.2 The immunoblotting of DPT1 1 – DPT4 4 
The probes that were labeled and bound to the protein of interest needed to be detected 
on the western blot using one of several methods such as colorimetric, radioactive, and 
fluorescent methods. However, chemiluminescent method is the most commonly used. 
Enhanced chemiluminescence (ECL) is a sensitive quantitative method that relatively 
quantifies protein of interest [231]. It is an indirect enzymatic method that follows these 
basic principles: I) 20 antibodies are labeled with an enzyme reporter, horseradish 
peroxidase (HRP), II) chemiluminescent substrate (usually luminol) is applied to the blot, 
III) luminol is oxidized in the presence of HRP and H2O2 to form an excited state product 
that emits light (this defines the method ECL), IV) the light produced by this enzymatic 
reaction is quantitatively detected by exposure to x-ray film (or a digital imaging with a 
camera) as shown in Figure 77. The reaction product produces luminescence that is related 
to the amount of the protein [38]. The blot images in Figures 73 – 75 for DPT1 1 - DPT4 4 
were achieved from the blot and analyzed by densitometry using ImageJ software program 
that analyzed the selected image lanes or bands on the film to measure the relative 
amount of each specific protein on the blot by comparing it with a control (Figure 76).  
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The concentrations used for each DPTH were 1, 10 100 µM. Observed inconsistencies 
include  a) in Figures 73, 74, 75 & 76 the concentrations (in µM) seem to show increase 
(↑) stimulation instead as follows:  (i): DPT1 1 1.00 ↑ pY - Akt, 10.00 ↑ of pY – Akt and pY 
– ERK 1 & 2, 100.00 ↑ pY – ERK 1 & 2, (ii): DPT2 2 1.00 ↑ pY – Akt, 10.00 ↑ pY – Akt, pY – 
ERK 1 & 2 & pY – EGFR, 100.00 ↑ pY – Akt and pY – ERK 1 & 2, (iii): DPT3 3 1.00 ↑ pY – 
Akt, pY – ERK 1 & 2and pY – EGFR, 10.00 ↑ pY – Akt & pY – ERK 1 & 2, 100.00 ↑ pY – Akt 
&  pY - EGFR, (iv): DPT4 4 1.00 ↑ pY – Akt and pY – ERK 1 & 2, 10.00 ↑ pY – Akt & pY – 
EGFR, 100.00 ↑ pY – Akt and pY – ERK 1 & 2; b) the Total ERK 1 & 2 appeared fainter than 
pY – ERK 1 & 2 in Figure 74; and c) lanes appear disjointedly arranged in Figure 75 as if 
depicting a lane has been missed. However, the positive control or reference shown in 
Figure 76 (i.e., +EGF) indicates the results are analytically reliable despite the discrepancies 
observed. WB procedures are packed with protocols, not only hard to master but also 
prone to fail because it depends on the quality of the primary antibodies as well as whether 
polyclonal antibodies are used as the secondary antibodies, which may reveal non-
Figure 77. The chemiluminescence reaction in WB bioanalysis. Luminol is oxidized in 
the presence of HRP and hydrogen peroxide to form an excited state product (3-
aminophthalate) that emits light at 425 as it decays to the ground state. Source: 
Alegria-Schaffer et al., 2009.   
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targeted proteins (as opposed to monoclonal antibodies) during development. WB is 
sensitive and specific, however, it can still misjudge results, a common feature inherent in 
all protocols, and the blotting itself that demands several repeat washings during and prior 
to ECL quantification can affect authenticity of the results. Moreover, ECL does produce 
light emission that fades exponentially over time, requires multiple exposures to capture 
optimal images, which can be subjective, especially when x-ray films are used to capture 
the resulting light emissions, and results can be hard to quantify, despite the several 
positive uses of ECL. Thus, when we merge these observations in WB and ECL we utilized 
for our work, some of the incongruities highlighted above may be explained [232, 233]. 
Therefore, the observations in the functional assays and immunoblotting results indicate 
there are positive conclusions to make. 
 5.3.3 Summary on bioevaluation 
a) The colorimetric (MTS) analyzed gave clues on the potential activities of compounds 
assayed, viz, DPT1 1 – DPT6 6, zm1 7 (crude product) & zm2 8, all of which indicated a level 
of activity, supporting their next stage of bioevaluation. However, this was not to be due 
to time and chemical challenges particularly with zm1 7 and zm1a 7. 
b) DPT1 1 – DPT4 4 are now lead candidates as shown by the WB results summary:  DPT1 
1 1.00, 10.00 & 100.00 µM showed strong pY – EGFR signals; DPT2 2 1.00 µM showed 
strong pY – EGFR signal but a weak pY – ERK 1 & 2 signal; DPT3 3 10.00 µM showed strong 
pY – EGFR signal but its 100.00 µM showed pY – ERK 1 & 2 signal and DPT4 4 1.00 µM 
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showed strong pY – EGFR signal but its 100.00 µM showed strong pY - EGFR signal. These 
compounds can be considered potentially active anti-oligomeric anti-EGFR new chemical 
entities   
 5.3.4 Future perspective  
1) Zm1 7, zm1a 7, and zm2 8 should be synthesized and bioevaluated using simpler 
techniques such as ELISA or a repeat of the western blotting. 
2) DPT5 5 & DPT6 6 can proceed to WB to establish their true RTKI-like activities. 
3) DPT 1 1 – DPT4 4 are confirmed potentially active anti-EGFR anti-oligomeric lead 
candidates. We need to a) optimized these agents to obtain potentially more active 
agents, and b) the biological evaluation of these compounds should be expanded to 
include other analytical methods like HPLC–MS that chemically characterize their 
biological activities against the said target. Flow cytometry or ELISA as a simpler or a 
combination of bioassay techniques are employable. 
4) We look forward to having a library or libraries of active anti-EGFR anti-oligomeric 
agents.  
5.4 Conclusion 
a) The consideration of other factors during the molecular modeling process, besides the 
Gscore status quo, seemed to assist effectively in DPT1 1 – DPT4 4 selection, despite their 
very low Gscores. The preliminary biolevaluation results show all the four have potential 
anti-EGFR anti-oligomeric activities. 
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b) The need to resynthesize compound (s) zm1 7 (and zm1a 7) is clear to commence their 
bioevaluation. 
c) Zm2 8 can be synthesized alongside its homologues for high-throughput bioevaluation 
screen since its colorimetric values indicated it as a strong potentially promising anti-EGFR 
anti-oligomer. 
d) The need to expand biological and chemical processes on these compounds seem clear.   
e) There are still more grids already generated and many compounds with ‘good’ DS that 
require exploitation. 
f) The need for a more specific oligomerization region – targeted ligands is necessarily 
helpful, especially now that multimeric rather dimeric structures are taking center stage in 
biomolecular science. 
h) The substantial number of docked compounds using different grids can still be explored. 
 
 
 
 
 
 
 
 
   
 
218 
 
References 
1. Bailar, J.C. and H.L. Gornik, Cancer undefeated. New England Journal of Medicine, 1997. 336(22): 
p. 1569-1574. 
2. Jemal, A., et al., Cancer statistics, 2008. CA: a cancer journal for clinicians, 2008. 58(2): p. 71-96. 
3. Who, World health statistics 2008. 2008: World Health Organization. 
4. Torre, L.A., et al., Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 2015. 65(2): p. 
87-108. 
5. Organization, W.H., World cancer report, 2014. WHO Report. Geneva: WHO, 2014. 
6. Parkin, D.M., et al., Cancer in Africa 2012. Cancer Epidemiology Biomarkers & Prevention, 2014. 
23(6): p. 953-966. 
7. Bray, F., et al., Global cancer transitions according to the Human Development Index (2008–2030): 
a population-based study. The lancet oncology, 2012. 13(8): p. 790-801. 
8. Ferlini, A. and S. Fini, Genetic Heterogeneity and Human Disease. Eur J Hum Genet, 2015. 23(4): p. 
559-559. 
9. Nwosu, V., et al., Heterogeneity of genetic alterations in prostate cancer: evidence of the complex 
nature of the disease. Human molecular genetics, 2001. 10(20): p. 2313-2318. 
10. Kamińska, K., et al., The role of the cell–cell interactions in cancer progression. Journal of cellular 
and molecular medicine, 2015. 
11. Tavazoie, S.F., et al., Endogenous human microRNAs that suppress breast cancer metastasis. 
nature, 2008. 451(7175): p. 147-152. 
12. Witz, I.P., The tumor microenvironment: the making of a paradigm. Cancer Microenvironment, 
2009. 2(1): p. 9-17. 
13. Weir, H.K., et al., The past, present, and future of cancer incidence in the United States: 1975 
through 2020. Cancer, 2015: p. n/a-n/a. 
14. Leaf, C., Why we're losing the war on cancer (and how to win it). FORTUNE-EUROPEAN EDITION-, 
2004. 149(5): p. 42-55. 
15. Carter, D., New Global Survey Shows an Increasing Cancer Burden. AJN The American Journal of 
Nursing, 2014. 114(3): p. 17. 
16. Pinto, G., A.A.M. Alhaiek, and J. Godovac-Zimmermann, Proteomics reveals the importance of the 
dynamic redistribution of the subcellular location of proteins in breast cancer cells. Expert review of 
proteomics, 2015(0): p. 1-14. 
17. Wall, A.M. and D.J. Abraham, Drug Resistance in Cancer Chemotherapy, in Burger's Medicinal 
Chemistry and Drug Discovery. 2003, John Wiley & Sons, Inc. 
18. Sharma, S.V., et al., Epidermal growth factor receptor mutations in lung cancer. Nature Reviews 
Cancer, 2007. 7(3): p. 169-181. 
19. Dodd, M.J., Side effects of cancer chemotherapy. Annual review of nursing research, 1993. 11: p. 
77-77. 
20. Boyd, M.R. and K.D. Paull, Some practical considerations and applications of the National Cancer 
Institute in vitro anticancer drug discovery screen. Drug Development Research, 1995. 34(2): p. 91-
109. 
21. Gibbs, J.B., Mechanism-based target identification and drug discovery in cancer research. Science, 
2000. 287(5460): p. 1969-1973. 
22. Davies, D.M., et al., Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically 
engineered T cells. Molecular Medicine, 2012. 18(4): p. 565. 
 
   
 
219 
 
23. Nicholson, R., J. Gee, and M. Harper, EGFR and cancer prognosis. European Journal of Cancer, 2001. 
37: p. 9-15. 
24. Mizuguchi, T., et al., Evaluation of dimerization–inhibitory activities of cyclic peptides containing a 
β-hairpin loop sequence of the EGF receptor. Bioorganic & medicinal chemistry, 2012. 20(19): p. 
5730-5737. 
25. Sequist, L.V., The Anticipated Next Season of EGFR Inhibitors. The oncologist, 2015. 20(4): p. 335-
336. 
26. Yarden, Y., et al., Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an 
unidentified ligand. The EMBO journal, 1987. 6(11): p. 3341. 
27. Rothe, M., et al., A novel family of putative signal transducers associated with the cytoplasmic 
domain of the 75 kDa tumor necrosis factor receptor. Cell, 1994. 78(4): p. 681-692. 
28. Mangelsdorf, D.J., et al., The nuclear receptor superfamily: the second decade. Cell, 1995. 83(6): p. 
835-839. 
29. Chawla, A., et al., Nuclear receptors and lipid physiology: opening the X-files. Science, 2001. 
294(5548): p. 1866-1870. 
30. Steck, T.L., THE ORGANIZATION OF PROTEINS IN THE HUMAN RED BLOOD CELL MEMBRANE A 
Review. The Journal of cell biology, 1974. 62(1): p. 1-19. 
31. Higashiyama, S., et al., Membrane‐anchored growth factors, the epidermal growth factor family: 
Beyond receptor ligands. Cancer Science, 2008. 99(2): p. 214-220. 
32. Bar-Sagi, D. and J.R. Feramisco, Induction of membrane ruffling and fluid-phase pinocytosis in 
quiescent fibroblasts by ras proteins. Science, 1986. 233(4768): p. 1061-1068. 
33. Basu, A., et al., Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor 
by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase 
regulation. Molecular and cellular biology, 1989. 9(2): p. 671-677. 
34. Tynan, C.J., et al., A tale of the epidermal growth factor receptor: The quest for structural resolution 
on cells. Methods, 2015. 
35. Downward, J., M.D. Waterfield, and P.J. Parker, Autophosphorylation and protein kinase C 
phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and 
ligand binding affinity. Journal of Biological Chemistry, 1985. 260(27): p. 14538-14546. 
36. Needham, S.R., et al., Structure-function relationships and supramolecular organization of the EGFR 
(epidermal growth factor receptor) on the cell surface. Biochemical Society transactions, 2014. 
42(1): p. 114-119. 
37. Hackel, P.O., et al., Epidermal growth factor receptors: critical mediators of multiple receptor 
pathways. Current Opinion in Cell Biology, 1999. 11(2): p. 184-189. 
38. Jensen, E.C., The Basics of Western Blotting. The Anatomical Record: Advances in Integrative 
Anatomy and Evolutionary Biology, 2012. 295(3): p. 369-371. 
39. Jorissen, R.N., et al., Epidermal growth factor receptor: mechanisms of activation and signalling. 
Experimental cell research, 2003. 284(1): p. 31-53. 
40. Wakeling, A., et al., Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-
anilinoquinazolines. Breast cancer research and treatment, 1996. 38(1): p. 67-73. 
41. Vogelstein, B. and K.W. Kinzler, Cancer genes and the pathways they control. Nature medicine, 
2004. 10(8): p. 789-799. 
42. Suter, C.M., D.I. Martin, and R.L. Ward, Germline epimutation of MLH1 in individuals with multiple 
cancers. Nature genetics, 2004. 36(5): p. 497-501. 
43. Pitot, H.C. and Y. Dragan, Facts and theories concerning the mechanisms of carcinogenesis. The 
FASEB journal, 1991. 5(9): p. 2280-2286. 
 
   
 
220 
 
44. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell, 1990. 61(5): p. 
759-767. 
45. Jia, L.-T., et al., Regulators of carcinogenesis: Emerging roles beyond their primary functions. Cancer 
Letters, 2015. 357(1): p. 75-82. 
46. Garrett, T.P., et al., The crystal structure of a truncated ErbB2 ectodomain reveals an active 
conformation, poised to interact with other ErbB receptors. Molecular cell, 2003. 11(2): p. 495-505. 
47. Shi, F., et al., ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze 
autophosphorylation. Proceedings of the National Academy of Sciences, 2010. 107(17): p. 7692-
7697. 
48. Bouyain, S., et al., The extracellular region of ErbB4 adopts a tethered conformation in the absence 
of ligand. Proceedings of the National Academy of Sciences of the United States of America, 2005. 
102(42): p. 15024-15029. 
49. Mendelsohn, J. and J. Baselga, The EGF receptor family as targets for cancer therapy. Oncogene, 
2000. 19(56): p. 6550-6565. 
50. Baselga, J., Why the epidermal growth factor receptor? The rationale for cancer therapy. The 
oncologist, 2002. 7(Supplement 4): p. 2-8. 
51. Grandis, J.R. and J.C. Sok, Signaling through the epidermal growth factor receptor during the 
development of malignancy. Pharmacology & therapeutics, 2004. 102(1): p. 37-46. 
52. Yarden, Y., The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic 
opportunities. European journal of cancer, 2001. 37: p. 3-8. 
53. Normanno, N., et al., Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006. 
366(1): p. 2-16. 
54. Babyatsky, M.W., G. Rossiter, and D.K. Podolsky, Expression of transforming growth factors alpha 
and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology, 1996. 110(4): p. 975-
984. 
55. Choi, S., J. Mendrola, and M. Lemmon, EGF-independent activation of cell-surface EGF receptors 
harboring mutations found in gefitinib-sensitive lung cancer. Oncogene, 2007. 26(11): p. 1567-
1576. 
56. Alroy, I. and Y. Yarden, The ErbB signaling network in embryogenesis and oncogenesis: signal 
diversification through combinatorial ligand-receptor interactions. FEBS letters, 1997. 410(1): p. 83-
86. 
57. Holbro, T. and N.E. Hynes, ErbB receptors: directing key signaling networks throughout life. Annu. 
Rev. Pharmacol. Toxicol., 2004. 44: p. 195-217. 
58. Harari, P., Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related 
Cancer, 2004. 11(4): p. 689-708. 
59. Burgess, A.W., EGFR family: Structure physiology signalling and therapeutic targets The EGFR family 
members regulate the production, survival, movement, and shape of many embryonic and adult cell 
types. Signalling from three of the family members EGFR, erbB3 and erbB4) are regulated by ligand 
dependent oligomerization and fourth, erbB2, by oligomerization with ligated forms of the other 
family members. Three of the family members (EGFR, erbB2 and erbB4) signal via activated tyrosine 
kinase scaffolds, the fourth, erbB3, by ligand induced oligomerization and activation of the other 
family members. Growth Factors, 2008. 26(5): p. 263-274. 
60. Ghosh, S., et al., Rational design of potent and selective EGFR tyrosine kinase inhibitors as 
anticancer agents. Current cancer drug targets, 2001. 1(2): p. 129-140. 
61. Kosaka, T., et al., Mechanisms of resistance to EGFR TKIs and development of a new generation of 
drugs in non-small-cell lung cancer. BioMed Research International, 2011. 2011. 
 
   
 
221 
 
62. Kawamoto, T., et al., Growth stimulation of A431 cells by epidermal growth factor: identification of 
high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. 
Proceedings of the National Academy of Sciences, 1983. 80(5): p. 1337-1341. 
63. Yewale, C., et al., Epidermal growth factor receptor targeting in cancer: A review of trends and 
strategies. Biomaterials, 2013. 34(34): p. 8690-8707. 
64. Li, Z. and P. Srivastava, Heat‐Shock Proteins. Current Protocols in Immunology, 2004: p. A. 1T. 1-A. 
1T. 6. 
65. Rouse, J., et al., A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP 
kinase-2 and phosphorylation of the small heat shock proteins. Cell, 1994. 78(6): p. 1027-1037. 
66. Georgopoulos, C. and W. Welch, Role of the major heat shock proteins as molecular chaperones. 
Annual review of cell biology, 1993. 9(1): p. 601-634. 
67. Marcu, M.G., T.W. Schulte, and L. Neckers, Novobiocin and related coumarins and depletion of heat 
shock protein 90-dependent signaling proteins. Journal of the National Cancer Institute, 2000. 
92(3): p. 242-248. 
68. Sreedhar, A.S., C. So, and P. Csermely, Inhibition of Hsp90: a new strategy for inhibiting protein 
kinases. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2004. 1697(1): p. 233-242. 
69. Richter, P. and E. Fahr, Synthesis of trans/syn‐and trans/anti‐Dimeric Uracil. Angewandte Chemie 
International Edition in English, 1969. 8(3): p. 208-209. 
70. Hadden, M. and B. Blagg, Dimeric approaches to anti-cancer chemotherapeutics. Anti-cancer 
agents in medicinal chemistry, 2008. 8(7): p. 807. 
71. Starok, M., et al., EGFR Inhibition by Curcumin in Cancer Cells: a Dual Mode of Action. 
Biomacromolecules, 2015. 
72. Adams, B.K., et al., Synthesis and biological evaluation of novel curcumin analogs as anti-cancer 
and anti-angiogenesis agents. Bioorganic & Medicinal Chemistry, 2004. 12(14): p. 3871-3883. 
73. Goodchild, J., Therapeutic oligonucleotides, in Therapeutic Oligonucleotides. 2011, Springer. p. 1-
15. 
74. Bischoff, A., et al., A global microRNA screen identifies regulators of the ErbB receptor signaling 
network. Cell Communication and Signaling, 2015. 13(1): p. 5. 
75. Morcos, P.A., Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino 
oligos. Biochemical and biophysical research communications, 2007. 358(2): p. 521-527. 
76. Uhlmann, E. and A. Peyman, Antisense oligonucleotides: a new therapeutic principle. Chemical 
Reviews, 1990. 90(4): p. 543-584. 
77. Mani, S., et al., Clinical Studies in Patients with Solid Tumors using a Second‐Generation Antisense 
Oligonucleotide (GEM® 231) Targeted against Protein Kinase A Type I. Annals of the New York 
Academy of Sciences, 2003. 1002(1): p. 252-262. 
78. Ciardiello, F., et al., Cooperative inhibition of renal cancer growth by anti-epidermal growth factor 
receptor antibody and protein kinase A antisense oligonucleotide. Journal of the National Cancer 
Institute, 1998. 90(14): p. 1087-1998. 
79. Su, J.-L., et al., The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer cell, 
2006. 9(3): p. 209-223. 
80. Ciardiello, F., et al., Antitumor effect and potentiation of cytotoxic drugs activity in human cancer 
cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. 
Clinical Cancer Research, 2000. 6(5): p. 2053-2063. 
81. Zhu, L., et al., B-cell epitope peptide vaccination targeting dimer interface of epidermal growth 
factor receptor (EGFR). Immunology letters, 2013. 153(1): p. 33-40. 
 
   
 
222 
 
82. Sato, J., et al., Biological effects in vitro of monoclonal antibodies to human epidermal growth factor 
receptors. Molecular biology & medicine, 1983. 1(5): p. 511-529. 
83. Senter, P.D., Potent antibody drug conjugates for cancer therapy. Current opinion in chemical 
biology, 2009. 13(3): p. 235-244. 
84. Leriche, G., L. Chisholm, and A. Wagner, Cleavable linkers in chemical biology. Bioorganic & 
medicinal chemistry, 2012. 20(2): p. 571-582. 
85. Ducry, L. and B. Stump, Antibody− drug conjugates: linking cytotoxic payloads to monoclonal 
antibodies. Bioconjugate chemistry, 2009. 21(1): p. 5-13. 
86. Smaglo, B.G., D. Aldeghaither, and L.M. Weiner, The development of immunoconjugates for 
targeted cancer therapy. Nat Rev Clin Oncol, 2014. 11(11): p. 637-648. 
87. Yang, R.Y., et al., Targeting the Dimerization of Epidermal Growth Factor Receptors with Small‐
Molecule Inhibitors. Chemical biology & drug design, 2010. 76(1): p. 1-9. 
88. Petch, D., et al., Design and synthesis of EGFR dimerization inhibitors and evaluation of their 
potential in the treatment of psoriasis. Bioorganic & medicinal chemistry, 2012. 20(19): p. 5901-
5914. 
89. Walsh, C.T., S. Garneau-Tsodikova, and G.J. Gatto, Protein posttranslational modifications: the 
chemistry of proteome diversifications. Angewandte Chemie International Edition, 2005. 44(45): p. 
7342-7372. 
90. Cohen, P., Protein kinases--the major drug targets of the twenty-first century? Nat Rev Drug Discov, 
2002. 1(4): p. 309-15. 
91. Hunter, T., Signaling—2000 and beyond. Cell, 2000. 100(1): p. 113-127. 
92. Muthuswamy, S.K., M. Gilman, and J.S. Brugge, Controlled dimerization of ErbB receptors provides 
evidence for differential signaling by homo-and heterodimers. Molecular and cellular biology, 1999. 
19(10): p. 6845-6857. 
93. Ceresa, B.P., Regulation of EGFR endocytic trafficking by rab proteins. 2006. 
94. Marianayagam, N.J., M. Sunde, and J.M. Matthews, The power of two: protein dimerization in 
biology. Trends in biochemical sciences, 2004. 29(11): p. 618-625. 
95. Blackwell, H.E., P.A. Clemons, and S.L. Schreiber, Exploiting site-site interactions on solid support to 
generate dimeric molecules. Organic letters, 2001. 3(8): p. 1185-1188. 
96. Al-Bassam, J., et al., Distinct conformations of the kinesin Unc104 neck regulate a monomer to dimer 
motor transition. The Journal of cell biology, 2003. 163(4): p. 743-753. 
97. Nooren, I. and J.M. Thornton, Diversity of protein–protein interactions. The EMBO journal, 2003. 
22(14): p. 3486-3492. 
98. Lemmon, M.A., et al., Two EGF molecules contribute additively to stabilization of the EGFR dimer. 
The EMBO Journal, 1997. 16(2): p. 281-294. 
99. Ferguson, K.M., et al., EGF activates its receptor by removing interactions that autoinhibit 
ectodomain dimerization. Molecular cell, 2003. 11(2): p. 507-517. 
100. Kosmidis, E.K., et al., Functional Aspects of the EGF-Induced MAP Kinase Cascade: A Complex Self-
Organizing System Approach. PloS one, 2014. 9(11): p. e111612. 
101. Ogiso, H., et al., Crystal structure of the complex of human epidermal growth factor and receptor 
extracellular domains. Cell, 2002. 110(6): p. 775-787. 
102. Gadella, T. and T.M. Jovin, Oligomerization of epidermal growth factor receptors on A431 cells 
studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine 
kinase receptor activation. The Journal of cell biology, 1995. 129(6): p. 1543-1558. 
 
   
 
223 
 
103. Klein, P., et al., A structure-based model for ligand binding and dimerization of EGF receptors. 
Proceedings of the National Academy of Sciences of the United States of America, 2004. 101(4): p. 
929-934. 
104. Olayioye, M.A., et al., ErbB receptor-induced activation of stat transcription factors is mediated by 
Src tyrosine kinases. Journal of Biological Chemistry, 1999. 274(24): p. 17209-17218. 
105. Bishayee, S., et al., Ligand-induced dimerization of the platelet-derived growth factor receptor. 
Monomer-dimer interconversion occurs independent of receptor phosphorylation. J Biol Chem, 
1989. 264(20): p. 11699-705. 
106. Clayton, A.H., et al., Ligand-induced dimer-tetramer transition during the activation of the cell 
surface epidermal growth factor receptor-A multidimensional microscopy analysis. Journal of 
Biological Chemistry, 2005. 280(34): p. 30392-30399. 
107. Yarden, Y. and J. Schlessinger, Self-phosphorylation of epidermal growth factor receptor: evidence 
for a model of intermolecular allosteric activation. Biochemistry, 1987. 26(5): p. 1434-1442. 
108. Martin-Fernandez, M., et al., Preformed oligomeric epidermal growth factor receptors undergo an 
ectodomain structure change during signaling. Biophysical journal, 2002. 82(5): p. 2415-2427. 
109. Gill, G.N., P.J. Bertics, and J.B. Santon, Epidermal growth factor and its receptor. Molecular and 
cellular endocrinology, 1987. 51(3): p. 169-186. 
110. Honegger, A., et al., Evidence for epidermal growth factor (EGF)-induced intermolecular 
autophosphorylation of the EGF receptors in living cells. Molecular and cellular biology, 1990. 10(8): 
p. 4035-4044. 
111. Baselga, J., Targeting tyrosine kinases in cancer: the second wave. Science, 2006. 312(5777): p. 
1175-1178. 
112. King, A.C. and P. Cuatrecasas, Exposure of cells to an acidic environment reverses the inhibiton by 
methylamine of the mitogenic response to epidermal growth factor. Biochemical and biophysical 
research communications, 1982. 106(2): p. 479-485. 
113. Monast, C.S., N. Mehta, and M.J. Lazzara, Diversity in Dimerization Topologies Enables Differential 
Control of Receptor Tyrosine Kinase Phosphorylation Dynamics. Cellular and Molecular 
Bioengineering, 2014. 7(1): p. 86-98. 
114. Seshacharyulu, P., et al., Targeting the EGFR signaling pathway in cancer therapy. Expert opinion 
on therapeutic targets, 2012. 16(1): p. 15-31. 
115. Yarden, Y. and G. Pines, The ERBB network: at last, cancer therapy meets systems biology. Nat Rev 
Cancer, 2012. 12(8): p. 553-63. 
116. Ferguson, K.M., A structure-based view of Epidermal Growth Factor Receptor regulation. Annual 
review of biophysics, 2008. 37: p. 353. 
117. Yarden, Y. and M.X. Sliwkowski, Untangling the ErbB signalling network. Nature reviews Molecular 
cell biology, 2001. 2(2): p. 127-137. 
118. Furuuchi, K., et al., Targeted antireceptor therapy with monoclonal antibodies leads to the 
formation of inactivated tetrameric forms of ErbB receptors. The Journal of Immunology, 2007. 
178(2): p. 1021-1029. 
119. Pinkas-Kramarski, R., et al., ErbB tyrosine kinases and the two neuregulin families constitute a 
ligand-receptor network. Molecular and cellular biology, 1998. 18(10): p. 6090-6101. 
120. Tzahar, E., et al., Bivalence of EGF‐like ligands drives the ErbB signaling network. The EMBO Journal, 
1997. 16(16): p. 4938-4950. 
121. Kozer, N., et al., Recruitment of the adaptor protein Grb2 to EGFR tetramers. Biochemistry, 2014. 
53(16): p. 2594-2604. 
 
   
 
224 
 
122. Graus-Porta, D., et al., ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a 
mediator of lateral signaling. The EMBO journal, 1997. 16(7): p. 1647-1655. 
123. Brown, P.M., et al., THE EXTRACELLULAR DOMAIN OF THE EPIDERMAL GROWTH-FACTOR 
RECEPTOR - STUDIES ON THE AFFINITY AND STOICHIOMETRY OF BINDING, RECEPTOR 
DIMERIZATION AND A BINDING-DOMAIN MUTANT. European Journal of Biochemistry, 1994. 
225(1): p. 223-233. 
124. Hurwitz, D.R., et al., EGF INDUCES INCREASED LIGAND-BINDING AFFINITY AND DIMERIZATION OF 
SOLUBLE EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR EXTRACELLULAR DOMAIN. Journal of 
Biological Chemistry, 1991. 266(32): p. 22035-22043. 
125. Ali, M.H. and B. Imperiali, Protein oligomerization: how and why. Bioorganic & medicinal chemistry, 
2005. 13(17): p. 5013-5020. 
126. Matthews, J.M. and M. Sunde, Dimers, oligomers, everywhere. Adv Exp Med Biol, 2012. 747: p. 1-
18. 
127. Fricke, F., M.S. Dietz, and M. Heilemann, Single‐Molecule Methods to Study Membrane Receptor 
Oligomerization. ChemPhysChem, 2014. 
128. Newton, G.J., et al., Regulated Shedding of EGFR Ligands is Controlled by Oligomerization, in 45th 
Annual Meeting of the American Society for Cell Biology. 2005. 
129. Axelrod, D., et al., Mobility measurement by analysis of fluorescence photobleaching recovery 
kinetics. Biophysical journal, 1976. 16(9): p. 1055. 
130. Hofman, E.G., et al., Ligand-induced EGF Receptor Oligomerization Is Kinase-dependent and 
Enhances Internalization. Journal of Biological Chemistry, 2010. 285(50): p. 39481-39489. 
131. Főrster, T., 10th Spiers Memorial Lecture. Transfer mechanisms of electronic excitation. Discussions 
of the Faraday Society, 1959. 27: p. 7-17. 
132. Defize, L., et al., Signal transduction by epidermal growth factor occurs through the subclass of high 
affinity receptors. The Journal of cell biology, 1989. 109(5): p. 2495-2507. 
133. Gamett, D.C., et al., Secondary dimerization between members of the epidermal growth factor 
receptor family. Journal of Biological Chemistry, 1997. 272(18): p. 12052-12056. 
134. Nagy, P., et al., Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by 
scanning near-field optical microscopy. Journal of cell science, 1999. 112(11): p. 1733-1741. 
135. Park, E., R. Baron, and R. Landgraf, Higher-Order Association States of Cellular ERBB3 Probed with 
Photo-Cross-Linkable Aptamers†. Biochemistry, 2008. 47(46): p. 11992-12005. 
136. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell, 2000. 103(2): p. 211-225. 
137. Yi, J.Y., I. Han, and E.-S. Oh, Transmembrane Domain Dependent Functional Oligomerization of 
Syndecans. The Scientific World Journal, 2006. 6: p. 457-459. 
138. Bardin, C., et al., Therapeutic drug monitoring in cancer – Are we missing a trick? European Journal 
of Cancer, 2014. 50(12): p. 2005-2009. 
139. Bessman, N.J. and M.A. Lemmon, Finding the missing links in EGFR. Nat Struct Mol Biol, 2012. 19(1): 
p. 1-3. 
140. Clayton, A.H., et al., Predominance of activated EGFR higher-order oligomers on the cell surface. 
Growth Factors, 2008. 26(6): p. 316-324. 
141. Kozer, N., et al., Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of 
living cells. Physical biology, 2011. 8(6): p. 066002. 
142. Kozer, N., et al., Exploring higher-order EGFR oligomerisation and phosphorylation—a combined 
experimental and theoretical approach. Molecular BioSystems, 2013. 9(7): p. 1849-1863. 
 
   
 
225 
 
143. Yamashita, H., et al., Oligomerization–function relationship of EGFR on living cells detected by the 
coiled-coil labeling and FRET microscopy. Biochimica et Biophysica Acta (BBA)-Biomembranes, 
2015. 1848(6): p. 1359-1366. 
144. Zanetti-Domingues, L.C., et al., Determining the geometry of oligomers of the human epidermal 
growth factor family on cells with 7 nm resolution. Progress in biophysics and molecular biology, 
2015. 
145. Becker, J., et al., Role of receptor tyrosine kinases in gastric cancer: new targets for a selective 
therapy. World journal of gastroenterology: WJG, 2006. 12(21): p. 3297-3305. 
146. Ghobrial, I.M., T.E. Witzig, and A.A. Adjei, Targeting apoptosis pathways in cancer therapy. CA: A 
Cancer Journal for Clinicians, 2005. 55(3): p. 178-194. 
147. Li, N., et al., Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One, 2011. 6(6): p. 
e20299. 
148. GULLICK, W.J., et al., Antibodies to the ATP‐binding site of the human epidermal growth factor (EGF) 
receptor as specific inhibitors of EGF‐stimulated protein‐tyrosine kinase activity. European Journal 
of Biochemistry, 1986. 158(2): p. 245-253. 
149. Schrodinger, L., Schrodinger Software Suite. New York: Schrödinger, LLC, 2011. 
150. Yun, C.H., et al., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: 
mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 2007. 11(3): 
p. 217-27. 
151. Kozer, N., et al., Recruitment of the Adaptor Protein Grb2 to EGFR Tetramers. Biochemistry, 2014. 
53(16): p. 2594-2604. 
152. Huang, H.-J., et al., Current developments of computer-aided drug design. Journal of the Taiwan 
Institute of Chemical Engineers, 2010. 41(6): p. 623-635. 
153. Bacilieri, M. and S. Moro, Ligand-based drug design methodologies in drug discovery process: an 
overview. Current drug discovery technologies, 2006. 3(3): p. 155-165. 
154. Blundell, T.L., Structure-based drug design. Nature, 1996. 384(6604 Suppl): p. 23-26. 
155. Moro, S., et al., Combined target-based and ligand-based drug design approach as a tool to define 
a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo [4, 3-e] 
1, 2, 4-triazolo [1, 5-c] pyrimidine derivatives as a key study. Journal of medicinal chemistry, 2005. 
48(1): p. 152-162. 
156. Cohen, C., O. Fischel, and E. Cohen, Molecular ConceptorTM for Training in Medicinal Chemistry, 
Drug Design, and Cheminformatics. Chemical Biology & Drug Design, 2007. 69(1): p. 75-82. 
157. Ferreira, L.G., et al., Molecular docking and structure-based drug design strategies. Molecules, 
2015. 20(7): p. 13384-13421. 
158. Kitchen, D.B., et al., Docking and scoring in virtual screening for drug discovery: methods and 
applications. Nature reviews Drug discovery, 2004. 3(11): p. 935-949. 
159. Mohan, V., et al., Docking: successes and challenges. Current pharmaceutical design, 2005. 11(3): 
p. 323-333. 
160. Prenzel, N., et al., The epidermal growth factor receptor family as a central element for cellular 
signal transduction and diversification. Endocrine-related cancer, 2001. 8(1): p. 11-31. 
161. Garrett, T.P., et al., Crystal structure of a truncated epidermal growth factor receptor extracellular 
domain bound to transforming growth factor α. Cell, 2002. 110(6): p. 763-773. 
162. Friesner, R.A., et al., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and 
assessment of docking accuracy. Journal of medicinal chemistry, 2004. 47(7): p. 1739-1749. 
 
   
 
226 
 
163. Eck, M.J. and C.-H. Yun, Structural and mechanistic underpinnings of the differential drug sensitivity 
of EGFR mutations in non-small cell lung cancer. Biochimica et Biophysica Acta (BBA)-Proteins and 
Proteomics, 2010. 1804(3): p. 559-566. 
164. Bologa, C.G., M.M. Olah, and T.I. Oprea, Chemical database preparation for compound acquisition 
or virtual screening, in Bioinformatics and Drug Discovery. 2006, Springer. p. 375-388. 
165. Kalyaanamoorthy, S. and Y.-P.P. Chen, Structure-based drug design to augment hit discovery. Drug 
Discovery Today, 2011. 16(17–18): p. 831-839. 
166. Baurin, N., et al., Drug-like annotation and duplicate analysis of a 23-supplier chemical database 
totalling 2.7 million compounds. Journal of chemical information and computer sciences, 2004. 
44(2): p. 643-651. 
167. Ghose, A.K., V.N. Viswanadhan, and J.J. Wendoloski, A knowledge-based approach in designing 
combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative 
characterization of known drug databases. Journal of combinatorial chemistry, 1999. 1(1): p. 55-
68. 
168. Zuegg, J. and M. A Cooper, Drug-likeness and increased hydrophobicity of commercially available 
compound libraries for drug screening. Current topics in medicinal chemistry, 2012. 12(14): p. 1500-
1513. 
169. Muegge, I., S.L. Heald, and D. Brittelli, Simple selection criteria for drug-like chemical matter. Journal 
of medicinal chemistry, 2001. 44(12): p. 1841-1846. 
170. Veber, D.F., et al., Molecular properties that influence the oral bioavailability of drug candidates. 
Journal of medicinal chemistry, 2002. 45(12): p. 2615-2623. 
171. Friesner, R.A., et al., Extra precision glide: docking and scoring incorporating a model of hydrophobic 
enclosure for protein-ligand complexes. Journal of medicinal chemistry, 2006. 49(21): p. 6177-6196. 
172. Adeniyi, A.A. and P.A. Ajibade, Comparing the suitability of autodock, gold and glide for the docking 
and predicting the possible targets of ru (ii)-based complexes as anticancer agents. Molecules, 
2013. 18(4): p. 3760-3778. 
173. Kellenberger, E., et al., Comparative evaluation of eight docking tools for docking and virtual 
screening accuracy. Proteins, 2004. 57(2): p. 225-42. 
174. Schneider, G., Virtual screening: an endless staircase? Nature Reviews Drug Discovery, 2010. 9(4): 
p. 273-276. 
175. Weber, L., JChem Base-ChemAxon. 2008, ROYAL SOC CHEMISTRY THOMAS GRAHAM HOUSE, 
SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND. p. 65-66. 
176. Singh, H., et al., QSAR based model for discriminating EGFR inhibitors and non-inhibitors using 
Random forest. Biology direct, 2015. 10(1): p. 10. 
177. Wang, D.D., et al., Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. 
Scientific reports, 2013. 3. 
178. Breiman, L., Random Forests. Machine Learning, 2001. 45(1): p. 5-32. 
179. Qi, Y., et al., Systematic prediction of human membrane receptor interactions. Proteomics, 2009. 
9(23): p. 5243-5255. 
180. Wiles, D. and T. Suprunchuk, Carbodihydrazones and oxalyl dihydrazones. Canadian Journal of 
Chemistry, 1968. 46(5): p. 701-705. 
181. Szmuszkovicz, J. and M.E. Greig, A Study of the Inhibitory Effect of Various Hydrazides on 
Monoamine Oxidase in vitro and in vivo. Journal of Medicinal Chemistry, 1961. 4(2): p. 259-296. 
182. Umesha, K., K. Rai, and M.H. Nayaka, Antioxidant and Antimicrobial Activity of 5-methyl-2-(5-
methyl-1, 3-diphenyl-1H-pyrazole-4-carbonyl)-2, 4-dihydro-pyrazol-3-one. International journal of 
biomedical science: IJBS, 2009. 5(4): p. 359. 
 
   
 
227 
 
183. Wu, D., et al., Synthesis, Structure–Activity Relationship, and Pharmacophore Modeling Studies of 
Pyrazole‐3‐Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors. Chemical biology & 
drug design, 2012. 79(6): p. 897-906. 
184. Katrizky, A.R., P. Barczynski, and D.L. Ostercamp, Mechanisms of heterocycle ring formation. Part 
5. A carbon-13 nuclear magnetic resonance study of pyrazolinone synthesis by the reaction of β-
ketoesters with substituted hydrazines. Journal of the Chemical Society, Perkin Transactions 2, 
1987(8): p. 969-975. 
185. Semple, G., et al., 3-(1 H-tetrazol-5-yl)-1, 4, 5, 6-tetrahydro-cyclopentapyrazole (MK-0354): a partial 
agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no 
vasodilatory activity in mice. Journal of medicinal chemistry, 2008. 51(16): p. 5101-5108. 
186. Ley, J.P. and H.-J. Bertram, Hydroxy-or methoxy-substituted benzaldoximes and benzaldehyde-O-
alkyloximes as tyrosinase inhibitors. Bioorganic & medicinal chemistry, 2001. 9(7): p. 1879-1885. 
187. Ley, J.P., et al., New bitter-masking compounds: hydroxylated benzoic acid amides of aromatic 
amines as structural analogues of homoeriodictyol. Journal of agricultural and food chemistry, 
2006. 54(22): p. 8574-8579. 
188. Wilson, J., Phenolic Analogs of Amino Carboxylic Acid Ligands for 99mTc. II. Synthesis and 
Characterization of N, N'-Ethylenebis [N-(o-Hydroxybenzyl)-glycines](ehbg). Australian Journal of 
Chemistry, 1988. 41(2): p. 173-182. 
189. Meyers, H., et al., Multiple simultaneous synthesis of phenolic libraries. Molecular Diversity, 1995. 
1(1): p. 13-20. 
190. Montalbetti, C.A.G.N. and V. Falque, Amide bond formation and peptide coupling. Tetrahedron, 
2005. 61(46): p. 10827-10852. 
191. Bart, J., et al., Room-temperature intermediate layer bonding for microfluidic devices. Lab on a Chip, 
2009. 9(24): p. 3481-3488. 
192. Barltrop, J.A., et al., 5-(3-carboxymethoxyphenyl)-2-(4, 5-dimethylthiazolyl)-3-(4-sulfophenyl) 
tetrazolium, inner salt (MTS) and related analogs of 3-(4, 5-dimethylthiazolyl)-2, 5-
diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell-viability 
indicators. Bioorganic & Medicinal Chemistry Letters, 1991. 1(11): p. 611-614. 
193. Vistica, D.T., et al., Tetrazolium-based assays for cellular viability: a critical examination of selected 
parameters affecting formazan production. Cancer Res, 1991. 51(10): p. 2515-20. 
194. Shoemaker, R.H., The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer, 2006. 
6(10): p. 813-823. 
195. Boyd, M., K. Paull, and L. Rubinstein, Data display and analysis strategies for the NCI disease-
oriented in vitro antitumor drug screen, in Cytotoxic Anticancer Drugs: Models and Concepts for 
Drug Discovery and Development. 1992, Springer. p. 11-34. 
196. Rubinstein, L.V., et al., Comparison of in vitro anticancer-drug-screening data generated with a 
tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl 
Cancer Inst, 1990. 82(13): p. 1113-8. 
197. Monks, A., et al., Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured 
human tumor cell lines. J Natl Cancer Inst, 1991. 83(11): p. 757-66. 
198. Anderson, W.K., A. Gopalsamy, and P.S. Reddy, Design, synthesis, and study of 9-Substituted 
ellipticine and 2-Methylellipticinium analogs as potential CNS-selective antitumor agents. Journal 
of medicinal chemistry, 1994. 37(13): p. 1955-1963. 
199. Neubig, R.R., et al., International Union of Pharmacology Committee on Receptor Nomenclature 
and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. 
Pharmacological Reviews, 2003. 55(4): p. 597-606. 
 
   
 
228 
 
200. Pawson, C.T. and J.D. Scott, Signal integration through blending, bolstering and bifurcating of 
intracellular information. Nature structural & molecular biology, 2010. 17(6): p. 653-658. 
201. Song, G., G. Ouyang, and S. Bao, The activation of Akt/PKB signaling pathway and cell survival. 
Journal of cellular and molecular medicine, 2005. 9(1): p. 59-71. 
202. Mebratu, Y. and Y. Tesfaigzi, How ERK1/2 activation controls cell proliferation and cell death: Is 
subcellular localization the answer? Cell cycle, 2009. 8(8): p. 1168-1175. 
203. Lowry, O.H., et al., Protein measurement with the Folin phenol reagent. J biol Chem, 1951. 193(1): 
p. 265-275. 
204. Bramhall, S., et al., A simple colorimetric method for determination of protein. Analytical 
biochemistry, 1969. 31: p. 146-148. 
205. Burnette, W.N., “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl 
sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody 
and radioiodinated protein A. Analytical biochemistry, 1981. 112(2): p. 195-203. 
206. Derer, S., et al., Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on 
effector mechanisms of EGFR antibodies. The Journal of Immunology, 2012. 189(11): p. 5230-5239. 
207. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Analytical biochemistry, 1976. 72(1): p. 248-
254. 
208. Recanatini, M., et al., QT prolongation through hERG K+ channel blockade: Current knowledge and 
strategies for the early prediction during drug development. Medicinal Research Reviews, 2005. 
25(2): p. 133-166. 
209. Ciaccio, M.F., et al., Systems analysis of EGF receptor signaling dynamics with microwestern arrays. 
Nat Meth, 2010. 7(2): p. 148-155. 
210. Liu, Z.-Q., T. Mahmood, and P.-C. Yang, Western blot: Technique, theory and trouble shooting. North 
American journal of medical sciences, 2014. 6(3): p. 160. 
211. Schneider, C.A., W.S. Rasband, and K.W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis. 
Nature methods, 2012. 9(7): p. 671-675. 
212. Rakowicz-Szulczynska, E.M., et al., Epidermal growth factor (EGF) and monoclonal antibody to cell 
surface EGF receptor bind to the same chromatin receptor. Archives of biochemistry and biophysics, 
1989. 268(2): p. 456-464. 
213. Schaefer, G., et al., A two-in-one antibody against HER3 and EGFR has superior inhibitory activity 
compared with monospecific antibodies. Cancer cell, 2011. 20(4): p. 472-486. 
214. Leach, A.R., B.K. Shoichet, and C.E. Peishoff, Prediction of protein-ligand interactions. Docking and 
scoring: successes and gaps. Journal of medicinal chemistry, 2006. 49(20): p. 5851-5855. 
215. Lengauer, T. and M. Rarey, Computational methods for biomolecular docking. Current Opinion in 
Structural Biology, 1996. 6(3): p. 402-406. 
216. Cohen, N.C., et al., Molecular modeling software and methods for medicinal chemistry. Journal of 
medicinal chemistry, 1990. 33(3): p. 883-894. 
217. Blaney, J.M. and J.S. Dixon, A good ligand is hard to find: Automated docking methods. Perspectives 
in Drug Discovery and Design, 1993. 1(2): p. 301-319. 
218. Webb, S.E.D., et al., Nanometric molecular separation measurements by single molecule 
photobleaching. Methods, 2015. 88: p. 76-80. 
219. Ultra, C., 12.0 Suite, Perkin Elmer. 2012. 
220. Sunderhaus, J.D. and S.F. Martin, Applications of multicomponent reactions to the synthesis of 
diverse heterocyclic scaffolds. Chemistry-A European Journal, 2009. 15(6): p. 1300-1308. 
 
   
 
229 
 
221. Brussel, W. and C. Van Sumere, N‐Acylamino acids and peptides VI. A Simple synthesis of N‐
acylglycines of the benzoyl‐and cinnamyl type. Bulletin des Sociétés Chimiques Belges, 1978. 
87(10): p. 791-797. 
222. Han, S.-Y. and Y.-A. Kim, Recent development of peptide coupling reagents in organic synthesis. 
Tetrahedron, 2004. 60(11): p. 2447-2467. 
223. Wang, S., et al., Enhancement of peptide coupling reactions by 4‐dimethylaminopyridine. 
International journal of peptide and protein research, 1981. 18(5): p. 459-467. 
224. Huang, K.T., Y.H. Chen, and A.M. Walker, Inaccuracies in MTS assays: major distorting effects of 
medium, serum albumin, and fatty acids. Biotechniques, 2004. 37(3): p. 406, 408, 410-2. 
225. Geenen, S., et al., HPLC–MS/MS methods for the quantitative analysis of 5-oxoproline 
(pyroglutamate) in rat plasma and hepatic cell line culture medium. Journal of pharmaceutical and 
biomedical analysis, 2011. 56(3): p. 655-663. 
226. Wang, P., S.M. Henning, and D. Heber, Limitations of MTT and MTS-based assays for measurement 
of antiproliferative activity of green tea polyphenols. PloS one, 2010. 5(4): p. e10202. 
227. Demetrashvili, N. and E.R. Van den Heuvel, Confidence intervals for intraclass correlation 
coefficients in a nonlinear dose–response meta‐analysis. Biometrics, 2015. 
228. Gewirtz, D.A., M.L. Bristol, and J.C. Yalowich, Toxicity issues in cancer drug development. Curr Opin 
Investig Drugs, 2010. 11(6): p. 612-4. 
229. Collins, J., Prospective predictions and validations in anticancer therapy. Pharmacokinetics in risk 
assessment: drinking water and health, 1987. 8: p. 431-440. 
230. Benfield, P.A. and B.D. Car, Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and 
Development, in Molecular Cancer Therapeutics. 2005, John Wiley & Sons, Inc. p. 255-286. 
231. Kurien, B.T. and R.H. Scofield, Western blotting. Methods, 2006. 38(4): p. 283-293. 
232. MacPhee, D.J., Methodological considerations for improving Western blot analysis. Journal of 
pharmacological and toxicological methods, 2010. 61(2): p. 171-177. 
233. Alegria-Schaffer, A., A. Lodge, and K. Vattem, Performing and optimizing Western blots with an 
emphasis on chemiluminescent detection. Methods in enzymology, 2009. 463: p. 573-599. 
 
 
 
 
 
 
 
 
 
 
 
   
 
230 
 
Appendix 
Appendix A – Selected lead candidates in colours 
 
Ambinter_ 
Ligand glide 
Gscor
e 
glide 
energ
y 
glide 
eintern
al 
glide 
emode
l 
Prime 
Energy 
MMGBSA 
dG Bind 
0 
Ligand 
Energy 
Receptor 
Energy 
Complex 
Energy 
glide 
posenu
m 
ZINC 
721318
21 
-3.824 -
24.20
3 
1.266 -
28.848 
-
23621.
7 
-50.486 -
105.09
3 
-23466.1 -
23621.7 
15 
ZINC20
537922 
-3.53 -
27.68
4 
3.837 -
36.075 
-
23515.
1 
-48.796 -0.15 -23466.1 -
23515.1 
3 
ZINC20
322301 
-3.346 -
27.47
7 
5.886 -
34.332 
-
23463.
2 
-47.496 50.474 -23466.1 -
23463.2 
12 
ZINC72
131820 
-3.301 -
22.55
1 
0.133 -
30.292 
-
23613.
6 
-43.26 -
104.21
5 
-23466.1 -
23613.6 
17 
ZINC67
847695 
-3.099 -
28.94
4 
7.746 -
33.793 
-
23481.
9 
-52.455 36.688 -23466.1 -
23481.9 
4 
ZINC67
847694 
-2.798 -21.11 0.464 -
26.499 
-
23602.
3 
-45.114 -
91.024 
-23466.1 -
23602.3 
20 
ZINC65
372018 
-2.735 -
22.32
8 
1.216 -
28.606 
-
23580.
1 
-37.862 -
76.134 
-23466.1 -
23580.1 
1 
ZINC71
771450 
-2.657 -
22.54
7 
1.221 -
25.633 
-
23474.
8 
-38.787 30.099 -23466.1 -
23474.8 
2 
ZINC67
741022 
-2.608 -
24.28
4 
6.594 -
28.105 
-
23503.
4 
-45.307 7.988 -23466.1 -
23503.4 
6 
ZINC67
955954 
-2.301 -
25.52
2 
3.836 -
29.083 
-
23530.
2 
-42.784 -
21.305 
-23466.1 -
23530.2 
4 
ZINC67
851668 
-2.07 -
16.43
2 
6.243 -
18.387 
-
23499.
5 
-26.138 -7.219 -23466.1 -
23499.5 
53 
ZINC72
457948 
-2.067 -
16.65
6 
3.45 -
21.841 
-
23497.
8 
-43.59 11.898 -23466.1 -
23497.8 
26 
ZINC67
774117 
-2.027 -
19.80
6 
0.567 -
20.478 
-
23445.
1 
-40.967 61.956 -23466.1 -
23445.1 
37 
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ZINC02
887281 
-1.962 -
26.22
8 
1.053 -
33.118 
-
23501.
3 
-39.033 3.889 -23466.1 -
23501.3 
24 
ZINC00
052413 
-1.946 -
20.72
2 
3.477 -
23.432 
-
23557.
8 
-34.545 -
57.171 
-23466.1 -
23557.8 
5 
ZINC67
919965 
-1.917 -
19.82
1 
2.928 -
23.492 
-
23510.
9 
-28.437 -
16.311 
-23466.1 -
23510.9 
11 
ZINC20
907761 
-1.815 -
20.08
2 
2.534 -
13.178 
-
23460.
8 
-44.806 50.104 -23466.1 -
23460.8 
1 
ZINC67
955955 
-1.712 -25.43 2.977 -28.91 -
23533.
6 
-45.976 -
21.467 
-23466.1 -
23533.6 
1 
ZINC39
515547 
-1.591 -19.8 2.194 -
22.303 
-
23472.
1 
-36.521 30.517 -23466.1 -
23472.1 
20 
ZINC22
926613 
-0.627 -
18.23
3 
6.405 -
12.213 
-
23455.
9 
-38.403 48.653 -23466.1 -
23455.9 
11 
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Appendix B – Some Colorimetric (MTS) & Western blotting protocols 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDS-PolyAcrylamide Gel Electrophoresis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gel Preparation 
Pour Resolving Gel into cast (~3 mL- up to top of green 
frame to leave room for Stacking gel) 
Gently layer 20% isopropanol over top to flatten and 
remove air bubbles 
Takes 45min to set 
When completely set, remove isopropanol 
Layer Stacking Gel over top and insert comb (10- or 15-
well) 
Takes 10min to set 
12% Resolving Gel 
(can make 8-12% depending on desired migration) 
1.20 mL 40% Acrylamide 
1.00 mL  1.5M Tris pH 8.8 
1.76 mL  dH2O 
40 μL 10%SDS 
20 μL APS 
2.8 μL Temed 
4% Stacking Gel 
200 μL 40% Acrylamide 
500 μL 0.5M Tris pH 6.8 
1.28 mL dH2O 
40 μL 10%SDS 
40 μL APS 
2.8 μL Temed 
Sample Preparation 
Prepare 20 μg protein up to 15 μL total volume, 
including 3μL 5X Laemmli Sample Buffer 
Puncture small hole in Eppendorf lid with syringe to 
prevent lid popping off 
Boil sample, 95ºC 5min 
Vortex then store on ice 5 min (careful, as tube is 
HOT!) 
Vortex then centrifuge, 5 min 14000 rpm 
  
MTS Assay Protocol 
The materials are [3-(4,5-dimethylthiazol-2-yl)-5-(carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-
tetrazolium(MTS), Dulbecco’s phosphate buffered saline(DPBS) and phenazine methosulphate(PMS) 
• Already prepared MTS Solution (2 mL of DPBS + 100 µL of PMS), containers wrapped with foil to 
protect from light and refrigerated at -20 
o
C, is thawed and used. Or else   
• 2.0 mL of MTS is removed from the amber reagent bottle aseptically into a test tube 
• Add 100 µL PMS solution to the test tube of the 2.0 mL MTS immediately. 
• A gentle swirl is required to effect a good mix of the solutions. Refrigerate at -20 
o
C until needed 
(a) 20 µL of the MTS/PMS solution is pipetted into each well of the 96 well assay plates  (in this case 4 for 
each drug) containing 100 µL of cells in culture medium 
(b) Plates are incubated at 37oC with CO2 for 1-2 hours 
(c) The absorbance is recorded at 490 nm using Microplate Reader, Bio-Rad Model 680, following the 
New Endpoint Protocol 
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5X Laemmli Sample Buffer 
12.5 mL Glycerol 
12.5 mL 0.5M Tris-HCl pH 6.8 
~1 mL  1% Bromophenol Blue (depends 
how blue you like it) 
Add 75 mg/mL DTT before use or keep at 
20ºC 
  
Transferring Gel (Semi-Dry) Transfers protein from gel to 
membrane 
Moisten 3x blotting paper in 1x Transfer Buffer and place on 
cathode 
Prepare PVDF Membrane by placing in Methanol 15sec, dH2O 
1 min, 1x Transfer Buffer 
Lay membrane over paper 
Line up gel in correct orientation 
Lay another 3x moistened blotting paper 
Place cathode on top, and run at 15 V for 45 min-1hr 10x Running Buffer 1L 
30.29 g Tris-Base 
144.13 g Glycine 
10.00 g SDS 
Make up to 1L with dH2O 
Store at 4 0C and dilute 1:10 for use 
10x Transfer Buffer 1L 
Same as Running Buffer but without SDS 
Dilute 10x Buffer:Methanol:Water 1:2:7 
Wet Transfer: 
Prepare and mark the membrane (right size, PVDF or Immobilon-P membrane) with a pencil; then soak it in 
Methanol for a few minutes, and rinse it with distilled water. 
Equilibrate the membrane, pads, filter papers (4 pieces) and transfer foam in Transfer Buffer (store in 4C) for 5 
minutes. 
Assemble transfer sandwich in the following order:  black frame (negative electrode) >> foam >> 3 pieces of filter 
papers >> SDS-PAGE gel >> membrane >> 3 pieces of filter papers >> foam >> red frame (positive electrode). Make 
the marked side of membrane face the gel.  Put it into transfer tank. 
Transfer the gel at 80V for 90mins in cold room. Alternatively, use ice bag and magnet stirring bar to transfer the 
gel in room temperature.  
Running Gel 
Take glass plates out of green brackets 
Secure in gel holder (front plates facing in) and place in tank 
Fill inner chamber with fresh 1x Running Buffer 
Fill outer chamber with sufficient recycled 1x Running Buffer 
Load samples and marker(M) into wells (remember the order 
you load eg M,1,2,3,4,M,1,2,3,4) 
Run gel at 200V for ~45min (until dye leaves gel) 
Carefully take gel out of glass plates and place in 1x Transfer 
Buffer 
(If gel comes off back plate, turn gel over to face the correct 
way- left to right) 
Western Blotting 
Once protein transferred, block membrane in 
5% skim milk for 1hr 
Wash 3x for 5min with PBS-Tween 0.01% 
Probe with primary antibody for 1hr room 
temp, or overnight at 4 ºC 
Wash 3x for 5 min with PBS-Tween 0.01% 
Probe with secondary antibody (mouse or 
rabbit) for 1hr room temp 
Wash 3x for 5 min with PBS-Tween 0.01% 
Expose to x-ray film with ECL reagent and 
develop 
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Lowry Method for Protein Quantification 
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DPT+EGF EGF-induced pY-EGFR 
activation 
EGF-induced pY-ERK1 
activation 
EGF-induced pY-ERK2 
activation 
(-EGF) 0 0 0 
(+EGF) 1 1 1 
DPT1-1uM 2.502566641 85.17276679 104.2224412 
DPT1-10uM 62.64462754 1.580823291 24.1959233 
DPT1-
100uM 
4.342151116 176.5379204 216.0222535 
    
DPT2-1uM 0.771180069 0.637417115 0.018254137 
DPT2-10uM 67.81419457 0.386611231 0.387944671 
DPT2-
100uM 
46.09391553 0.373124364 15.98103543 
    
DPT3-1uM 1.067637307 0.296768789 15.98103543 
DPT3-10uM 3.470947384 0.655056811 0.669164313 
DPT3-
100uM 
0.19058069 2.852395573 2.909691707 
    
DPT4-1uM 1.576258786 91.99206185 3.81722737 
DPT4-10uM 1.071542476 2.70388399 91.94953502 
 
Table showing the densitometry values obtained using ImageJ 
 
   
 
236 
 
Appendix C – Spectral data for the ‘synthesized’ hit leads (zm1 7, ‘zm1a 7’ & zm2 8) 
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13
CNMR: zm1 7, [1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbohydrazide] 
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[M + H]
+
: zm1 7, 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbohydrazide 
 
   
 
239 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FTIR: zm1 7, 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbohydrazide 
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1HNMR: zm2 8, 2-hydroxy-N-(4-hydroxybenzyl)-2-(4-hydroxyphenyl) acetamide 
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13
CNMR: zm2 8, 2-hydroxy-N-(4-hydroxybenzyl)-2-(4-hydroxyphenyl acetamide] 
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[M + H]
+:  zm2 8, 2-hydroxy-N-(4-hydroxybenzyl)-2-(4-hydroxyphenyl)acetamide 
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FTIR: zm2 8, 2-hydroxy-N-(4-hydroxybenzyl)-2-(4-hydroxyphenyl) acetamide 
